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ABSTRACT
Trachoma is a chronic keratoconjunctivits caused by ocular infection with
Chlamdydia trachomatis (CT). It is a major cause of blindness. This thesis addresses
issues important for the rational use of the antibiotic azithromycin, one of the
cornerstones of WHO's strategy for trachoma elimination.
An entire sub-village in Rombo District, Tanzania was invited to participate.
Consenting individuals were examined and had swabs taken for quantitative PCR
(directed against the single-copy CT gene ompl), at baseline (before treatment). and
two, six, twelve and eighteen months after, mass distribution of single-dose
azithromycin. At the time of drug distribution, both weight and height of each treated
individual was recorded.
Four findings are highlighted. (1) Before treatment, and at each post-treatment time
point, children below the age of ten years harboured the bulk of the community's ocular
CT. Control programmes should view this age group as their principal target in
antibiotic distribution campaigns.
(2) Signs of active trachoma were much less useful than age thresholds for
predicting population subsets with heavy infections.
(3) Based on a summary statistic referred to as the community ocular CT load, or
COCTL, the overall community burden of organism fell dramatically following
azithromycin distribution, and stayed low for the entire eighteen months of follow-up.
The COCTL was 13% of its baseline level at two months. 8% of baseline at six months,
and 4% at both twelve and eighteen months. This may have been due to the high
treatment coverage (98%) achieved.
(4) In the population studied, height was a good proxy for weight for determining
azithromycin dose.
These studies contribute new information about the epidemiology of ocular CT
infection, provide dramatic evidence of the potential effect of azithromycin when uptake
is high, and should help to streamline azithromycin distribution efforts by simplifying
determination of dose in the field.
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1. INTRODUCTION
Infectious diseases confront man today as at no time since before the antibiotic era.
Current estimates suggest that malaria kills approximately one million people each year
in tropical Africa alone [1, 2]. HNIAIDS, unrecognised before 1981, is now a global
catastrophe [3, 4]. Tuberculosis is resurgent: one third of the world's population is
probably infected with tubercle bacilli, which may be the world's leading killer of
adults [5, 6]. Worldwide, annual child mortality from each of these three pathogens is
overshadowed by that due to diarrhoeal disease, which is in tum eclipsed by the number
of children who die yearly from acute lower respiratory tract infections [7, 8]. The
emergence of new multi-drug resistant strains of Mycobacterium tuberculosis [9] and
vancomycin- and epidemic methicillin-resistant Staphylococcus aureus [10-14]; the
possible implications of global warming on the geographical range of tropical pathogens
[6, 15]; the very recent threat of smallpox, ebola, anthrax, plague or tularaemia being
used as instruments ofbioterrorism [16-18]; and the sudden appearance of severe acute
respiratory syndrome (SARS) [19, 20] have alarmed the medical community,
governments, and the public [21-23] alike.
Amidst this cast of new and familiar foes competing for the attention of policy
makers, research scientists and donors, one of the oldest - trachoma - suddenly, and
perhaps transiently, looks vulnerable to attack. Pfizer's donation of an effective, single
dose, well-tolerated, oral antibiotic for trachoma to six endemic countries has
invigorated an international alliance against the disease - so much so that elimination of
trachoma by the year 2020 is now a World Health Organization-supported target [24].
This provides a rare opportunity for optimism amongst those who take a public health
approach to infectious disease control. It is critical that the momentum provided by
Pfizer's donation is used to best effect. This is a good reason to choose trachoma as a
priority subject for research, despite good claims from the other infections listed above.
There is another reason, however, that is just as important.
Trachoma is a blinding disease, responsible for about 15% of global blindness [25].
It is, first and foremost, a disease of poverty: the millions of eyes blind from trachoma
are set almost exclusively in the faces of the desperately poor - those least able to help
themselves. The economic impact of blindness is huge in any environment, but for
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someone whose family is already socially and economically vulnerable, it is
devastating. Even if the suffering of the nearly 150million people with clinically active
trachoma is ignored, the effect of this disease on communities in which it is endemic is
grave. Preventing trachoma blindness not only helps individual sufferers, but delivers
enduring benefit to their families, to their village, and to future generations [26].
Trachoma has long been a neglected disease. We need effective interventions to
eliminate it. The work presented in this thesis will hopefully contribute a little to their
development.
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2. REVIEW OF PREVIOUS WORK
2.1 AETIOLOGY
Trachoma has been recognised for millennia as a blinding disease. It has been
known in China for more than 4600 years, in the Middle East for 4000 years, and in
Egypt for 3800 years [27-29]. Its contagious nature was recognised in Syria in the
thirteenth century [30], but upon first coming to the attention of European surgeons
during the Napoleonic campaigns in Egypt in 1798-99, the French determined that it
was due either to sand or noxious night vapours. The British, on the other hand,
believed that it was caused by a virus, and took appropriate measures; their infantry
suffered a lower incidence of blindness [28]. In the late nineteenth and early twentieth
century, the discovery of clinical trachoma in would-be US immigrants disembarking at
Ellis Island, New York, was responsible for more than half of all medical detentions
there, and meant certain deportation back to the port of origin [31, 32].
The causative agent of trachoma was not visualised until 1907, when Halberstaedter
and von Prowazek described the presence of inclusion bodies (Halberstaedter-Prowazek
bodies) inside infected cells. They believed the organism to be a protozoon [33]. The
transmissibility of trachoma was by then already firmly established in the minds of the
public. Hundreds of Russian and Austria-Hungarian First World War conscripts, for
example, evaded military service by infecting their own eyes with discharges wiped
from the eyes of trachoma patients [28]. Meanwhile, unconvinced by the findings of
Halberstaedter and von Prowazek, researchers nominated a variety of bacteria, fungi,
and viruses as the underlying pathogen [28]. It was not until 1957 in Peking that T'ang
et al. completed the first successful isolation', using chick embryos whose yolk sacs had
been inoculated with material from infected human eyes [36]. They were able to
serially passage the organism in eggs, and to use this material to infect the eyes of
rhesus monkeys, producing characteristic clinical signs of trachoma and - on one
occasion - inclusion bodies. Based on filtration experiments. they believed the
trachoma agent to be a virus [36]. T'ang et al.'s methods were successfully replicated
by Collier and Sowa in The Gambia in 1958 [37]. The isolates obtained were noted
both to share a common antigen with, and to physically resemble. the agents of
iMacchiavello claimed to have isolated the causative agent of trachoma in Ecuador in 1944 [34], by inoculating
material from a 17-year old "who had suffered from a disease diagnosed as trachoma for three years" into the yolk
sac of chick eggs. Because doubt was cast over the clinical diagnosis [35], however, his claim to first success has not
been supported.
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psittacosis" and lymphogranuloma venereum [37], and the agent of some cases of
cervicitis and mucopurulent conjunctivitis of the newborn [39].
As knowledge of the nature of these organisms accumulated, there was
considerable debate over whether they represented a transitional remnant on the
degenerate evolutionary pathway that Green had hypothesized [40] for the descent of
viruses from bacteria, or whether they should be placed wholly within one or other of
these classes. In 1966, Moulder published a comprehensive review of the growth,
division, structure, chemical composition and metabolism of the group, taking into
account the definitions of viruses and bacteria that had been recently proposed by Lwoff
and Stanier respectively. He concluded fairly unequivocally that chlamydiae were
intracellular bacteria, with a distinctive developmental cycle and unique structure [41].
The Taxonomy Committee of the American Society for Microbiology unified the
organisms in the genus Chlamydia, and supported their status as bacteria [42]iii. Today,
some fifteen major bacterial groupings are recognised, and the chlamydiae are the only
ones whose members are all exclusively intracellular parasites of eukaryotes [43].
2.1.1 Developmental cycle
Chlamydiae lack cytochromes, so can not synthesise their own adenosine
triphosphate (ATP). They are therefore obligate intracellular organisms, requiring
energy-rich metabolic intermediates from host cells in order to complete their
replication cycle [44]. To permit egress from infected cells and entry of new ones, a
metabolically inert, extracellular, infectious form known as the elementary body (EB)
alternates with the metabolically active, dividing, intracellular form (the reticulate body,
orRB).
EBs of chlamydiae are spherical (or, rarely, pear-shaped) and 0.2-0.3 pm in
diameter [45]. They appear to bind to susceptible host cells via heparin bridges. There
is considerable interest in identifying the chlamydial ligands involved in heparin
binding: candidates include the major outer membrane protein, and the cysteine-rich
protein OmcB, both of which are found in the chlamydial outer membrane complex
(COMC) [46, 47]. More about both of these molecules (and about other COMC
proteins) will follow in subsequent sections. Successful attachment of the EB is
ii the isolation of which had been reported by Bedson and Western in 1930 [38]
iii The name Chlamyciw Jones, Rake and Steams, 1945 is derived from the Latin chlamys, which in tum is from the
Greek Ichlamus: a short mantle fastened at the shoulder, worn by men in ancient Greece. It took priority over the
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followed by its entry into the host cell. Though hosts are non-professional phagocytes,
their oxidative and glycolytic pathways must be intact for entry to occur, suggesting that
they participate actively in EB ingestion [48]. Tyrosine phosphorylation of host cell
proteins and actin cytoskeletal rearrangement may be involved [49, 50]. Active
participation of the EB, on the other hand, appears minimal: EB envelopes are
internalised just as efficiently as whole EBs [51]. Processes involved in attachment and
uptake may differ between the various species of chlamydiae, and even between
variants of the same species [50, 52].
Once inside a host cell, the EB reorganises into a 0.5-1.0 pm diameter RB within a
membrane-bound vacuole known as an inclusion. The RB grows and replicates by
binary fission, remaining within the inclusion membrane (derived from the cytoplasmic
membrane of the host) for the entire duration of the organism's intracellular phase.
After a period of logarithmic multiplication, progeny differentiate back into EBs. A
number of 'late phase' proteins are synthesised during the RB to EB transformation,
including COMe proteins OmcB and OmcA, and two histone HI-like proteins, Hcl and
Hc2, which are involved in compaction of the chlamydial chromosome [45, 53]. EBs
are released into the extracellular environment by fusion of the membrane of the
inclusion with that of the host cell, or upon host cell lysis [44, 48]. The specific
processes involved in cellular exit are poorly defined. In tissue culture, the entire
developmental cycle from attachment to exit takes between forty-eight and seventy-two
hours.
2.1.2 Structure and chemical composition
<a>Electron microscopy
Using an electron microscope, an EB is seen to have a granular cytoplasm,
reflecting the presence of 70S ribosomes, and an eccentrically-placed nucleoid
containing condensed DNA [54]. The cell envelope is double-layered, resembling the
cell envelope of gram-negative bacteria [44]. The cell wall (the portion of the cell
envelope lying external to the cytoplasmic membrane) can itself be resolved into two
layers: an inner- ('p') layer composed of hexagonally arrayed structures with a
periodicity of 16.7nm, and a granular outer layer containing the outer membrane [45,
54]. The inner layer therefore lies within the periplasmic space (Figure 2.1, p.23).
validly published names Bedsonia Meyer, 1953, and Rakeia Levaditi, Roger and Destombes, 1964, as well as over
Miyagawanella Brumpt, 1938, which had not been validly published [42].
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Figure 2.1: Model of the EB cell wall, after Everett and Hatch [55].
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Cylindrical projections radiate from the outer membrane of the EB (Figure 2.2).
Each projection is about 30nm long, and has its inner end at the cytoplasmic (inner)
m mbran ,extending outwards to penetrate the outer membrane through the centre of a
membrane-bound rosette. A rosette is made up of eight or nine protein subunits: the
number of subunits varies between different species of chlamydiae. DNA strands can
be seen connecting the nucleoid with the cytoplasmic membrane subjacent to the
proj ections [54, 56].
Figure 2.2: Transmission electron micrograph of a chlamydial EB, showing projections
(arrows). n=nucleoid; c=cytoplasm. The granulations in the cytoplasm are 70S
ribosomes. The bar at the bottom right of the picture represents 0.15 urn (Electron
micrograph by Matsumoto (1988) [57]).
t
.WWW.chlamydiae.com
A. Matsumoto.
RBs are Jarg r than EBs, and contain diffuse, fibrillar DNA plus a high
concentration of ribo omes [58]. The cell envelope appears less complex than that of
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the EB, lacking the hexagonally packed structures of the EB periplasmic space. The
surface of the outer membrane, however, contains projections and rosettes at even
higher density than are seen on EBs [58]. The outer end of the projections appear to
contact the inclusion membrane, leading to the hypothesis that projection / rosette
complexes have a secretory function analogous to the type III secretory system found in
other bacterial species [45, 59].
(b) Lack of peptidoglycan
Most bacteria have peptidoglycan, a complex cross-linked polymer, in their cell
envelope. In gram-negatives, peptidoglycan is found in the periplasmic space, while in
gram-positives it lies immediately outside the cytoplasmic membrane and may comprise
up to 50% of total cell wall material [44]. Its function is to help maintain cell shape and
integrity despite the relatively high internal osmotic pressure of the bacterium.
Penicillin and other P-Iactam antibiotics inhibit growth of susceptible organisms by
preventing formation of peptide cross-links in peptidoglycan. This effect is mediated
through bacterial penicillin binding proteins (PBPs). Chlamydiae produce PBPs, and
their growth is inhibited by penicillin, but - surprisingly - they do not appear to contain
appreciable amounts of peptidoglycan [60, 61]. This paradox raises interesting
questions about the biology of the organism [62, 63], and demands an alternative
explanation for the rigidity and osmotic stability of the EB. These properties are
currently thought to be conferred by the COMC.
(c) Components, organisation and properties of the COMC
The COMe was first defined in 1981, when Caldwell et al. [60] reported the
outcome of their experiments with the detergent Sarkosyl", which had been shown to
selectively solubilise the cytoplasm and cytoplasmic membranes of gram-negative
bacteria [64]. Transmission electron microscopy of Sarkosyl-treated EBs showed
empty EB particles with an apparently intact outer membrane [60]. Caldwell et a/.'s
method has since been used as the standard method for purification of the COMC.
Using sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) of EB
lysates, the same group identified a protein with a molecular weight of about 40kDa that
was found in a number of chlamydial strains. They went on to show that this protein,
which soon became known as the major outer membrane protein (MOMP), was one of
the elements of the Sarkosyl-insoluble COMC, and that it comprised some 60% of the
total protein mass of the EB cell wall. Two other research groups (Hatch et al. [65]; and
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Salari and Ward [66]) independently discovered MOMP at around the same time [67].
125I-Iabelling of the protein indicated that it was surface exposed [60, 65, 66].
Hatch et al., trying to extract MOMP from other components of the cell wall, noted
that it could not be dissolved in SDS alone, or in mercaptoethanol alone, but was
soluble in a solution containing both of these agents. This implied that disulfide bonds
were important in binding MOMP into the COMC, and perhaps in maintaining the
overall structural stability of the cell wall [65].
It was quickly recognised that the importance of MOMP was not confined to its
structural role. Salari and Ward were able to extract MOMP from 14 of the 15 then-
known serovars (see Section 2.1.4, p.27) of the chlamydial species Chlamydia
trachomatis (see Section 2.1.3, p.26), and noted minor serovar-specific variation in its
molecular weight [66]. The existence of species- and sub-species-specific epitopes
within the protein was noted [68,69], before it became clear that MOMP also contained
serovar-specific epitopes [70, 71]. Even more importantly, polyclonal [72] and then
monoclonal [73] antibodies to MOMP were shown to neutralise infectivity of the live
organism. These discoveries raised hopes that the protein would be useful in the
development of a protective subunit vaccine. Unfortunately, such hopes have so far
remained unfulfilled [74].
Though multiple strands of evidence suggest that MOMP is surface exposed, other
data have localised parts of the molecule to the periplasmic space [75]. These two
conclusions are consistent with MOMP being an integral membrane protein. It now
seems likely that MOMP's physiological function is as a membrane channel or 'porin'
permeable to ATP. Prevention of uptake of host cell ATP could potentially be a
mechanism by which antibodies to MOMP block cellular infection [76]. Although the
protein is thought to form trimeric aggregates within the outer membrane [77], its actual
conformation within intact chlamydiae is unknown [78].
Two other components ofCOMC have already been briefly mentioned: the cysteine
rich proteins (CRPs) OrncB (57-62 kDa; also variously designated omp2, EnvB, large
CRP, and CT443 [55, 79]) and OmcA (12-15 kDa; also - confusingly - designated
omp3, EnvA, small CRP, and CT444 [55, 79]). The question of whether part ofOmcB
is surface localised is a matter of some debate. Evidence has been found that the protein
can bind to tissue culture cells known to be susceptible to chlamydial infection [80], that
it can be cleaved by application of trypsin to intact EBs [80, 81], that it binds heparin,
iv sodium N-lauroyl sarcosine
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and that monoclonal antibodies specific for the OmcB amino-terminal domain bind at
the EB surface [47]. These observations are consistent with surface exposure, and a
possible role in host cell attachment, as suggested earlier. Other studies, however, have
found OmcB unaffected by trypsin [55], or failed to find surface-exposed epitopes by
immunoelectron microscopy [82]. There seems to be consensus that the bulk of, if not
all, the molecule is localised on the inner surface of the outer membrane [81], and it has
been proposed that subunits composed of the carboxy-terminal portion of OmcB may
make up the hexagonal array seen in the EB periplasmic space [45]. OmcA is a
cysteine-rich lipoprotein that is not surface exposed, though it is probably attached to
the outer membrane via its lipid moiety [45]. A model of the cell envelope structure has
been suggested by Everett and Hatch [55] (Figure 2.1, p.23). It has been hypothesised
that the structural stability of EBs is maintained by disulfide cross-linking between
cysteine residues of MOMP, OmcB and OmcA [55, 83]. A similar supramolecular
structure is absent from RBs, which are osmotically fragile. Protein cross-linking
appears to occur during the last twenty-four hours of the intracellular phase of the life
cycle [84].
Another family of proteins, the polymorphic membrane proteins (Pmps) was first
identified by genetic analysis of a chlamydial strain that causes abortion in sheep [85].
Similar sequences were later described in other chlamydiae. Some of these proteins
resemble autotransporters, but no evidence of secretory activity has yet been uncovered
[45], and in the species causing human trachoma, only two of the nine Pmp proteins
predicted on the basis of genome analysis have been identified as constituents of the
COMC [86]. Alternative roles for particular Pmps have been proposed, including the
suggestion that PmpD may be a cytolysin producing host cell rupture at the time of EB
release [87]. The structure, intracellular location, regulation of expression, and likely
function of this family of proteins is presently an area of energetic inquiry [45].
All species of chlamydiae identified to date share a common lipopolysaccharide
(LPS) that differs from the LPS of other bacteria. The molecule is present in the outer
membrane of the cell envelope throughout the life cycle [88-90], and contains
polysaccharide epitopes recognised by the human humoral immune system [44,91].
2.1.3 Taxonomy
In 1980, when the Approved Lists of Bacterial Names were first published, the
chlamydiae had two species: Chlamydia trachomatts (CT) and Chlamydia psittaci [92,
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93]. In 1989, isolates previously identified as the TWAR strain of C. psittaci [94] were
proposed as a third species, Chlamydia pneumoniae; it was differentiated from other
chlamydiae on the basis of the shape of the elementary body, serology, and DNA
analysis [95]. Another group of strains originally classified as C. psittaci were
subsequently reassigned to Chlamydia pecorum, following further DNA and serological
analyses [96].
In 1999, then, the bacterial family Chlamydiales contained one genus, Chlamydia,
and four species: C. pneumoniae, C. psittaci, C. trachomatis, and C. pecorum. This
classification enjoyed broad-based support. An emended classification based on
ribosomal, biochemical, serological, ecological and DNA-DNA hybridization data was
published by Everett et al. in the International Journal of Systematic Bacteriology in
that year, reclassifying the family into two genera, Chlamydia and Chlamydophila,
which together contain a total of nine species [43]. C. trachomatis strains naturally
found in hosts other than man become new species within the genus Chlamydia.
Subsequent phylogenetic analyses of five protein coding genes and the ribosomal
operon are consistent with this revision [97, 98]. The new nomenclature has
nevertheless proven controversial [99, 100]. Fortunately, whether or not the proposed
changes enter general use, the designation of the pathogen responsible for human
trachoma will remain Chlamydia trachoma tis . Because the new nomenclature has not
yet gained widespread acceptance, the old classification will be used as the basis for
discussion here, with parenthetical reference made to the new classification where
appropriate.
2.1.4 Classification and tropism of C. trachomatis strains
Three biovars (groups of strains distinguishable from others of the same species on
the basis of physiological characteristics) of C. trachomatis were recognised before the
Everett et al. revisions: mouse pneumonitis (MoPn), lymphogranuloma venereum
(LGV), and trachoma.
The MoPn biovar gains species status (c. muridarum sp. nov.) in the new
classification. Two strains have been identified: MoPn, which is found in the
respiratory tract of mice, and SFPD, which has been isolated from the intestines of
hamsters [43]. Neither strain is known to infect humans, and neither will feature
prominently in this thesis.
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The other two C. trachomatis biovars preferentially infect man. They are closely
related, and have remained grouped as a single species in the reclassification of the
chlamydiae [43]. There are four serotypes or serovars currently included in the LGV
biovar, and fifteen in the trachoma biovar. Each of the nineteen can be distinguished
from the others on the basis of binding affinity for monoclonal antibodies. They can
also be differentiated by polymorphisms in the sequence of MOMP, or in the sequence
of the gene ompl , which codes for MOMP (see below). There is very limited variation
in these sequences between isolates of any given serovar [43]. Separation of LGV and
trachoma strains into two biovars is based on tissue tropism: LGV strains can invade
lymphatic tissue, while trachoma strains are restricted to mucosal epithelial cells.
The LGV serovars (LI, L2, L2a and L3) are rare. All are sexually transmitted,
though the eye may also act as the portal of entry. Infection is associated with a
suppurative adenitis, usually of the inguinal or perirectal nodes, as well as systemic
symptoms. The disease is most commonly seen in tropical and subtropical areas [44).
The trachoma serovars of C. trachomatis are designated by the letters A through 1(,
plus Ba, Da, la and Ja [43, 101]. Different serovars have different tissue preferences.
Serovars A, B, Ba and C are the usual ocular isolates from patients with clinical
trachoma in trachoma-endemic regions, while D to K, Da, la and Ja are typically
associated with genital tract disease. The latter group are the commonest causes of
urethritis and mucopurulent cervicitis in females, and non-gonococcal urethritis in
males. They have also been linked to female pelvic inflammatory disease, infertility,
ectopic pregnancy and chronic pelvic pain; male epididymitis, prostatitis and infertility;
neonatal conjunctivitis and pneumonia; and various arthritides.
Strains are tissue selective, rather than specific. Even where trachoma is endemic,
'genital' serovars are found in the eye. Serovars D [102, 103, 104], E [103, 104], F
[103-105], J [106], K [104] and L2 (with serovar A co-infection) [103], have all been
isolated from conjunctival swabs taken from individuals with typical clinical signs of
active trachoma. Similarly, 'ocular' C. trachomatis strains are not infrequently isolated
from the genital tract. Frost et al. determined the serovars of 435 isolates taken from
male and female attendees at sexually transmitted disease, perinatal and family planning
clinics in Canada, and found that 5% were serovar Ba and 2% serovar C strains [107].
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2.1.S Genome of C. trachomaiis
(8) Chromosome
Chlamydia trachomatis contains a single -1,043,000 base-pair chromosome [108].
The first gene to be analysed was that coding for MOMP, which was designated omp1.
In 1986, Stephens et al. sequenced omp1 from a C. trachomatis L2 strain, after cloning
and expressing the gene in an Escherichia coli Abacteriophage [109]. Comparison of
this gene with that from C. trachomatis serovars that were subsequently sequenced
revealed extensive amp} sequence variation. Most of the polymorphisms were
localised to four 4(}-90 base-pair-long variable domains (YOs), designated VDl, VD2,
VD3 and Y04, regularly distributed amongst the relatively conserved constant domains
(CDs). Examination of the accessibility of MOMP segments to digestion by proteolytic
enzymes suggests surface exposure of VD-encoded peptide sequences, with localisation
of the protein's amino- and carboxy-termini inside the periplasmic space [75]. Serovar
specificity of CT appears to be determined by particular residues within YO1,Y02 and
VD4 [75, 110]. Yuan et al. found that for each serovar, the VD coding for the most
hydrophilic and charged amino acid sequence contained the serovar-specific epitope
[111]. Later studies, though, indicate that amp1 of a given serovar can incorporate
multiple distinct serovar-specific epitopes, each of which may be found in a different
VD [110]. Collectively, these findings (Plus the demonstration that anti-MOMP
antibodies neutralise the organism [72, 73], as discussed above) indicate that the omp1
gene product, MOMP, spans the outer membrane of the cell envelope, and presents
immunologically important epitopes, coded for by one or more VDs, at the cell surface.
The likely biological function of this protein has already been discussed.
Heterogeneity in omp1 constant domains between urogenital and trachoma isolates
of the same Ba and C serovar has been identified. The altered nucleotide sequences
produce changes in the amino acid sequences of MOMP, and could potentially playa
role in determining tissue tropism or virulence of the organism [112]. More extensive
analysis by Stothard et al. of sixty-nine strains representing seventeen serovars has not,
however, supported an association between omp1 sequence and tissue tropism, disease
presentation, or epidemiologic success [101].
The first complete C. trachomatis genome sequence (a serovar D isolate) was
published by Stephens et al. in 1998 [108, 113]. Notable findings included the
localisation of an entire set of genes required for peptidoglycan synthesis (despite the
lack of demonstrable peptidoglycan in the organism, as discussed above), genes
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encoding ATP biosynthetic pathways (despite CT's apparent inability to make its own
ATP), and nine genes encoding putative Pmps, paralogues of which had just been
shown to be surface-exposed immunogens in a strain of C. psittaci (Chlamydophila
abortus gen. nov., sp. nov.) pathogenic to sheep [114, 115]. The genome sequence of a
C. trachomatis MoPn strain (c. muridarum sp. nov.) was subsequently also analysed,
which highlighted the presence of a 'plasticity zone' near the chlamydial chromosome's
origin of replication [116]. This zone includes genes coding for enzymes involved in
tryptophan synthesis. Ocular but not genital serovars of the CT trachoma biovar have
recently been found to carry a deletion or frame-shift mutation at this locus, rendering
the former unable to synthesize tryptophan from exogenous indole [117, 118]. This
finding is the first known point of difference in the biosynthetic capabilities of ocular
and genital strains [117].
(b) Plasmid
In addition to the chromosome, chlamydiae commonly possess an
extrachromosomal genetic element. The 7.4-kb plasmid pCT was first isolated from a
C. trachomatis L2 strain by Palmer and Falkow in 1986 [119]. Their studies identified
pCT DNA in laboratory strains of all the C. trachomatis serovars that cause human
infection, as well as in 200 separate clinical isolates. The plasmid is very highly
conserved, with less than 1% variation in nucleotide sequence [120, 121]. Because of
this sequence conservation, and because maintenance of superfluous extrachromosomal
DNA seems unlikely in a bacteria with a genome one quarter the size of that of E. coli,
it was suggested that the plasmid might be essential for chlamydial growth or
replication [119, 122]. However, several naturally-occurring C. trachoma tis strains
lacking the plasmid have since been isolated, including an L2 cultured from a patient
with proctocolitis [123], a genotype B variant cultured from a male urethral swab [124],
and a serovar E cultured from a male urethral swab [125]. Fortunately, such strains are
thought to be rare [121], and no plasmid-free ocular isolates have been reported to date.
Estimates for the mean number of plasm ids per EB include 10 [119] (determined using
a C. trachomatis L2 strain), 7-10 [126] (c. trachomatis L2), and 4 [127] (c.
trachomatis LI). This estimate, and the possibility of chlamydial infection without the
presence of plasmid DNA both have implications for determining the likely sensitivity
of some laboratory assays for CT, as will be discussed later.
What, then, is the function of plasmid genes? They are expressed during
chlamydial growth in eukaryotic cells [119]. Putative roles have been assigned to
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protein products of several loci, but few definitive conclusions can be drawn [121].
Tantalisingly, antibodies to pgp3, one of the proteins encoded by peT, have been found
in a high proportion of sera from HIV positive individuals who lack other laboratory
evidence of chlamydial infection [128], but are not found in healthy blood donors [129].
The significance of this finding is unclear.
2.2 NATURAL HISTORY AND CLINICAL FEATURES
Clinically, trachoma can be divided into its acute (active) and chronic or late-stage
manifestations, but acute and chronic signs can occur at the same time in the same
individual. In endemic areas, repeated episodes of active disease occur, particularly
during childhood, and are probably required for later development of the chronic
sequelae [130]. This concept will be briefly discussed in Section 2.4 (p.33).
The degree of distress caused by active ocular infection with C. trachoma tis ranges
from minimal to severe. Many infections are asymptomatic. In other cases, following
an incubation period of 5-10 days, conjunctival infection produces an irritable, red eye,
and scanty mucopurulent discharge. Involvement of the cornea in the acute
inflammatory process can cause pain and photophobia [131]. In general, symptoms are
milder than would be expected from the appearance of the eye [132].
The first sign of infection is a non-specific vasodilation of conjunctival blood
vessels [131]. Specific changes may be noted after infection of two to four weeks
duration, with the development of follicles subjacent to the conjunctivae of the fornices,
the tarsal plates, and the limbus. Follicles are lymphoid germinal centres, and are found
immediately below the epithelial cell layer. They are white, grey, translucent or yellow
masses 0.2-3.Omm or more in diameter [133]; those with a diameter less than 0.5mm
are not considered evidence of pathology. It is not uncommon to find one or two
follicles in normal healthy eyes, usually towards the lateral or medial canthi. Because
the superficial layer of the conjunctival stroma lacks lymphoid tissue until about three
months after birth [134], newborns are unable to mount a follicular response to ocular
chlamydial infection [135]. Papillae may also be noted at this stage: in mild cases, a
few isolated, small, red dots can be seen with the naked eye. With the aid of a slit lamp,
papillae appear as small swellings of the conjunctiva, each with a central vascular core.
When inflammation is severe, an intense papillary reaction on the tarsal conjunctiva is
associated with a diffuse thickening of the conjunctiva, obscuration of the deep tarsal
vessels, and sometimes, eyelid oedema. If the cornea is involved in the inflammatory
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process, a superficial punctate keratitis may be noted upon instillation of fluorescein
into the conjunctival sac. Superficial infiltrates or pannus" also indicate corneal
involvement. Follicles, papillae, and these corneal signs are features of active disease.
The signs discussed below are all manifestations of late-stage trachoma.
Resolution of follicles is accompanied by scarring of the sub-epithelial conjunctiva.
Scar deposition is most prominent in the upper tarsal plate, though the conjunctival
fornices, the bulbar conjunctiva and the upper part of the cornea may also be involved.
In trachoma-endemic areas, upper tarsal plate scar derived from repeated episodes of
infection can eventually accumulate to such an extent that it becomes visible
macroscopically after eversion of the upper lid, appearing as white bands against the
erythematous background of the conjunctiva. At the limbus, replacement of follicles by
scar results in the formation of depressions called Herbert's pits.
If sufficient scar accumulates, contraction of it over years will cause the upper
eyelid to turn inward so that the lashes rub against the globe. This is known as
trichiasis. When the whole lid margin is turned in, the condition is known as entropion.
Scars around the bases of hair follicles can pull individual eyelashes into contact with
the cornea, even without entropion [131]. Trichiasis is intensely irritating. Sufferers
may use home-made forceps to remove their own lashes, or attempt to keep their lids
elevated with strips of cloth tied round their heads.
Besides being painful, trichiasis damages the cornea. Collagenous scar is laid down
as part of the repair process. Because scars are opaque, vision can be affected by
scarring that involves the central part of the cornea.
2.3 PATHOLOGY
Histologically, active trachoma is characterised by the development of lymphoid
follicles subjacent to the palpebral, forniceal and bulbar conjunctival epithelium.
Follicles are dense collections of inflammatory cells, including B- and T-lymphocytes,
plasma cells, monocytes, and macrophages. Mature follicles have pale-staining
germinal centres surrounded by a mantle of proliferating lymphocytes. The nucleus of a
germinal centre contains metabolically active plasma cells [133, 136, 137]. A diffuse
infiltrate of plasma cells and polymorphonuclear lymphocytes, as well as some
macrophages, mast cells, and eosinophils, is seen in the conjunctival stroma between
v Subepithelial infiltration of fibrovascular tissue into the peripheral cornea. Duke-Elder believed that "some degree
of pannus is present in every case of trachoma" [28](p.1609).
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follicles, and between follicles and the basement membrane of the epithelium. Both
CD8+ and CD4+ T-lymphocytes are recruited as part of the inflammatory response to
acute infection, with CD8+ T-cells predominating [138]. Stromal capillaries are dilated
and engorged. A band of plasma cells lines the deep surface of the basement membrane
and surrounds the acini of accessory lacrimal glands. A few dendritic cells can be found
at the boundary between stroma and epithelium. The epithelium itself is generally
hyperplastic, though thinning is observed over follicles. Infected cells contain
inclusions [136, 137, 139].
In the conjunctivae of patients with late-stage trachoma (conjunctival scarring with
or without trichiasis or entropion), inclusion bodies are rarely seen. The conjunctival
epithelium is atrophic, with a reduction in the number of columnar epithelial cells;
goblet cells are absent [139, 140J. Infoldings of epithelium may form retention cysts
(pseudocysts of Henle's glands) containing inspissated secretions [140]. There is a
proliferation of fibroblasts, and deposition of vertically oriented, parallel collagen fibres
in a layer adherent to the tarsal plate. Newly-deposited collagen is predominantly of
type V, which is absent from the normal conjunctiva [141]. This scar tissue replaces the
normal thin, loose, vascular stroma, and causes apparent thickening of the tarsus [140].
Meibomian glands are infiltrated by lymphocytes, and are atrophic or deformed by
scarring, with thickening of the basement membrane around the germinative cell layer
[139, 140]. Plasma cells are rare in the stroma of patients with scarring trachoma,
unless there is concurrent active trachoma [142, 143]. The T-Iymphocytes found in the
Meibomian gland epithelia and stroma of these cases are predominantly CD8+. It has
been speculated that the CD8+ lymphocytes are suppressor T-cells involved in down-
regulating the anti-chlamydial immune response [143].
In the scarred cornea, there is degeneration and irregularity in the thickness of the
epithelium. Bowman's membrane may be destroyed. There is disorganisation of the
normal perpendicular orientation of the collagen lamellae in the stroma, sometimes with
calcification. Capillaries or ghost vessels may be seen in the superficial and middle
stromal layers [144, 145].
2.4 IMMUNITY AND PATHOGENESIS
In some areas hyperendemic for trachoma, most children have signs of active
disease [146, 147]. Only a small proportion go on to develop trachomatous corneal
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opacity. A brief outline of current concepts in immunity to ocular chlamydial infection
and the pathogenesis of trachoma blindness is presented below.
2.4.1 Factors attributable to the host immune response
The innate immune system responds to the presence of chlamydiae. There is an
influx of neutrophils to the site of infection, and production of pro-inflammatory
cytokines, including interleukin (IL)-Ia, IL-l{3, platelet-derived growth factor (pDGF)
and tumour necrosis factor (TNF)-a, by infected epithelial cells and conjunctival
macrophages [148-150]. Normal conjunctival cells do not express IL-I [150]. Infected
cells, on the other hand, release cytokines continuously from about 20 hours post EB-
entry; additionally, released IL-l a seems able to stimulate cytokine production in
adjacent, uninfected cells [151]. Based on animal models, it has been suggested that a
more florid innate response in the early stages of infection is associated with a shorter
duration, less intense infection, and therefore an improved outcome [149].
Unfortunately, inflammatory responses may be responsible for some of the tissue
damage attributed to infection, and may not necessarily clear the organism from the
epithelium. In a case-control study in The Gambia, subjects with scarring trachoma
were significantly more likely than controls to have TNF-a detectable in tears, and to
have a particular allele (-30BA) of the TNF-a gene promoter [IS2].
Strain-specific protective immunity against ocular or genital C. trachomatis
infection seems to be induced by repeated infection [IS3, IS4]. In trachoma-endemic
communities, induction of anti-chlamydial immunity seems likely to underlie the
observed decrease in the duration of both infection and disease with age, and the
increase in intensity of inflammation within the shorter disease episodes of older people
[ISS]. Precise mechanisms for the development of the adaptive immune response are
unclear; a brief description of conclusions drawn on current data is made difficult by the
variety of in vitro and in vivo models used, and the fact that responses to primary
infection and reinfection appear to differ [IS6]. Cytokines released as part of the innate
response (which are predominantly of the TH-l type) likely contribute to initiating
adaptive immunity, and both cell-mediated and antibody-mediated systems seem to be
recruited. Local mucosal and circulating antibodies are both produced [IS7]. MOMP-
specific antibodies are the first to be detectable [IS7]; as noted earlier, anti-MOMP
antibodies can block EB attachment and internalisation. Unfortunately, variant strains
that have MOMP sequences differing by as little as one amino acid are uninhibited by
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monoclonal or polyclonal antibodies that effectively neutralise the type strain [158]. It
seems likely that antibodies make a modest contribution to, but are not essential for,
protection [156]. It is also possible that anti-chlamydial IgG in tears actually enhances
the infectivity of CT for human conjunctival epithelium [159].
Cell mediated immune mechanisms (the TH-I response), and CD4+ cells in
particular, seem to be critical in clearing infection [156, 160]. There is evidence that
individuals who develop scarring do not have adequate anti-chlamydial TH-I responses.
In lymphocyte proliferation assays [161], peripheral blood mononuclear cells of
individuals with conjunctival scarring have reduced responses to CT antigens compared
to matched control subjects, but equivalent responses to other antigens [162].
CD4+ T-Iymphocytes recognise antigens presented in association with class II
major histocompatibility complex (MHC) molecules. Generally, class IImolecules are
not found on the conjunctival epithelium. In trachoma-endemic communities, however,
conjunctival epithelial cells of patients with ocular CT infection express class IIMHCs
[163]. In animal models, there is a marked increase in the number of CD4+ cells in
conjunctival tissue after experimental inoculation with CI' [138].
The TH-I cytokine interferon (IFN)-'Y has an uncertain role [149]. It has been
demonstrated to inhibit the growth of CT in vitro and in vivo, is important in mice for
the clearance ofCT infection [164], and is probably responsible for inducing expression
of MHC class II antigens on conjunctival epithelial cells in infected humans [163].
However, it may also induce a state of chlamydiallatency within the epithelium, or have
a direct cytotoxic action on infected cells [165]. CD8+ cytotoxic T lymphocytes
(CTLs), which recognise antigen presented by class IMHC molecules (found on all
nucleated cells and platelets) can lyse infected cells and produce IFN-'Y and other
cytokines. Cl-specific CTLs have been identified. Injection of this cell line into
immuno-naive mice can protect them against challenge with C. trachomatis. This effect
is dependent on both CTL-derived and non-CTL-derived IFN-'Y [164, 166].
1.4.1 Facton attributable to the organism
There is little to suggest that there are major differences in inherent virulence
between different ocular serovars of eT, though possible strain variation in
susceptibility to IFN-'Y has been hypothesised [167]. Several species-specific
characteristics deserve comment.
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Firstly, intracellular chlamydiae inhibit phagosome-lysosome fusion by
mechanisms that are yet to be defined [51]. This allows the organism to survive and
replicate within conjunctival epithelial cells.
Secondly, laboratory test-detectable infection sometimes persists in human
conjunctival tissue after the resolution of (or without) clinical signs [168, 169]. This
can be termed 'persistent' infection; unfortunately, there is no consistency in the
literature in the use of this term, Additionally, interrupted chlamydial development with
resultant chronic, laboratory test negative, 'cryptic' infection has been documented in
vitro [170-172]: if such a phenomenon occurrs in vivo, it is possible that a clinically
quiet, test negative human conjunctiva could nevertheless have a chronic C. trachomatis
infection. The natural history of infection and its relationship with clinical disease will
be mentioned again in Section 2.6.l2(iii) (p.66).
If a CT strain is able to establish chronic infection - regardless of the associated
clinical and laboratory profile - it represents either failure or subversion of the adaptive
immune response. It seems reasonable to assume that the greater the duration (and
intensity) of conjunctival infection, the greater the exposure of conjunctival tissues to
putative er -derived pro-inflammatory factors. Three such candidate molecules will be
briefly described.
(1) The chlamydial heat shock protein (hsp)-60 is homologous to HtpB of Coxiella
bumetti, GroEL of E. coli, and Hsp60 of Mycobacterium tuberculosis [173]. It induces
a delayed-type hypersensitivity response in the conjunctivae of previously sensitised
experimental animals [174]. In humans, serum antibodies to this protein have been
associated with scarring, though whether anti-hsp-60 itself contributes to
immunopathology or is simply found more commonly in people with long standing
infection is not known [175].
(2) In addition to genes for tryptophan synthesis, the plasticity zone of the Cf
chromosome contains genes encoding proteins homologous to the large cytotoxins A
and B of Clostridium difJicile [176]. Protein is preformed within EBs at the time of
cellular infection, and induces host cell rounding and cytoskeletal collapse - changes
identical to those induced by clostridial cytotoxin B. These putative Cl' cytotoxins also
have homology to the E. coli lymphostatin protein LifA, which inhibits lymphocyte
activation. Whether or not they are involved in mediating immune evasion in the
human eye is presently unclear [176].
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(3) Chlamydial proteasome-like activity factor, or CPAF, is a recently identified
protein secreted into the host cell cytoplasm [177]. It may be involved in down-
regulating expression ofIFN-,),-inducibleMHC class II [178], and constitutive and IFN-
,),-inducibleexpression of MBC class I [179] molecules by infected cells. It may
therefore help the organism to evade immune recognition.
2.4.3 Pressure of infection
A single episode of CT-stimulated inflammation resolves in weeks or a few
months, even without treatment [155]. Conjunctival scarring produced by a single
infection is unlikely to produce trichiasis. Grayston et al. [130] believed that repeated
re-infection over a number of years was required for the development of cicatricial
complications. In trachoma hyperendemic areas, however, recrudescence or reinfection
occurs within weeks or months of resolution of the previous episode of active disease
[180-182].
The number, duration and intensity of infections required for the accumulation of
significant scar in the human conjunctiva is not known. Laboratory and natural
experiments suggest that intermittent exposure, or even intense exposure of brief
duration, is insufficient:
First, eleven inoculations of live strains of C. trachomatis into the eyes of a near-
blind human volunteer over a seven year period, in addition to repeated challenge with
various heat-inactivated chlamydial materials, was not associated with clinical sequelae,
even after twenty years of follow-up [183]. Second, in 1965, Detels et al. [184]
reported the prevalence of clinical signs of trachoma in communities of Punjabi Indians
in British Columbia. The individuals examined, or their parents or grandparents, had all
emigrated from Punjab State in the years between 1905 and 1964. Before and during
that period, trachoma was hyperendemic in northern India [185]. Signs of trachoma
were rarely found in members of the community who were Canadian-born, suggesting
that the incidence of transmission in the displaced communities was low. In Indian-
born subjects over thirty years of age, the prevalence of blinding sequelae was 8%
amongst those who had lived in India for less than twenty years before emigrating, and
23% amongst those who had lived in India for between 20 and 39 years",
vi Insufficient data are provided in the peper to permit adjustment for age, which is a likely confounder in this
association.
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In contrast, progression of disease and development of blinding sequelae is well
documented in individuals who remain in hyperendemic areas. Nearly 30% of a cohort
of ninety-eight Tanzanian pre-school children who had severe inflammatory trachoma
(TI - see Section 2.5.4(ii), p.43) on at least three of four examinations in 1989 had
developed visible scarring at follow-up seven years later [186]. Of 523 adult women
with visible conjunctival scarring at baseline, forty-eight (9.2%) had developed
trichiasis within seven years: an average incidence of 1.3% per year for that cohort
[187].
Presumably, as Emerson et al. [188] have suggested, there IS a threshold
transmission intensity below which trachoma will cease to cause blindness in a
community. Exactly where this threshold lies, or even how it could be measured, are
presently matters only for speculation.
2.4.4 Patbogenesis of corneal opacity
Corneal damage by in-turned eyelashes is generally assumed to be the ultimate
mechanism for blindness due to trachoma. Unsurprisingly, then, trichiasis is a risk
factor for developing corneal scar. A longitudinal study of patients with cicatricial
trachoma in The Gambia showed the presence of trichiasis at baseline to increase seven-
fold the risk of corneal opacity twelve years later, compared to those who had scarring
but not trichiasis at baseline [189].
It seems likely that anatomical factors, such as the position of the insertion of the
pretarsal orbicularis (which will affect the direction of its pull on the lid), and the
relative strength of the marginal fibres of this muscle in comparison to the pretarsal
portion (which may determine the risk of tarsal plate inversion) will help to determine
how quickly corneal scar accumulates in patients who have conjunctival scar or
trichiasis [190]. Other features of the trachomatous eye likely also contribute. Scarring
of forniceal-mucous, lacrimal and Meibomian glands reduces their secretory output and
disturbs the tear-film architecture, drying the eye. Corneal drying accelerates
epitheliopathy. The concentrations of lactoferrin and lysozyme in tear fluid are reduced
[191], presumably due to a disproportionate reduction in the aqueous phase. All of
these changes, particularly when added to repetitive epithelial injury from misdirected
eyelashes, predispose the cornea to secondary bacterial and fungal infection. Such
infections generate an added burden of corneal scar. The use of traditional eye
medicines may also contribute to corneal damage [192].
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2.5 CLINICAL DIAGNOSIS
2.5.1 History
Because active trachoma is usually found in children, is an almost universal
experience of residents of hyperendemic communities, and seems to cause little
discomfort, there are generally few reported symptoms. Individuals with trichiasis can
be symptomatic. The degree of distress depends on the number of lashes touching the
globe, whether or not the cornea is abraded, and whether there is associated
blepharospasm. Symptoms have been described above in the paragraphs (Section 2.2,
p.31) on natural history.
2.5.2 Examination
Examination of the eye for the clinical signs of trachoma involves the careful
inspection of the lashes, cornea and limbus, then eversion of the upper lid and
inspection of the tarsal conjunctiva. Binocular magnifying loupes (2.5x) and adequate
lighting are required. Signs of interest are as described in Section 2.2 (p.31).
2.5.3 Differential diagnosis
Follicles are not pathognomonic for trachoma, but are a reasonably specific sign for
it when seen in individuals living in trachoma-endemic communities. The differential
diagnosis of follicular conjunctivitis includes adult inclusion conjunctivitis (caused by
infection with urogenital strains of C. trachomatis); other bacterial infections,
particularly Moraxella spp., Streptococcus pneumoniae and Borrelia burgdorferi; viral
infections, including adenovirus, molluscum contagiosum, and HSV; pediculosis
palpebrarum; and toxic conjunctivitis secondary to topical drugs or eye cosmetics. The
giant 'cobblestone' papillae of vernal keratoconjunctivitis ('spring catarrh') may be
mistaken for follicles at first glance, but are both clinically and histologically distinct
[134, 135, 193).
Papillae are poorly specific for trachoma. They form part of the conjunctival
tissue's response to many acute and chronic inflammatory disorders, and are therefore
seen in bacterial, viral and allergic conjunctivitides.
In trachoma-endemic areas, pannus, conjunctival scarring and trichiasis are nearly
always attributable to trachoma. Herbert's pits are pathognomonic of past trachomatous
inflammation. Corneal opacity, though, may result from a variety of causes, including
previous traumatic injury, severe measles, herpes simplex keratitis, or corneal ulceration
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of any cause: considered alone, the prevalence of corneal scar will overestimate the
contribution of trachoma to the total burden of blindness and visual impairment.
2.5.4 Grading systems
Grading systems are used in an effort to standardise diagnosis in field surveys and
research studies. In literature in English since 1900, at least ten different complete
systems or variations on systems have been published: by MacCallan, 1908 [194];
MacCallan, 1931 [27]; the WHO Expert Committee on Trachoma, 1962 [195]; the
Fourth WHO Scientific Group on Trachoma Research, 1966 [196]; Tarizzo, 1973 [197];
Dawson, Jones and Darougar, 1975 [198]; Dawson, Jones and Tarizzo, 1981 [132];
Darougar and Jones [133]; Tielsch, West, Johnson, Tizazu, Schwab, Chirambo and
Taylor, 1987 [199]; and Thylefors, Dawson, Jones, West and Taylor, 1987 [200]. (In
addition, Sarkies, 1965 [201] contributed a three-stage classification of trachomatous
entropion, which has been rarely, if ever, used by other authors.) The several variants
of the MacCallan trachoma classification [27, 194] were probably derived from a
description of the 'four stages of trachoma' by Aetus of Amida in the sixth century
[202], and were durably popular in the ophthalmological literature of the first half of the
twentieth century'", despite (a) implying that the clinical course is linear, ignoring
trachoma's multicyclic nature; (b) not mentioning corneal opacity or visual impairment,
and therefore having little prognostic value; and (c) lacking clear-cut definitions that
would allow one 'stage' to be reliably differentiated from the next [29, 132, 133, 198].
Some of the later schemes are exceptionally complex: the 1966 proposal by the Fourth
WHO Scientific Group on Trachoma Research, for example, took more than four pages
to outline, recommending the grading of up to nineteen signs, each of which had its own
scale [196]. Two classifications are in current general use and will be discussed here.
The others have largely been superseded.
(I) Dawson, Jones and Tarizzo, 1981 ('the modified WHO system' or 'tbe FPC
system')
This grading system was developed "to describe more precisely the intensity of
active trachoma" [198](P.279) than did the MacCallan classification. An embryonic
wi The MacCallan system still occasionally appears in papers in peer-reviewed journals: in 2000, the Paediatric
Infectioua Diseases Journal published the results of a Senegalese survey that usc:<!the MacCallan scheme [203]. It is
also described (alongside the WHO simplified system - see main text) in the Wills Eye Manual 3nt edition (1999), a
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version of the FPC system can be found in the 1962 WHO Expert Committee on
Trachoma Third Report [195]. Its evolution can be traced through a number of
subsequent publications [197, 198], before its appearance in final (for WHOviii) form in
the 1981 WHO manual "Guide to trachoma control in programmes for the prevention of
blindness" [132]. The modified system includes five signs, each of which is graded
independently in the right and left eye, as follows:
Upper tarsal follicles (F)
Fo No follicles
FI Follicles present, but no more than 5 in zones 2 and 3 together"
F2 More than 5 follicles in zones 2 and 3 together, but less than 5 in zone 3
F3 Five or more follicles in each of the three zones
Upper tarsal papillary hypertrophy and diffuse infiltration (P)
Po Absent: normal appearance
PI Minimal: individual vascular tufts (papillae) prominent, but deep
subconjunctival vessels on the tarsus not obscured
P2 Moderate: more prominent papillae, and normal vessels appear hazy, even when
seen by the naked eye
P3 Pronounced: conjunctiva thickened and opaque, normal vessels on the tarsus are
hidden over more than half of the surface
Conjunctival scarring (C)
Co No scarring on the conjunctiva
Cl Mild: fine scattered scars on the upper tarsal conjunctiva, or scars on the other
parts of the conjunctiva
C2 Moderate: more severe scarring but without shortening or distortion of the upper
tarsus
book intended as a consulting room reference for ophthalmologists, emergency room physicians, primary care
physicians and medical students [204].
riii Darougar and Jones published a minimally altered version of the system in 1983 [133]. For interobserver trials
conducted in 1987, Tielsch et al. [199] used a different version with (other) minor changes.
ix MForscoring follicles, the upper tarsal conjunctival surface is divided into three approximately equal zones. These
zones are defined by two imaginary lines which, as viewed on the everted ~sa1 surface, are approximately parallel
with the upper tarsaI border and curve upward towards their lateral extremities ... Zone I includes the entire upper
tarsal border and adjacent lateral tarsal surface; zone 2 occupies the area between zones 1 and 3 and extends to the
lateral quarters of the lid margin; zone 3 includes the tarsa1 conjunctiva adjacent to the central half of the lid margin
and, at its centre, covers just less than half the vertical extent of the tarsa1 surface." [132](P.14).
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C3 Severe: scarring with distortion of the upper tarsus
Trichiasis and/or entropion (TIE)
TlEo No trichiasis or entropion
TIEl Lashes deviated towards the eye but not touching the globe
T!E2 Lashes touching the globe but not rubbing on the cornea
TlE3 Lashes constantly rubbing on the cornea
Corneal scarring (CC)
CCo Absent
CC) Minimal scarring or opacity but not involving the visual axis, and with clear
central cornea
CC2 Moderate scarring or opacity involving the visual axis, with the pupillary margin
visible through the opacity
CC3 Severe central scarring or opacity with the pupillary margin not visible through
the opacity
The system selects the upper tarsal conjunctiva to provide an "index of
trachomatous inflammation in the eye as a whole" [132](p.14). The intensity of
inflammation is classified as trivial, mild, moderate or severe using Table 2.1, which is
reproduced here as it appears in the WHO guide. In that document, the meaning of "key
sign" is not explained.
Table 2.1: "Intensity of inflammation" classification scheme proposed by Dawson et al.
[132](p.14)
Intensity Follicles Papillae Key sign
Severe F3 (or F2 or Fit P3 P3
Moderate F3 P2 F3
Mild F2 Po, PI or P2 F2
Trivial (insignificant or Fo or F) Po, PI or P2 Fo orF)
absent)
Using this classification system (with a few minor alterations), Tielsch et al. [199]
found the intra- and inter-observer agreement of four well-trained, experienced
ophthalmologists working in the field to be variable and often poor. For non-specialist
• "The follicles may be obscured by severe papillary hypertrophy and diffuse infiltration (P3)" (132) p.14.
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health personnel, the modified WHO system is thought to be too complex [200].
However, it still enjoys a degree of popularity with some experts [205-207].
(ii) Thylefors, Dawson, Jones, West and Taylor, 1987 ('the WHO simplified
system')
The WHO simplified system [200] was designed as a cut-down version of the FPC
system, with which it was intended to co-exist. Thylefors et al. considered the
simplified scheme suitable for use by "less experienced observers" in ''population based
surveys or for the simple assessment of the disease at the community level"
[200](P.480). It provides considerably less information than the FPC scale. However,
the simplified system has enjoyed broad-based acceptance, and is now widely used in
research, community assessment and programme monitoring by both non-specialists
and ophthalmologists alike. It was used in the studies described later in this thesis, and
is therefore discussed in some detail here.
The system requires the examiner to assess an individual for the presence or
absence of each of five signs (Figure 2.3, p.44):
TF Trachomatous inflammation - follicular: the presence of five or more follicles at
least O.5mmin diameter, in the central part of the upper tarsal conjunctiva
TI Trachomatous inflammation - intense: pronounced inflammatory thickening of
the upper tarsal conjunctiva obscuring more than half the normal deep tarsal
vessels
TS Trachomatous conjunctival scarring: the presence of easily visible scars in the
tarsal conjunctiva
IT Trachomatous trichiasis: at least one eyelash rubs on the eyeball, or evidence of
recent removal of in-turned eyelashes
CO Corneal opacity: easily visible corneal opacity over the pupil, so dense that at
least part of the pupil margin is blurred when viewed through the opacity
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Figure 2.3: the WHO simplified system (photos from WHO trachoma grading card)
(a) Normal conjunctiva,
showing area to be examined
_--- --._
/' .........(' '>
\ /
/
......... /'
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(c) TI (and TF)
(e) TT
(b) TF
(d) TS
(f) CO
Preliminary testing of this system by its developers (after trialing and modifying a
pr lv d four observers each examining 179 cases [200]. The inter-observer
nt m ur m nt found in this study are presented in Table 2.2, as they
pp r d in th original paper.
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Table 2.2: Inter-observer agreement for the WHO simplified system: 'Second study'
from Thylefors et al. (1987) 200](P.4 79)
Sign Average K- statistic" K-statistic "range"
TF 0.70 0.66-0.74
TI 0.45 0.38 - 0.49
TS 0.75 0.67 -0.79
TT 0.76 0.68 -0.81
CO 0.68 0.48 - 0.71
Improved inter-observer agreement was reported from further trials of the system in
Tanzania [209]. This trial involved comparisons between an experienced
ophthalmologist who had participated in the original development of the system, and
two ophthalmic nurses and an ophthalmologist trained by that individual. Two separate
studies were performed to assess inter-observer agreement. In the first, 25 eyes were
examined by each of four observers, and the scores of the three others compared to
those of the instructor. In the second, a single ophthalmic nurse and the instructor
evaluated TF, TI and TS only, in 20 eyes. Results are shown in Table 2.3 and Table
2.4.
Table 2.3: Interobserver agreement for the WHO simplified system: 'First trial' from
Taylor et al. (1987) [209](P.486), following 3 hours training, 25 eyes
Sign
Grader Average K- statistic
2 3 4
TF 0.80 0.91 0.60 0.77
TI 0.66 0.71 0.88 0.78
TS 0.73 0.39 0.27 0.46
TT 1.00 1.00 1.00 1.00
CO 1.00 0.63 0.83 0.82
Table 2.4: Interobserver agreement for the WHO simplified system: 'Second trial' from
furthTaylor et al. (1987) r209](p.487) following several hours er training, 20 eyes
Sign K- statistic
TF 0.79
TI 0.95
TS 0.87
It is notable from these data that good agreement is not guaranteed even when the
observers under comparison are all qualified, experienced personnel trained by the same
iii The kappa (K) statistic is a measure of observer reliability for categorical data. It estimates the extent of agreement
not due to chance between two sets of observations of the same variable. Kappa has possible values between -I and
+ I, with -I indicating complete disagreement, and + I complete .agree~nt. ~dis and Koch (1977) set arbitrary
divisions for desaibing the relative strength of agreement associated ~th this measurement, as follows: <0.00 poor,
0.00-0.20 slight, 0.21-0.40 fair, 0.41-0.60 moderate, 0.6I-O.S0 substantial, O.SI-l.00 almost perfect [20S].
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teacher. The reliability of examiners with variable amounts of training, experience and
enthusiasm, operating under different conditions and at different times, or even of the
same observer over time, has not been determined, This is not unique to the WHO
simplified system [210], and has been a long-standing problem for evaluating trachoma
control interventions [211]. In fact, diagnostic reproducibility has been rigorously
proven for few signs in clinical medicine.
2.5.5 Comparability of grading schemes
The WHO simplified and FPC systems are often said to be directly comparable,
allowing derivation of simplified system grades from FPC grades without separate
assessment of patients. In the original paper describing the simplified system, Thylefors
et al. included a table comparing it with Dawson et al.'s FPC scheme (Table 2.5).
Table 2.5: "Comparison of the simple grading of trachoma with the grading used in a
more detailed system" from Thylefors et al.11987) [20Ql_fu_.480)
Simple system Detailed system [132] Implication[200]
TF F2 or F3 Presence of inflammatory trachoma
TI P3 Severe intensity of inflammation
TS c., C2 orC3 Presence of cicatricial trachoma
TT TlE20rTlE3 Potential!Y_disablin_g_lesion
CO CC20rCC3 Visually disabliI!8_lesion
This comparison is not strictly correct: the systems are not directly comparable,
though the discrepancies are relatively minor. A diagnosis of TF requires five or more
follicles in the central part of the upper tarsal plate, while F2 is defined as more than five
follicles (Le. six or more) in zones 2 and 3 together: the boundaries 'TF absent' v 'TF
present' and F, v F2 do not coincide. Additionally, the woolliness of the definitions of
conjunctival scarring in both systems make comparison of grades for this sign
problematic.
2.6 LABORATORY DIAGNOSIS
In general, the diagnosis of trachoma is made on clinical grounds. Laboratory
testing is typically unavailable or unatl'ordable for clinical care in trachoma-endemic
areas. Furthermore, the antibiotics used against active disease can usually be provided
at low or no cost to the patient, and are well tolerated by both children and adults,
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making presumptive treatment for suspected chlamydial infection a logical therapeutic
approach.
For research purposes, however, confirmation of the presence of C. trachomatis
infection may be necessary, for reasons that will be discussed later. Available assays
include microscopy of conjunctival scrapings, isolation in cell culture, direct fluorescent
antibody, enzyme immunoassay, serology, nucleic acid hybridization probes, and the
nucleic acid amplification tests.
2.6.1 Microscopy
Examination of stained conjunctival scrapings for C. trachomatis inclusion bodies
is the oldest method for detection of ocular infection. With Giemsa, the stain used by
Halberstaedter and von Prowazek [33] and the one still most commonly used [212-216]
until microscopy was superseded by superior diagnostic techniques, mature inclusions
appear as dark purple masses in the cytoplasm of epithelial cells. Iodine and acridine
orange are alternative stains [197]. Gram staining, however, is unreliable: the reaction
is negative or variable [44]. Microscopy requires trained technicians [212], is time
consuming, and is probably the least sensitive method for diagnosis [217].
Additionally, collection of conjunctival scrapings with a metal blade is painful and
unpopular [218]. The availability of less traumatic, more rapid and more sensitive tests
has displaced microscopy of scrapings to the sidelines of chlamydia diagnostics.
2.6.2 Cell culture
Chlamydiae are fastidious organisms. Successful culture relies on the use of rich
transport media (2-SP, M4) and strict maintenance of the cold chain during transport.
In the laboratory, clinical specimens are inoculated onto McCoy cells [103, 146, 171,
217-228], HeLa 229 cells [66, 69, 103, 229-231], or IA34 mouse fibroblasts [232].
Usually the cell layer is irradiated [197, 219], or pre-treated with cycloheximide [103,
146, 171, 217, 218,220,222-228], diethylaminoethyl dextran [66, 221, 229, 231, 233,
234], or mitomycin C [232] to enhance growth of the organism. The specimen is
centrifuged onto the monolayer to aid cellular infection, and the culture is incubated for
two to three days. Determining whether the culture is positive or negative requires
staining with iodine or Giemsa, or the use of labelled poly- or mono-clonal antibody
[235]. One or more 'blind passages' (in which apparently negative cultures are
homogenised and inoculated onto fresh monolayers) are usually performed to ensure
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that low-level infection is not overlooked. Identification of one inclusion is sufficient to
record a positive result [232].
Despite the high specificity of isolation, there are a number of problems associated
with using it as a diagnostic test. Inhibition of chlamydial growth in culture can, in
theory, be caused by cytokines or antibodies produced by infected tissues and
introduced into the culture medium with the clinical sample [236, 237]. Even when
using purified elementary body stock which (by definition) should be free of inhibitors,
data suggest that only about one EB in 200 is capable of successfully infecting tissue
culture cells [238]. Because the protocol for culture is complicated, there are multiple
opportunities for variation in factors that impact upon isolation efficiency and,
therefore, on sensitivity [239]. This makes it difficult to compare results between
laboratories, or even to compare one run to the next in the same laboratory.
Additionally, chlamydial culture is expensive, time-consuming, and requires specialised
expertise.
Though considered the gold standard for laboratory diagnosis and still legally
required to prove chlamydial infection in UK courts [232], it is now accepted that
isolation of C. trachomatis in cell culture is less than 100% sensitive [217, 227, 231,
232, 239, 240].
2.6.3 Direct fluorescent antibody (DFA)
Immunofluorescence is a technique for detecting cellular molecules. Reagents
labelled with fluorescent dye that bind specifically to target proteins are used. A
number of different immunofluorescence techniques are possible, depending on whether
sample antibody or antigen is the target molecule, and on whether the fluorescent dye is
attached to the reagent that binds to the sample ('direct immunofluorescence') or
attached to the reagent that binds to an intermediate reagent that binds to the sample
(,indirect immunofluorescence'). A direct fluorescent antibody (DFA) test, the Syva
Micro'Irak" (Syva, Palo Alto, CA, USA) was the first diagnostic instrument that used
monoclonal antibody against C. trachomatis, and began the move away from culture to
techniques that do not rely on chlamydial viability [241]. The MicroTrak uses labelled
antibody to detect a species-specific epitope in MOMP.
For the clinician, specimen collection for DFA is straightforward: conjunctival cells
and exudates from a swab are smeared onto a slide in the field or clinic, fixed with
methanol [217], and air dried. The slides are easy to ship and store [218]. In the
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laboratory, the fixed sample is stained with fluorescein-isothiocyanate-conjugated
monoclonal antibody, and examined under a fluorescence microscope. Chlamydial
inclusions are highlighted apple-green against the red background of conjunctival
epithelial cells. Performing an epithelial cell count provides a straightforward method
for determining the adequacy of the collected sample [242]. Samples taken from the
upper tarsal conjunctiva yield a greater concentration of infected cells than those from
the lower fornix [243].
The MicroTrak performed extremely well in initial sensitivity and specificity trials
[244], and the fact that specimens could be transported at ambient temperature to the
laboratory gave it a considerable advantage over tissue culture. As a result, the
MicroTrak has been widely used in trachoma research studies [103. 146, 168, 181,217,
222,223,226,245-247]. Comparison between studies is made difficult by the fact that
the threshold for defining a positive slide varies from one group of investigators to the
next. The major practical disadvantages with DFA are the reliance on the competence
of the microscopist, and the length of time required for screening, which averages more
than twenty minutes per slide [242].
Biological issues probably also affect the reliability ofDFA. Taylor et al., defining
a positive slide as one in which five or more EBs were seen, found a discordance of
10% within pairs of replicate DFA ocular specimens taken from the same individuals
five minutes apart [242]. This was attributed to sampling variation. Itwas felt unlikely
that this result was due to inadequate specimen collection in one or both of the samples,
since all the samples comprising the discordant pairs had satisfactory conjunctival
epithelial cell counts. Rather, discordance seemed to occur when a low chlamydialload
was present. Discordance within pairs of samples taken two to eight days apart was
22%, suggesting a degree of short-term biological variation in addition to the difference
attributable to sampling [242].
2.6.4 Enzyme immunoassay (EIA)
'lmmunoassays' include processes that test for specific antigens, and those that test
for specific antibodies. Enzyme-linked imrnunosorbent assays (ELISA), also known as
enzyme immunoassays (EIA), are designed to detect antigens or antibodies by
producing an enzyme-triggered colour change. For C. trachomatis, EIA usually refers
to an antigen detection test, using synthetic antibody to detect chlamydial antigen
contained in the specimen. The Abbott Cblamydiazyme" kit (Abbott Laboratories,
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North Chicago, IL, USA) [lSI, 217, 225, 24S] was the first EIA to be produced for
commercial release [249].
In the Chlamydiazyme, chlamydia) antigens are eluted from collected swabs in
specimen dilution butTer. An aliquot of sample eluate is placed in the well of a plastic
plate with a polystyrene bead, which adsorbs chlamydial antigens. Polyclonal rabbit
anti-chlamydial antibodies are added [250, 251]. Chlamydial antigens reacting with
these antibodies include epitopes of LPS and MOMP [252]. A solution of horseradish
peroxidase-conjugated goat antibody to rabbit immunoglobulin is then introduced [251].
Following a washing step to remove unbound components, a colourless substrate that is
transformed by peroxidase to a coloured product is added to the well. The presence of
chlamydial antigen-antibody complexes is demonstrated by measuring the colour
change with a spectrophotometer.
The Chlamydiazyme does not require immediate refrigeration of clinical specimens
following collection [253], and specimen processing can be completed in four hours
[249]. High throughput can be achieved. Ifprocessing is delayed, however, prolonged
sample storage can reduce the sensitivity of the test [242]. Specificity is also a problem.
Chlamydial LPS has at least two antigenic sites, one of which is also found on the LPS
of other bacterial species [254]. As a result, Staphylococcus aureus, Haemophilus
aegyptius, Klebsiella pneumoniae, Gardnerella vaginalis, Neisseria gonorrhoeae,
Escherichia coli, Streptococcus agalactiae, Moraxella lacunata, Chlamydia psittaci; the
Salmonella minnesota Re mutant, Acinetobacter Iwoffi and Acinetobacter calcoaceticus
var. anitratus, can all react in the Chlamydiazyme test [217, 250, 255, 256].
Conjunctival infection or sample contamination with any of these organisms could
therefore produce a false positive result. A confirmatory assay that selectively blocks
binding of the chlamydia-specific epitope can be used to separate true positives from
false positives, and thereby increase the specificity of the test [254].
Several commercial EIA alternatives to the Abbot Chlamydiazyme are available,
including the Syva MicroTrak EIA® (Syva, Palo Alto, CA, USA), and the Pathfinder
ElA e (Sanofi Diagnostics Pasteur (formerly Kallestad Diagnostics), Chaska, MN,
USA).
The Boots CellTech (later Dako) IDEIA ® (Boots CellTech, Slough, England) [171,
182. 224. 253. 257] incorporated a detection system with the potential for improved
specificity. using murine monoclonal antibody to chlamydial lipopolysaccharide (LPS)
in place of the polyclonal antibody used in the other tests [249, 252]. The detection
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principles were later further altered by attaching multiple copies of an anti-LPS
monoclonal antibody-alkaline phosphatase complex to a dextran backbone. In this
format, designated 'polymer conjungate enhancement' or PCE, each copy ofLPS in the
sample is able to capture multiple copies of the enzyme, resulting in dual amplification
of the signal [258].
A number of rapid 'point-of-care' tests using the EIA format are also available,
including Clearview Chlamydia" (Unipath, Nepean, Ontario, Canada) and the Quidel
QuickVue®(Quidel, San Diego, USA). The consensus on these tests seems to be that
they sacrifice sensitivity for speed [249, 259, 260).
2.6.5 Serology
The first serological test used for diagnosis was a complement fixation (CF) test
that detected serum antibodies against the polysaccharide antigens of LPS. Because
these epitopes are common to all chlamydial species [91], the specificity of the test was
low [261]. Additionally, it had low sensitivity for ocular infections [213].
The microimmunofluorescence (MIF) technique developed by Wang and Grayston
[262] was the first method used to classify strains of Chlamydia trachomatis into
serovars. The serovar-specific antigens delineated by this test can be used in an indirect
fluorescent antibody assay to detect anti-chlamydial antibodies in serum or tears, with
greater sensitivity than achieved with CF [261]. Serial dilutions of the sample are
placed on glass slides to which antigens of different C. trachomaus serovars have been
fixed (Individual Antigen Serovar Kit, Washington Research Foundation, Seattle, WA,
USA). Following incubation, the slides are probed with fluorescein-labelled anti-human
immunoglobulin. Testing for the presence of 19A, IgG and IgM can be performed
separately [242, 263].
Detecting antichlamydial antibody in serum is difficult, SUbjectiveand tedious, and
has poor specificity and poor reproducibility. The potential advantage of distinguishing
between acute, subacute and chronic infection is not borne out, even with the use of
paired acute and convalescent sera [261, 264], because production of IgM antibody is
not stimulated by ocular reinfection with a previously encountered C. trachomatis
serotype [261]. Its uses are limited. Tear MIF has better correlation with clinical
trachoma, but suffers from the same practical disadvantages [242].
51
2.6.6 Direct hybridization probe tests
Early attempts to use direct nucleic acid hybridization for the diagnosis of
chlamydia) infection used radiolabelled C. trachomatis DNA and autoradiography,
which required an exposure time of thirty-six hours or more. Itwas successfully used to
detect infected cells from tissue cultures, ocular swabs and cervical smears [221, 222].
Unfortunately, sensitivity was thought to be lower than culture [221]. Commercial
applications of the technique incorporate significant improvements.
The Gen-Probe PACE 2® (Gen-Probe, San Diego, CA, USA) is a nucleic acid
probe (NAP), or hybridization probe test. The probe is a synthetic single-stranded DNA
molecule complementary to a region of chlamydial ribosomal RNA (rRNA). The
sample is heated so that cells are lysed and rRNA released. The probe, labelled with an
acridinium ester (AE), is added; it forms a stable DNA:RNA hybrid with its target
sequence. Detection is performed with a 'hybridization protection assay': following
binding, 'selection reagent' is added, which hydrolyses the AB on unhybridized probes
and thereby deactivates it; the AE on hybridized probes is protected within the double
helix of the DNA:RNA complex. With subsequent addition of hydrogen peroxide,
bound acridinium ester releases a pulse of light that can be detected with a luminometer.
Because there are about 2000 copies of rRNA per chlamydial cell, high sensitivity is
achieved without amplification of nucleic acid [265, 266].
A second hybridization probe test, the Hybrid Capture I:r® (HClI, Digene,
Gaithersburg, MD, USA), uses an EIA to achieve signal amplification, and is therefore
classed as a nucleic acid probe/signal amplification assay, or NAPSA. Alkali is added
to the clinical sample to lyse cells and denature double-stranded DNA (separate it into
its two component strands). An RNA hybridization probe with nucleotide sequence
complimentary to chlamydial DNA is introduced; because the DNA has been denatured,
the probe can anneal to its target region. The RNA:DNA complex is then captured by
antibody bound to microwell plates. Antibodies labelled with alkaline phosphatase are
added to bind to the bound complex. After washing, the presence or absence of bound
DNA can be determined by adding a substrate for alkaline phosphatase: cleavage of the
substrate results in emission of light [265, 267]. The test is rapid and reproducible
[267], but, for the diagnosis of ocular chlamydial infection, direct hybridization assays
have been largely overlooked in favour of the nucleic acid amplification tests discussed
below.
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2.6.7 Polymerase chain reaction (peR)
The polymerase chain reaction is a technique for amplifying DNA: assays based on
it are part of the group of nucleic acid amplification tests, or NAA Ts. PCR uses the
enzyme DNA polymerase. A variant of this enzyme is found in the nucleus of all
replicating cells. In vivo, its function is to duplicate DNA during the cell's preparation
for its own division. In 1983, Mullis realised that exponential growth in the number of
copies of a target DNA sequence could be achieved in vitro if repeated rounds of DNA
polymerase-catalysed duplication were made to occur back-to-back [268, 269].
To undertake PCR, sample is added to a reaction mixture containing an excess of
deoxyribonucleotide triphosphates, heat stable DNA polymerase, and two primers.
Primers are short, synthetic oligonucleotides that flank the region to be amplified. One
primer is complementary to the sense (+)-strand, and one to the antisense (-)-strand at
the opposite end of the target sequence.
There are three phases of the reaction. All take place in the same vessel, but at
different temperatures. The mixture is first heated to a temperature between 90 and
95°C to denature DNA. At a reduced temperature, the primers anneal to their respective
binding regions. The mixture is then again heated to enhance the activity of the DNA
polymerase, which extends each chain from the 3' end of its annealed primer to produce
two double-stranded copies of the target sequence. Both of the two newly-synthesized
primer extension products contain the appropriate primer-binding regions, and, after
heat-induced separation from the target, can themselves function as templates -
alongside the original templates - in the next round of duplication. Multiple repetitions
of the denaturation I annealing I extension process therefore result in exponential
accumulation of the target. PCR is now usually automated in a thermal cycler, which
rapidly and reliably changes the temperature of the reaction vessel to provide
appropriate conditions for each stage of the amplification process.
peR was originally developed as a method for detecting the changes in the (3_
globin gene that underlie sickle cell anaemia [269]. Its uses, though, are far more wide-
ranging. peR is ideally suited to the detection of DNA of fastidious and non-
cultivatable infectious agents, since it does not rely on the presence of viable organism
in the sample. The tirst bacterium for which a PeR-based detection method was
published was Chlamydia trachomatis [270].
A number of different nucleic acid sequences have been used as targets in peRs for
the detection of C. trachomatis. These include the chlamydial cryptic plasmid (PCT)
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[105, 225, 231, 257, 271], ompJ coding for MOMP [225, 234, 270-272], the gene
coding for 16s rRNA [225, 231, 273], and omp2 coding for OmcB [79, 274]. With the
exception of peT, all of these targets are sequences found on the Cf chromosome,
which includes two complete rRNA operons, and single copies of ompJ and omp2.
peR directed at plasmid genes [257] or ompl [234] is thought to be both sensitive
and specific for the diagnosis of C. trachomatis infection. Primers designed for the
chlamydial rRNA gene amplify this DNA sequence in C. trachomatis, C. psittaci and C.
pneumoniae [231], which reduces the specificity of the assay. The omp2-based peR
has also been found to return positive results on samples containing any of these three
species; subsequent restriction endonuclease digestion and gel electrophoresis permits
species and strain identification of isolates [274), but this assay has not been extensively
utilised in published studies to date.
Mahoney et al. [225] estimated that plasmid-based peRs are between 10 and
10,000 times more sensitive than peRs directed against chromosomal genes. This is
probably at least partly attributable to the presence of multiple copies of the plasmid per
chlamydial cell [225,257,271]. Baileyet al. [206] also suggested that using a plasmid
target gives greater sensitivity. Using serial dilutions of DNA standards, they calculated
the lower detection limit of their plasmid-based peR to be 1 to 10 EBs, compared with
10 to 100 EBs for a PCR against ompl.
A commercially produced peR kit, Amplicor Chlamydia'" (Roche Diagnostic
Systems, Branchburg, NJ, USA) targets a 207 base-pair sequence within peT. An
aliquot of prepared sample is added to the peR master mix, which contains heat stable
polymerase, an internal control (see below), two biotinylated primers, cofactors,
deoxynucleotide triphosphates (dNTP), and the enzyme AmpErase® (uracil-N-
glycosylase). The dNTP deoxyuridine triphosphate (dUTP) is included in place of
deoxythymidine triphosphate (dTTP). Together, the substitution of thymidine by
deoxyuridine in the reaction mixture (and therefore, ultimately, in the amplified
product) and the addition of AmpErase help to prevent DNA produced during peR
from contaminating subsequent runs [275]. AmpErase degrades DNA containing
deoxyuridine by breaking the deoxyribose chain at the Cl position. Naturally-occurring
DNA does not contain deoxyuridine, and is therefore not a substrate for the enzyme. As
the reaction mixture is heated in the first thermal cycling step, any contaminating
product DNA molecules are cut into short oligonucleotides by breakages induced at
each deoxyuridine residue, rendering them non-amplifiable. AmpErase becomes
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inactive above 55°C, and, because the reaction vessel is held above this temperature for
the duration of the amplification process, the target amplicon is not affected. Following
amplification, before the reaction mixture has a chance to cool, AmpErase is destroyed
by immediate addition of 'denaturation solution' [276].
Denaturation after cycling also separates the double-stranded amplified product into
single strands of DNA. An aliquot of the reaction solution is placed in a microwell to
which oligonucleotide probes complementary to the pCT target sequence have been
bound. Specific amplified product hybridizes to the probes, and the microwell plate is
washed. Avidin horseradish peroxidase conjugate is then added, which binds to any
amplicon that has been captured in the microwell. After another washing step,
hydrogen peroxide and 3,3',5,5' -tetramethylbenzidine (TMB) are added; bound
horseradish peroxidase catalyses the formation of a coloured compound from the TMB.
Optical density (OD) can be read with a photometer [276].
Reproducibility problems have been reported in a very small proportion of samples
tested with the Amplicor assay, with results obtained from multiple aliquots of the same
specimen yielding ODs ranging from negative (00<0.200) to the upper positive limit of
the photometer (00)3), even when tested in the manufacturer's own laboratories [277].
Similarly, the result obtained from a peR using primers for peT does not invariably
correspond to that from a PCR using primers for omp1 [277]. Possible explanations
include contamination of peR tubes, contamination of the microwell plates used in the
detection step, non-specific binding of primers during amplification, non-specific
hybridization during detection, a very low concentration of organism, technical errors,
or the presence of inhibitors that undergo time-dependent inactivation [277-279].
Investigation of the reasons for these inconsistencies is still ongoing [280].
The possible presence of inhibitors to DNA amplification within samples needs to
be kept in mind. They can be found in specimens obtained from the conjunctiva and
from the urogenital tract [168, 226, 281]. Inhibition may in some instances be
overcome by prolonged storage prior to processing, which presumably allows time for
degradation of the inhibitory factor [226, 278, 282], sample dilution [168, 226, 279,
281], freezing at -7WC [279], or heat treatment at 95°C for 10 minutes [281]. The
Amplicor assay gives the user the additional option of monitoring each individual test
for inhibition by including an internal control (K') in each amplification reaction. The
Ie is a synthetic nucleic acid sequence with primer binding regions identical to those of
the test-specific target, and a randomised internal sequence that has similar length and
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base composition to the target. As a result, the Ie and the target region of the plasmid
from the clinical specimen are co-amplified with equivalent amplification efficiency.
The probe binding region of the Ie is unique, allowing reliable differentiation from
plasmid DNA [276]. Post-amplification, detection of the target and Ie are undertaken
separately. A positive test for amplification of the IC indicates that PCR was not
inhibited, and therefore that inhibition was unlikely to have produced a false negative
result.
The nature of peR, in which small quantities of DNA are exponentially multiplted,
makes it inherently vulnerable to spuriously positive results following contamination of
samples during collection, preparation and processing. Airborne target DNA in the
laboratory is a particular danger [257]. Use of separate laboratory zones for sample
preparation, amplification and detection; restriction of sample handling to negative
pressure safety cabinets; stringent adherence to procedures for decontamination; and
inclusion of negative controls all help to protect (and demonstrate protection of) the
integrity of results. Similar precautions must also be taken to safeguard reliability of the
other nucleic acid amplification tests, described below.
Roche also produce an automated version of the Amplicor system, known as the
Cobas Amplicor", For urogenital swabs and urine, the two formats appear to have
comparable sensitivity and specificity [283].
2.6.8 Ligase chaiD reaction (LCR)
DNA ligase is an enzyme that links (ligates) fragments of DNA, by inducing the
formation of phosphodiester bonds between the 5' phosphate of the first fragment and
the 3' hydroxyl of the second. Its function is to repair 'nicks' in the phosphodiester
backbone of double-stranded DNA, so will only catalyse the linkage of DNA fragments
that are annealed adjacent to each other opposite their complementary sequences. LeR
uses this enzyme as part of an iterative process of denaturation, annealing and ligation.
Prepared specimens are added to a reaction mixture containing heat stable ligase,
and two pairs of labelled oligonucleotide probes. One probe of each pair is labelled
with a capture hapten, and one with a detection hapten. Sample DNA is denatured by
heat. The two probes in each pair hybridize adjacent to each other, one pair binding to
the sense strand, and the other to the antisense strand of the denatured target. DNA
ligase seals the nick within each pair of juxtaposed probes, forming products that can
serve as targets for the next round of the reaction. Repeated cycling effectively results
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in amplification of covalently-linked DNA probe pairs dually-labelled with both capture
and detection haptens, in subtle contrast to the target amplification ofPCR [284].
In gapped LCR, DNA ligase functions alongside DNA polymerase in a process that
combines LCR with PCR. Each pair of probes is designed to anneal to adjacent regions
on the same strand leaving a gap of a few nucleotides. This gap is filled by DNA
polymerase. DNA ligase then joins the 3' probe of each pair to the intervening
nucleotide sequence [285].
The Abbott LCxill (Abbott Laboratories, Abbott Park, IL, USA) targets a sequence
of pCT [286] in a gapped LCR that is now widely used for laboratory diagnosis of
genital and ocular infection. Its detection step employs microparticle-bound antibody to
the capture hapten, which is then collected in a glass fibre matrix. Unattached detection
hapten is washed away. The presence of attached detection hapten is revealed through
the use of an enzyme immunoassay [284]. Because DNA ligase is inhibited by even a
one base-pair mismatch near the inner ends of the probes (at the site of the nick), high
specificity is obtained without the use of an oligonucleotide hybridization probe in the
detection protocol [287]. Unfortunately, Lex lacks an internal control, so there is no
inbuilt check for inhibition of amplification.
2.6.9 Strand displacement assay (SDA)
The strand displacement assay was developed as an alternative to peR and LeR for
amplifying target DNA sequences. Fundamentally, SDA is a variant of the polymerase
chain reaction. It uses a restriction endonuclease to create a nick in one strand of
double-stranded DNA. and an exonuclease-deficient form of the Escherichia coli DNA
polymerase I (or equivalent) to extend from the site of the nick whilst displacing intact
the downstream complement of the target [288]. Because repeated denaturation is not
required. the reaction can proceed isothermally.
The BDProbeTec~T (Becton Dickinson, Franklin Lakes, NJ, USA) is a
commercially-produced SDA that targets c. trachomatis plasmid DNA. It incorporates
a real-time fluorescence detection system, allowing amplification and detection to occur
in the same sealed microwell. This reduces specimen handling, and minimises the
potential for cross-contamination through release of amplified DNA from the reaction
tube [289, 290]. The assay is rapid, simple, and requires little in the way of hands-on
time from laboratory staff. According to the manufacturer, as few as ten to fifteen C.
trachomatis EBs can be reliably detected [289]. No published studies have used either
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SDA or the next assay discussed, transcription mediated amplification, for identifying
chlamydiae in ocular swabs.
2.6.10 Transcription mediated amplification (TMA)
Transcription mediated amplification mimics the RNA replication strategy of
retroviruses, producing an RNA amplicon by means of complementary DNA (cDNA)
intermediates [291]. It can be used against any type of nucleic acid target. The
commercial assay developed for detection of C. trachomatis, the Gen-Probe AMP-CT
(Gen-Probe, San Diego, CA, USA), is directed against ribosomal RNA. Reverse
transcriptase (RT) and RNA polymerase are used to achieve amplification. A primer
binds to target rRNA, allowing RT to make a DNA copy by extending the primer from
its 3' end. The rRNA of the DNA:rRNA hybrid is degraded by the RNAase-H activity
of RT. A second primer binds to the cDNA, and RT extends it to complete a double-
stranded DNA molecule. The first primer includes a promoter sequence for RNA
polymerase; this enzyme now recognises that promoter and transcribes 100-1000 copies
of RNA, each of which can serve as template for RNA-dependent DNA synthesis
catalysed by RT. Like the SDA, TMA can be carried out without thermal cycling.
Detection is performed using the same hybridization protection assay technique
described earlier for the Gen-Probe PACE 2 [266].
2.6.11 Quantitative peR
Culture, DFA and the first generation of EIAs can be optimised to function as semi-
quantitative techniques. Unfortunately, these tests lack sensitivity. The nucleic acid
amplification tests discussed so far (which are highly sensitive) are purely qualitative.
The difficulty with using nucleic acid amplification for quantification is the exponential
nature of DNA reproduction: small changes in amplification efficiency will produce a
large change in the amount of DNA produced [292]. In other words, the amount of
DNA present at the end of forty peR cycles may depend as much on minor variations in
reagent concentrations, the properties of any contaminating DNA, or the presence of
inhibitors, as it does on the amount of DNA present in the original sample. Small
between-tube variations on the same run may be caused by temperature differences
along the heating block, and other factors that are difficult to characterise. In addition,
as will be explained below, peR amplification efficiency changes as the reaction
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proceeds. Reliable quantification of a sample can therefore not be achieved by
comparing end-PeR yield with that of an external control [292].
In each peR cycle (i), the number of copies of product at the end of the extension
step (Pi) is determined by the number present at the end of the previous cycle (Pi-I) and
the efficiency of DNA synthesis in that cycle (E,.:a number between 0 and 1) [293].
Pi = Pi-I + (Pi-I x Ei) (1)
An alternative way of expressing this is
Pi = Pi-I x (1 + Ei) (2)
The amount of product after the first cycle is therefore given by
(3)
and after two cycles by
Pz=p/ x (I +Ez) (4)
Substituting equation (3) into (4):
Pz = Po x (l + EJ)(I + Ez) (5)
After n cycles, the amount of product present will be given by
"P.=Pox(OO +Ei»
;-1
(6)
where
•
0(1+Ei) = (1+EI)(1 + E2)(1 + E3) ... (1 + Ell) (7)
;.1
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P" can be determined with a spectrophotometer once thermal cycling is complete,
but this alone is unhelpful in determining Po, because the values of E; are not known.
This problem can be solved in one of two ways. In relative quantification (co-
amplification, or end point quantitative PCR), a known amount of unrelated DNA
(standard) is co-amplified with the sample (target) in the same reaction tube, and the
amount of both the standard and target sequences measured at the conclusion of the
reaction. Assuming that the amplification efficiencies E[s] (for the standard) and E[T]
(target) are the same in each cycle'", the ratio of the amounts of the two sequences after
peR will reflect their starting ratio [293].
The alternative solution is kinetic quantitative peR. A PCR can be considered to
have three phases: (1) an early background phase, in which the background signal
(often, for example, fluorescence) from the detection system is greater than the signal
generated by the amplified product; (2) an exponential phase; and (3) a plateau phase,
when amplification efficiency falls due to a build up in inhibitory reaction products, the
concentration of polymerase becoming limiting, and product renaturation competing
with primer binding during annealing [294].
Figure 2.4: peR profile. The signal (shown on the vertical axis) is related to the amount
of amplified product, and in this example has been acquired once per cycle.
(l)=background phase, (2)=exponential phase, (3)=plateau phase (modified from
Rasmussen (2001) [294]).
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.. The efficiency of the reactions can change over the course of the amplification period, provided E[s] and E[T]
change synchronously [293].
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Kinetic quantitative peR assumes that E is constant in each cycle. Because this is
only true during the exponential phase, the background and saturation phases of the
reaction must be disregarded. If E is constant, equation (6) becomes
(8)
If} is the number of cycles that elapse between two successive measurements ofP,
II'E = -1 + (Pi/ Pi:;) 'J (9)
To ensure that E has remained constant up to the point at which the last
measurement of product is made, E must be estimated at least twice. As a result, the
number of copies of target present in the reaction vessel must be determined three or
more times during amplification. To prevent the underestimation of E, it is critical that
the method used to detect the target gives a signal linearly dependent on the amount of
product present, or, if compression of the signal occurs, that this is compensated for.
Once the value of E has been calculated, Po can be derived from the measured amount
of product by rearranging equation (8) [293]:
(10)
True kinetic (or 'real-time') peR can be achieved by having the reactions take
place in closed, optically clear glass vessels, and analysing product generation by
detection and quantification of a fluorescent reporter after each extension step. This
eliminates the need for repeated tube opening and post-PCR processing, improves
accuracy, reduces the risk of sample contamination, and enhances automation [293,
295). The LightCycler (LC, Roche Molecular Systems, Branchburg, NJ, USA) has
been designed using these principles. It uses glass capillaries as reaction vessels [296].
Samples are loaded into bulbs at the top of the capillaries and spun into columns at the
capillary tips by centrifugation [297]. Prepared capillaries are placed in a circular
carousel that rotates within the Lighteycler's cylindrical sample chamber. A heating
cartridge and venting fan control the temperature of the chamber. Because the heat
capacity of air is low, the volume of the capillaries small and their surface to volume
ratio high, cycling can be rapid, the requirement for expensive reagents is minimised,
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and the temperature of the reaction mixture is homogeneous. The fluorescent signal,
generated by one of a number of alternative reporter systems (see below), is obtained
from each capillary during the elongation phase, by sequentially positioning each tube
in a beam of photodiode-generated light. Data can be displayed as fluorescence v cycle
number (in the manner of Figure 2.4, p.60) in real time for each sample [297].
Three different approaches to fluorescence monitoring have been developed.
(1) Double-stranded DNA (dsDNA) binding dyes include ethidium bromide
[298, 299], YO-PRO-l [300] and SYBR® Green I (Molecular Probes, Eugene, OR,
USA) [301]. These dyes are intercalaters: they bind to double-stranded but not single-
stranded DNA. However, because some background fluorescence is detectable even in
the absence of dsDNA, and because higher concentrations of dsDNA show
proportionally Jess fluorescence (presumably because the amount of dye is limiting'")
[301], the fluorescence intensity is not linearly proportional to the concentration of
dsDNA. As a result, the graph of fluorescence intensity against time or cycle number
will not be the same as [dsDNA] against time [299]. Calibration using a graph of
fluorescence v [dsDNA], which can be generated using samples containing known copy
numbers, is required [299].
Double-stranded DNA dyes bind to all double stranded DNA. This makes them
economical, but means that the non-specific products that accumulate after multiple
cycles of amplification will result in the generation of a fluorescent signal.
Characterisation of the DNA product by gel electrophoresis [297] or melting curve
analysis [302, 303] is important to ensure specificity. The latter technique involves
continuous monitoring of fluorescence throughout a complete temperature cycle.
Denaturation can be observed as a loss of fluorescence as the temperature passes the
melting point, which is dependent on the length, G+CIA+T ratio, and sequence of the
product [302]. Additionally, modified forms of DNA polymerase, such as
HotStarTaqTM (Qiagen) can be useful for maximising specificity: this enzyme has no
activity at ambient temperatures, being activated by a fifteen minute 95°C incubation
step prior to the first amplification cycle. As a result, no misprimed products or primer
dimers are formed during setup of the PCR [304]. Accurate quantification oflow copy
number samples is then limited only by stochastic effects [303].
(2) A number of methods rely on release of fluorescence quenching. Dual-
labelled hydrolysis probes have two covalently bound fluorophores. Upon irradiation,
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one of the fluorophores (e.g. fluorescein [301] or 6-carboxy fluorescein (FAM) [295])
transfers resonance energy to the other (e.g, rhodamine [301] or 6-carboxy-tetramethyl
rhodamine (TAMRA) [295]) rather than fluorescing. This is termed 'quenching'.
Probes are designed to anneal to an internal region of the target sequence. Polymerase
replicates DNA to which the probe is bound, and its 5' -exonuclease activity [305]
cleaves the probe between the points of attachment of the donor (reporter) fluorophore
and the quencher. When excited by incident light, the reporter will emit fluorescence,
the intensity of which increases in proportion to probe cleavage. No signal is generated
in the absence of product [301]. TaqMan® probes (Applied Biosystems) use this
approach.
Molecular beacons are oligonucleotide probes with reporter and quencher
fluorophores bound at either end, and 5' -terminal and 3' -terminal sequences that are
complementary to each other. As a result, when the oligonucleotide is free in solution,
it assumes a hairpin shape, bringing reporter and quencher dyes into close
approximation. This suppresses reporter fluorescence. When the probe binds to the
amplified product, it undergoes a conformational change, separating reporter and
quencher by sufficient distance to permit fluorescence on irradiation [306].
(3) Two separate specific oligonucleotide probes can also be used. One is
labelled with a donor fluorophore, such as fluorescein, and one with an acceptor
fluorophore, such as LightCycler Red 640 [307, 308] or CyS [297, 301]. The two
probes are designed to independently hybridize (in head-to-tail conformation) to
adjacent sequences on the amplified product, which results in very high specificity
[307]. Incident light excites the donor fluorophore. Excitation energy is transferred to
the acceptor, which emits fluorescence. No fluorescent signal is generated in the
absence of product [301].
Ompl and plasmid sequences of C. trachomatis have both been used as targets in
quantitative PCR assays developed for the LightCycler. This will be discussed further
in Section 7.1.2 (p.176).
1.6.12 Correlation or laboratory tests with clinical signs of trachoma
Advances in techniques for the laboratory diagnosis of C. trachomatis have
generally been driven by the requirement for improved detection of urogenital
infections. As a result, the bulk of the literature examines their utility in that setting.
Iii IfSYBR Green I is used at high concentration «1:7000 dilution), it inhibits amplification [301].
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This analysis considers only the relationship of test positivity with clinical signs of
ocular disease, and only uses results of studies using either the FPC or WHO simplified
grading schemes. Where information from trachoma treatment trials has been included,
only baseline (pre-treatment) data are presented. Data are shown in Appendix 1 (p.192).
The data suggest that - even in areas hyperendemic for trachoma - not all
individuals with active disease test positive for ocular CT, regardless of the assay
employed. Equally, the absence of signs is no guarantee of a negative result.
Hypotheses for the poor correlation of laboratory tests with clinical findings fall into
three categories: wrong test result; wrong clinical diagnosis; and true finding.
Consideration of the last of these possibilities may help us further elucidate the natural
history of human ocular chlamydial infection.
(i) Factors influencing the accuracy of the test
Collecting a conjunctival swab or scrape involves sampling cells. If the intensity of
infection is low, the proportion of conjunctival cells that are infected will be low, so the
number of chlamydiae collected in a fixed number of sampled cells will have Poisson
distribution. Chance (sampling variation) will determine the likelihood that one swab
contains sufficient cells with sufficient numbers of EBs and RBs to exceed the test's
threshold for returning a positive result.
Unfortunately, it is impossible to collect a fixed number of conjunctival cells.
Factors affecting cell yield include the intensity and maturity of infection; the
abrasiveness and absorptive ability of the swab; the force with which the swab is
applied; the speed, distance travelled and rotation of the swab head; the subject's
reaction to the procedure; and the presence of any pathology rendering the conjunctival
tissues more friable. The relative contribution of antigen or nucleic acid from free EBs
within extracellular fluid is equally difficult to quantify.
Trachoma is usually found in more remote communities of poor countries.
Suboptimal storage conditions and delays in shipping or processing can be expected. In
these circumstances, deterioration of the sample between collection and testing is
possible, and may affect test performance [169, 309].
Occasional technical errors and minor variations in protocol are inevitable, and may
affect the reliability of any assay. Inadequate sampling of conjunctival epithelium
(particularly in children unwilling to submit to examination), or cross-contamination of
samples at the point of collection are both potential problems. In the laboratory, several
64
tests are particularly operator dependent: microscopy, culture and DFA each demand
expertise, patience, and concentration; microscopy and MIF are by nature somewhat
subjective.
Billion-fold amplification of chlamydial nucleic acid in the NAATs raises the
possibility of cross contamination of samples that are subsequently tested in the same
laboratory.
Some substances present in ocular specimens might inhibit chlamydial growth in
tissue culture. Some substances present in ocular specimens inhibit DNA or RNA
polymerase, DNA ligase, or reverse transcriptase. The Amplicor kit gives the user the
option of specifically checking each assay for successful amplification, and strategies
(such as preheating the specimen to 95°C) that inactivate some inhibitors of nucleic acid
amplification have been empirically determined. Equivalent steps to exclude the
presence of growth inhibitors in culture would be more expensive and time-consuming.
Some assays target epitopes (EIA for LPS) or genes (peR for rRNA or omp2) that
react with similar molecules in organisms other than C. trachomatis. Even when the
target is specific, non-specific nucleic acid amplification or non-specific hybridization
during detection can theoretically occur, producing false-positive results.
The existence of plasmid-free strains of C. trachomatis has already been mentioned
(Section 2.1.5(b), p.30). The usefulness of Amplicor and LCx as diagnostic tools
depends critically on the fact that these strains are extremely rare.
(U) Factors influencing the accuracy of clinical diagnosis
Currently accepted thresholds for clinical diagnosis of trachoma exclude some
individuals with good evidence of disease [206]. For example, using the WHO
simplified system [200], five follicles in the central part of the upper tarsal conjunctiva
is labelled 'active trachoma', while four follicles (assuming there are no other signs of
trachoma) is called 'normal ,xiv. In both the WHO simplified system and the FPC
system [132], pannus (once considered a sine qua non of diagnosis [202, 310]), and
follicles seen at the limbus or in the fornices must be ignored.
Conversely, both grading systems force a diagnosis of trachoma on individuals with
inflammatory conjunctival disease of other aetiology. As already mentioned, papillae
IIiY The presentation by Thylcfors et al. of "Normal conjunctiva" under the heading ''The grading system and its use"
[2(0)(P.478) (rather than separately - in the ~troduction to the s~te~ ~or ex~le) was unfortunate, since it can be
interpreted as indicating that the scheme has. SIX mutuall~ exclusive clinical dlV1slOn~. In fact, TF, TI, 1'8, IT and CO
can all be seen in the same eye at the same time. Each Sign needs to be graded as being present or absent.
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ar p or! predi ti of chlamydia! infection when seen in the absence of follicles, or in
an r a of 10 trachoma endemicity. It has also been postulated that the characteristic
trachomatou folli ular reaction may be elicited by non-chlamydial stimuli in
indi idual ithahistoryofacti etrachoma[311].
In bri f th n, th clinical grading schemes in current use have imperfect sensitivity
and p if it . Final judgement of diagnostic tests on the basis of a comparison with
th pres ne or ab ne of the standardised signs is inappropriate.
(iii) Factors relating to the natural history of infection
It is conc i able that in the absence of any clinical signs of disease, some positive
tests r pr nt transient contamination of the eye with an inoculum too small to
establi h inti lion of pithelial cells (Figure 2.5(a)).
Th r is good e iden e that the development and resolution of signs lags behind the
start and fini h of th p nod of laboratory positivity by DFA and EIA [181] (Figure
2.5 b. imilar off: t between laboratory evidence of infection and clinical status has
b n noted u in P R [206]. In other words, it is possible that active disease may
be om lini II appar nt \ eks to months after infection, and that a similar period
m n 1 arance of infection (or cessation of bacterial shedding) and the
di appearan lini al disease [206]. Additionally, 'persistent' (Figure 2.5(c)) and
, rypti igur 2.5(d» c. trachomatis infection have both been hypothesised, as
m ntion in ection _.4.2 (p.35).
Figur 2. : Hypoth siz d models for the relationship between infection, disease, and
t t p iti it following introduction of C. trachoma tis into the conjunctival sac ( .. = C.
Ira hall/ali ina ulum
(a) Two Inocula fail to establish productive conjunctival infection
I I
1~(f;Sii
Time
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(b) Inoculum establishes productive infection, which results in the appearance of clinical
signs of active trachoma
I
EPITHELIAL INFECTION
ACTIVE TRACHOMA
'" ,'h' NAAT POSITIVE'~
Time
(c) 'Persistent' infection
I Persistent infection
EPITHELIAL INFECTION
ACTIVE TRACHOMA
NAAT POSITIVE
Time
(d) 'Cryptic' infection
I Cryptic infection
EPITHELIAL INFECTION
ACTIVE TRACHOMA
NAAT POSITIVE
Time
2.6.13 n iti ity and pecificity of laboratory tests
ulture h long be n regarded as the 'gold standard' of Chlamydia diagnosis
b eau it it is thought to be near-perfect. Its sensitivity is known to be
inf tion status has therefore been impossible to determine and,imp rG t. Tru
num ri al alu ign d to the specificity or sensitivity of diagnostic tests vary
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significantly from one estimate to the next. Despite this, such values are routinely
quoted.
Newer tests, such as the NAATs, are believed (for biological reasons) to be more
sensitive than cell culture. Investigators comparing the performance of these tests
against that of culture assume that at least some of the apparent false positives (by the
new test) are actually true positives that have been missed by culture. To estimate the
performance characteristics of the new test, these apparent false positives are often
evaluated using 'discrepant analysis'. In this procedure, gold-standard-negative, new-
test-positive samples are further tested by one or more other appeal assays; the return of
one or more positive results from these assays labels the sample a true positive. In
evaluating the nucleic acid amplification tests for C. trachomatis, the appeal tests used
have typically been other NAA Ts, often using a different method of amplification or a
different target nucleic acid sequence [312-314].
Hadgu has argued that discrepant analysis is fundamentally flawed, because the
restriction of retesting to the apparent false positives must upwardly bias sensitivity and
specificity estimates for the new test, regardless of the accuracy of the appeal tests used
for resolution [314, 315]. In fact, any test used for resolution, no matter how
ridiculous". can only improve or leave unaltered the calculated sensitivity and
specificity of the new test [316]; the magnitude of the bias depends on the underlying
prevalence of disease and the independence of the appeal and new tests [312, 316].
This criticism has provoked vigorous and often heated debate [313, 317, 318-324].
Despite the rancour, there is probably broad acceptance that nucleic acid
amplification tests represent a significant advance in the diagnosis of chlamydial
infections. They appear to be significantly more sensitive than assays available
previously, with the potential to detect chlamydiae "beyond clinically relevant levels"
[287](P. 731). Using dilutions of purified EBs, and assuming the presence of 10
plasmids per organism, Shattock et al. estimated the detection limits of the Cobas
Amplicor, Amplicor plate kit, and LCx assays to be approximately 1-2, 2-4, and 2 EBs
(per tested aliquot) respectively [325]: several orders of magnitude better than the
sensitivity estimated by Miyashita and Matsumoto [89] for IDEIA. Additionally, the
NAA Ts seem to be highly specific. Quality control in manufacturing and the skill of
the user may now be more likely to affect NAAT accuracy than the underlying
biological characteristics of the assay [280].
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2.6.14 The place of laboratory tests in community assessment
In the Surket district of Nepal in 1997, Baral et al. examined all children aged one
to ten years from six arbitrarily chosen villages. Forty-six of 726 children (6%) had
clinical signs of active disease (TF and/or TI) in the right eye. Swabs were taken from
the same eye of all those with active disease and a random selection of one in eight of
those without active disease. All samples were negative by an LCR directed against
pCT and by an LCR directed against ompJ. Microscopy disclosed the presence of non-
chlamydial bacteria on three of fifteen swabs: gram-negative bacilli consistent with
Moraxella sp. on two slides, and gram-positive cocci consistent with Streptococcus
pneumoniae on one. It is possible that these and other organisms are able to reproduce
the clinical picture of active trachoma, particularly in those who have previously had a
follicular reaction to ocular chlamydial infection [311]. In a separate study in low
prevalence areas of Nepal and China, only 8% of clinically active cases were LCR-
positive [326]. Additionally, even in hyperendemic areas, the correlation between
disease and infection appears to worsen following antibiotic treatment [327].
Using highly sensitive assays for C. trachomatis, the lack of evidence of ocular
chlamydiae in populations with a low but measurable prevalence of signs of active
trachoma raises the question of how elimination of trachoma from an area will be
certified. Absence, or a very low prevalence of C. trachomatis conjunctival infection in
a representative sample of the population, proven by nucleic acid amplification tests,
may ultimately be required. The expense of this method of assessment could be
reduced by pooling specimens [327, 328]. Diamant et at. have determined that if the
expected population prevalence of infection is around 10%, up to fourteen specimens
can be pooled per test without overly widening the confidence interval of the resulting
prevalence estimate.
2.7 EPIDEMIOLOGY AND MECHANISMS OF TRANSMISSION
2.7.1 Global prevalence and geographical range
WHO defines blindness as visual acuity in the better eye of less than 3/60 with best
possible refractive correction, which predicts the inability to safely walk without
assistance. There are thought to be some 5.9 million people in the world who fulfil this
criterion because of corneal opacity secondary to trachoma. It is the second most
common cause of blindness, after cataract [25].
nMc:Adam(316). for ~Ie. suggests tossing a coin.
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In addition to those already blind, an estimated ten million need surgery for
trichiasis, 146 million have active infection, and some 600 million people live in
trachoma-endemic areas in Africa, the Middle East, and parts of Central and South
America, Asia, Australia, and the Pacific Islands [24, 25]. Because of global population
growth and reductions in mortality from acute infections, Schachter and Dawson have
suggested that - in the absence of effective control measures [329] - the prevalence of
trachomatous blindness is likely to increase in the future [330].
2.7.2 Patterns of distribution
Within endemic areas, the distribution of disease is heterogeneous. Some
communities are badly affected, while others with seemingly similar community-level
risk factors (see below) are not. In affected communities, clustering of active disease by
sub-village [331], compound [228], and bedroom [228] has been noted. This clustering
at different scales is reminiscent of fractal geometry [332].
2.7.3 Risk factors for active trachoma
<a>Poverty and crowding
Taking a global view, it is readily apparent that highly-endemic trachoma is found
almost exclusively in poor countries, with occasional pockets of disease in
disadvantaged populations of the industrialised West. It is a disease associated with
poverty'" and sociocultural, economic or geographic upheaval [28, 333-337]. In all of
these circumstances, overcrowding is typical.
At a finer epidemiological level, a number of studies have shown an association
between risk of active trachoma and the number of people per unit of sleeping area, or
number of people per sleeping room, in the house [338-343]. Usually, all infected
members of a household harbour the same C. trachomatis serotype [130] and strain
variant [240]. Sharing a bedroom with an active case doubles one's risk of having
active disease [224]; individuals who live in endemic villages but who sleep in
bedrooms by themselves are unlikely to have signs of active trachoma [228]. These
findings would seem to underline the importance of intra-familial transmission, long
thought to be important in sustaining trachoma [102, 344, 345]. They probably reflect
an increased risk of exposure to infected secretions that results from a scarcity of living
niDuke-Elder observed that trachoma was "overwhelmingly associated with the dirt, squalor and intimate proximity
of the poorer classes" (28)(p.1 596).
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and sleeping space. The "frequent, unrestricted, and indiscriminate mixing of ocular
contacts or of ocular discharges" was called "ocular promiscuity" by Jones [29](P.19).
Poverty and population transition are also often associated with poor nutrition and
inadequate access to water and sanitation, both of which have been examined as
possible risk factors for trachoma: see below.
(b) Age and exposure to children
The prevalence of both clinical active disease and laboratory evidence of infection
generally decline with age after a peak in early childhood [146, 155,331,345-354]. In
a cross-sectional survey in a hyperendemic area of central Tanzania, for example, the
prevalence of active disease was 60% in pre-school children, falling to 8% in 15-35
year olds, and 2% in those over the age of 55 [331]. It has therefore been postulated
that the bulk of the ocular CT reservoir in a community is found in children, and that
children constitute the major source of organisms for transmission to others. Congdon
et al. evaluated 460 adult Tanzanian women for clinical signs of trachoma, and
determined whether or not they were currently taking care of children aged between one
and seven years; lived with, but did not care for such children; or did not have one-to-
seven year old children in the house (controls). The age-adjusted odds ratio for active
trachoma rose significantly with increasing current exposure to young children [355].
As was mentioned in Section 2.4.1 (p.34), although the prevalence of active
trachoma falls with age, Bailey et al. [155] have suggested that this may result from a
decrease in the duration of each disease episode, with the difference in the incidence of
disease between old and young being less marked. The intensity of inflammation, in
contrast, may increase with age [155].
(c) Gender
In cross-sectional surveys, females are consistently more likely to have every sign
of trachoma [146, 331, 353, 356]. Usually the difference between the genders is
minimal in childhood and increases with age, though one Tanzanian survey suggested
that female pre-school children were already twice as likely to have constant TI as male
pre-school children [357].
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(d) Education
In an island-wide trachoma survey in Taiwan in 1960-61, Assaad et al. noted that
households in which the head had a job in the professional, administrative or executive
category had the lowest prevalence of active trachoma. Clerical and sales workers,
workers in service and transport occupations, miners and craftsmen, and farmers and
fishermen headed households with progressively higher prevalences of active disease
[338]. A similar trend was noted in 1960 in Jordan [358]. Parental illiteracy has been
shown to predict children having active trachoma, and cicatricial trachoma, in Ethiopia
[359], and having active trachoma in the Sudan [360]. In a survey of 10,559 children
under ten years of age in Mali, Schemann et al. found that children whose fathers had
spent at least one year at primary school were significantly less likely to have active
disease than those whose fathers had not. Maternal education was of marginal
significance in this study [361], but the analysis may have been made difficult by the
very low level of female enrolment - in 1990, less than 16% of Malian girls of primary
school age were school-enrolled [362]. The association of trachoma with parental
education may be confounded by exposures related to poverty (Section 2.7.3(a), p.70)
or hygiene (Sections 2.7.3(e) and (f), immediately below).
(e) Water and face-washing
Trachoma is typically found in dry dusty regions where water is scarce. In a
number of settings, increased distance of a household to the nearest water source has
been found to correlate with an increased risk of trachoma [340, 343, 351, 363-365],
and with younger age of disease [363]. The biological explanation for these
associations is not proven. It is postulated that decreasing the required distance that
people must travel to collect water might increase the volume of water collected and so
increase water availability in the household, which might in tum increase the likelihood
that some water is allocated for personal hygiene activities. Dirty faces (ocular
discharge, nasal discharge, food on the face, dust on the face, flies on the face) are
associated with the presence of active trachoma [343, 351, 366] xvii, and increased
frequency of face washing in a household or community seems to reduce trachoma
prevalence [339, 367]. Face washing might impact trachoma by decreasing the
nii As wt:st eI al. [366) acknowl~ge, ocular er infectio~ stimulates pr~uct~on of eye and nose discharges.
Discharges attract flies. These Signs could therefore be nsk f~tors for l.nfectJOn,markers of existing infection, or
both. The distinction may be hard to resolve, but the hypothesis that a dirty face predisposes to infection of the eye is
worth supporting because facial cleanliness is potentially subject to change through education.
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accessibility of infected secretions to flies and fingers, which are putative carriers of
infectious inocula; by washing fly-attracting substances off both infected and yet-to-be-
infected faces; or by removing chlamydia-free secretions that could provide a portal of
entry for the organism into a new eye. Similarly, hand washing might reduce
transmission of trachoma if fingers provide a mechanism for carriage of chlamydiae
from infected to uninfected eyes [188).
Unfortunately, some of the links in this distance to water - household availability -
hygiene - trachoma chain are not corroborated by published data, or are supported by
some findings and not by others. For example, a recent study in Ethiopia found that
trachoma was actually more common in households fifteen minutes walk or less from
the nearest water source than it was in households located sixteen to thirty minutes from
water [359]. The relationship between the prevalence of trachoma and daily water
consumption is variable: more trachoma has been found in households with lower water
use in Morocco [368) and in The Gambia [369), but no association was found in a study
in Tanzania [340]. Several studies have failed to find an association even between the
distance to water and daily per capita water usage [340, 368]. It may be that when
water availability is restricted, families value it too much to waste it washing clothes or
faces, and so do not use much even when a source is located near the house [363].
Caimcross and Feachem have suggested that there may be a plateau effect: water
consumption increases as the distance to the source decreases, up to the point at which
the journey time from the household to the source and back is reduced to thirty minutes.
According to their hypothesis, if the distance to water is reduced still further, no
additional increase in consumption is seen until the source is actually located within the
compound [370].
It is possible that some other socioeconomic or environmental factor is linked to
proximity to water, and independently protects against trachoma. In other words,
distance to water may be a confounder. In nineteenth century London, trachoma was a
problem of sufficient magnitude to inspire the foundation of Moorfield's Eye Hospital
[371], yet few Londoners then or now would complain that the city suffers from a lack
of rainwater. From a trachoma control point of view, the important question is this:
does provision of water sources closer to the household or community, or conducting an
intervention to encourage improved personal hygiene actually impact trachoma?
Unfortunately, no rigorously controlled intervention study to evaluate the effect of
an improved water supply on the prevalence or severity of trachoma has been performed
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[188, 363]. A community-randomised trial examining the effect of an intensive face-
washing education programme on the prevalence of trachoma has shown such an
intervention to be effective in reducing the prevalence of severe active trachoma in
children [367], and will be discussed in Section 2.8.3 (p.84).
(I) Flies and latrines
Synanthropic flies (flies that live in close proximity to humans) have been
suspected to be vectors of trachoma for more than 400 years [188]. Recently, several
pieces of evidence seem to have confirmed this association.
In hand-net collection studies in trachoma-endemic villages in The Gambia, the
bazaar fly (Musca sorbens) has been shown to make 90% of fly-eye contacts, with the
house fly (M. domestica) accounting for the remainder [372]. These fly species are able
to carry viable C. trachomatis, both externally and in their gut, and to transmit active
trachoma from the eyes of experimentally-infected to disease-free guinea pigs [373].
In trachoma-endemic communities, household fly density, as measured by the 'fly
board' method [374], is significantly associated with active trachoma [374], with
intense active trachoma (TI) [351], and with a positive DFA for ocular C'I' infection
[146]. The number of flies landing on an individual's face during a five-second facial
inspection is an even stronger risk factor for trachoma, as well as being easier to
determine than a household fly count [375]. Emerson et al. found that two of 395 flies
caught from the eyes of children with clinical evidence of active trachoma in The
Gambia were PeR-positive for C. trachomatis plasmid DNA [372]. Some
trachomatologists have used this unexpectedly low level of chlamydial DNA carriage
by flies to downplay the suggestion that they are important in transmission. However,
in areas hyperendemic for malaria, prevalences of 1% or less for Plasmodium
falciparum infection of Anopheles mosquitoes are not considered unusual [376], and
Plasmodium has a much more complex relationship with its mosquito intermediate host
than the simple mechanical transfer hypothesised for carriage of Chlamydia by eye-
seeking flies.
The most useful data on the role of flies in transmission come from intervention
studies. Two community randomised trials in The Gambia have shown a reduction in
the number of new prevalent cases of active trachoma in villages in which flies were
controlled with insecticide [377, 378]. Because M. sorbens preferentially breeds on
human faeces [378] but is not found emerging from the drop holes of pit latrines [372],
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and because a number of surveys have associated having a household latrine with
decreased risk of disease [341, 351, 359, 364], it seems intuitive to suggest that
improved availability and use of latrines could reduce muscid fly density and the
prevalence of trachoma. A community randomised trial designed to demonstrate this
showed evidence of such an effect, but lacked sufficient power to definitively prove the
impact of the intervention [378].
(g) Cattle
In Kongwa, children between the ages of one and seven years are more likely to
have active disease if the family herds cows [340]. Cattle herding is also associated
with a positive DFA [146]. De Sole [379] undertook a cross-sectional study in
Ethiopia, examining the prevalence of active trachoma in villages with and without
cattle. Active disease was over twenty-six times more prevalent amongst cattle herders
than amongst camel herders. Within cattle herding communities, trachoma was less
prevalent in a village that had been formed by individuals who had lost their cattle herds
in a recent drought. De Sole, whilst admitting that confounding factors (ethnicity,
location, behaviour) could not be excluded, postulated that cattle ownership was
associated with the transmission of active trachoma because cattle manure encouraged
flies. Though there is some evidence from The Gambia that human faeces is the
optimal (and preferred) larval medium forM sorbens, and that the flies caught from the
eyes of children are from the same population as those found emerging from human
faeces, females of this species can and do oviposit on the manure of cows and other
domestic animals [380]. It has therefore been suggested that positioning cattle pens
away from living quarters might be effective in reducing household fly density [379,
381]. No proof of this hypothesis exists.
(b) NUtritioD
In Mali, night blindness and Bitot spots - the clinical features of vitamin A
deficiency - seem to be associated with active trachoma, even after controlling for
socio-economic status [361]. In the only study published to date that examines the
effect of overall nutritional status (measured in that study by mid upper arm
circumference), no association was found between malnutrition and the presence of
either active or severe active trachoma [382]. However, this study had a relatively small
sample size. Severely malnourished children are known to have low peripheral blood
7S
concentrations [383] and abnormal function (384] of T-Iymphocytes, as well as
abnormal delayed-type hypersensitivity responses (384]: the possible link between
nutrition status and trachoma may warrant re-examination.
2.7.4 Extraocular reservoin of C. trachomatis
From 128 children living in three trachoma-endemic villages in Egypt, Malaty et al.
were able to isolate C. trachomaiis in cell culture from nasopharyngeal swabs of eight
children (6%), rectal swabs of nine (7%), and conjunctival swabs of thirty-six (28%).
Two children were culture positive only from the nasopharynx, and five only from the
rectum [220]. A study in Kongwa District, Tanzania, examined swabs taken from
inside the nostrils of 232 randomly-selected children; sixty-two (27%) were positive for
C. trachomatis DNA by peR [246]. Nasal swabs were more likely to be positive in
children with clinical evidence of active disease, or who had PeR-positive eye swabs.
No animal reservoirs of human C. trachomatis strains have been identified [43,
135.385].
2.7.S Mechanisms of transmission
The actual mechanisms of transmission of ocular C. trachomatis infection are
unproven. Factors associated with increased risk of active disease suggest that flies,
fingers, and fomites could be involved in carriage of EBs from infected to uninfected
eyes within the family environment. The potential role of droplet transmission seems to
have been ignored. Given that there are good data on nasopharyngeal carriage of C.
trachomatis [220, 246], and that the aerosol route is accepted as a transmission
mechanism for Chlamydia psittaci (Chlamydophila psittaci) and C. pneumoniae
(Chlamydophila pneumoniaei [44, 386], this possibility probably deserves investigation.
2.7.6 Risk fadon for cicatricial trachoma
(a> Age
The prevalences of TS and TT [186, 189, 339, 346, 350, 352-354, 387-389] and
trachomatous corneal opacity [189, 346, 387, 388] all increase with age, as would be
expected from the natural history model outlined in Section 2.2 (p.31). A 1987 survey
of a village in the Nile Delta appears to show the prevalence of cicatricial disease rising
more or less linearly with increasing age above the 3-5 year age group, with 90% of
residents aged twenty-five or over showing moderate or severe conjunctival scarring
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[350]. Munoz et al., though, used age-specific prevalence data from a large cohort of
Tanzanian women to estimate age-specific incidences of conjunctival scarring, trichiasis
and corneal opacity in a hyperendemic area. The incidence of each condition seemed to
increase with age, suggesting that the chronic manifestations of trachoma develop at an
accelerating pace as individuals get older [387].
Surgical management of trichiasis will be discussed in Section 2.8.1 (p.80). In the
Sultanate of Oman, trichiatics over sixty have a higher incidence of post-surgical
recurrence than their younger counterparts [390].
(b) Gender
Conjunctival scarring occurs more commonly in women [102, 171, 186, 331, 348,
350, 353, 354, 358, 359], as does trichiasis [331, 339, 348-350, 353, 364, 389, 391,
392J. In fact, women may have up to a four-fold increased risk of trichiasis compared
to men in some areas [331]. In cohorts of patients who already have trichiasis, females
have a significantly increased risk of recurrence of trichiasis after corrective lid surgery
[390], and of developing visual impairment [392] compared to males. A national
survey of blindness and low vision in The Gambia suggested that women were three
and a half times more likely than men to have visual impairment as a result of trachoma
[393].
(c) Poverty
Turner et al. conducted a case-control study of trichiasis in rural Tanzanian women.
They found a positive association between a subject having trichiasis and the number of
deaths amongst her children. It seems likely that this finding relates to, for example, the
socioeconomic status of the mother or the family's access to health care, rather than
representing a causal association [391]. In Tunisia, Dawson et al. found that type of
housing was associated with the presence of conjunctival scarring or trichiasis in people
over fifteen years of age, with those living in single-family dwellings, multiple-family
dwellings and tents having progressively higher prevalences of these signs [346].
(d) Edue.don
In Tanzania, adult education sessions are held in many villages. Topics may
include nutrition, disease prevention and health, child care, and literacy. Turner et al.
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identified never having attended these classes as a risk factor for trichiasis [391]. It is
possible, though, that this association is confounded by socioeconomic status.
(e) Family history and genetics
Tuner et 0/. 's study suggested that women with trichiasis are three and a halftimes
more likely than age-matched control women to have a mother who had trichiasis [391].
Genetic analysis was not performed, but it could be hypothesized that genetic
polymorphisms at loci important in hypersensitivity or scarring might be involved.
Alternatively, the predisposition of members of certain families to develop
complications of trachoma could be another marker for socioeconomic status, or just
demonstrate the importance of transmission of infection between family members.
(I) Cumulative CT -induced conjunctival inflammation
The excess risk of scarring and trichiasis borne by women is usually thought to
result from increased exposure to ocular C. trachomatis infection, related to the
traditional role of women as primary caretakers of young children. Congdon et al.
evaluated the prevalence of signs of trachoma in Tanzanian women with different levels
of exposure to young children (as determined at the time of the survey), and found no
trend for cicatricial trachoma, though there were significant associations between caring
for children and active trachoma in women (mentioned above), and between trichiasis
and currently caring for at least one child with active disease [355]. Obtaining accurate
information on chronic exposures (such as lifetime contact with young children) is
inherently difficult, and was not attempted in this study. In fact, few papers examine
environmental risk factors for the late complications of trachoma.
The few longitudinal studies that have been published seem to support a link
between inflammatory trachoma and later development of scarring. InTunisia, even the
presence of moderate to severe inflammation at a single examination carried an
increased risk of severe conjunctival scarring fourteen or more years later [330].
Another study in Tanzania [186] suggested that constant, severe trachoma (defined as
the presence of severe inflammatory trachoma (TI) on at least three of four
examinations over the course of a year, at baseline) was associated with the presence of
conjunctival scarring after a seven year interval. It is unclear whether these individuals
have high levels of exposure to infection, an increased susceptibility for development of
severe inflammation, or both [186].
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However, West et al. calculated the population attributable risk percent (the
proportion of disease in the study population attributable to the exposure) of their
constant, severe trachoma variable, and estimated it at only 28%. This implies that most
scarring occurs in individuals who do not have this sign, and that control measures
should not be targeted solely at those with prolonged, severe disease [186].
(g) Cumulative exposure to other conjunctival irritants
In the Turner et al. study, sleeping in a room with a cooking fire during the
childbearing years was associated with nearly double the risk of trichiasis [391]. In
Saudi Arabian men, kohl (an ancient eye cosmetic made from crushed lead sulphide ore
and applied to the inside of the eyelid with a special applicator or the fingers [394]) has
been identified as a risk factor for both active trachoma and any trachoma [388].
Whether eye powder or smoke induce chronic conjunctival inflammation and thereby
contribute to scarring, or whether - in the case of kohl - sharing of the applicator is a
transmission mechanism, is not known. However, foreign bodies resembling carbon
and silica particles have been noted in the conjunctival substantia propria of South
African trichiasis patients [395], suggesting at least that exogenous compounds can
penetrate the conjunctival epithelium.
2.8 MANAGEMENT
The only effective treatment for corneal blindness is keratoplasty, which generally
involves the placement of a full thickness corneal graft. In the trachomatous eye,
reduced tear secretion, corneal vascularisation and distortion of the lid all tend to
worsen graft prognosis. Even though several groups have managed to achieve moderate
success using corneal grafting for trachomatous corneal opacity [144, 396-398], the
logistical difficulties, necessary financial resources, and disappointing long-term
outcomes make establishing such a programme a low priority for most trachoma-
endemic countries.
The focus of trachoma control programmes therefore needs to be preventative
[397]. Unfortunately, a vaccine capable of invoking useful immunity to ocular
chlamydia! infection is unlikely to become available within the next decade. Current
strategies for the management and control of trachoma are aimed at interrupting the
pathogenic cascade that leads to blindness: reduction in the transmission of infection
from person to person through fly control and the removal of infected ocular secretions
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from children's faces, treatment of established infections with antibiotics, and correction
of trichiasis and entropion before patients become blind. Because the latter group are at
most immediate risk of developing trachomatous visual impairment, surgery is the
intervention that should be undertaken most urgently in a trachoma-endemic area. The
acronym 'SAFE', used to encapsulate the trachoma control strategy recommended by
the World Health Organisation, places the four elements of control in order of their
priority: ~urgery for trichiasis and entropion, Antibiotics for active disease, and lace
washing and Environmental improvement to reduce transmission.
2.8.1 Surgery
Surgical treatment of trichiasis and entropion aims to stop abrasion of the cornea by
in-turned lashes, and thereby minimise ongoing deterioration in vision. Many
techniques have been described, ranging from the minimally invasive, such as the use of
sticking plasters to adhere offending lashes to the skin of the lid and orbital margin
[399], through to the frankly disfiguring, such as the complete excision of the ciliary
margin of the lid with granulation of the raw edge advocated by Stellwag in 1883 [400].
Other procedures nominated include part-resection of orbicularis oculi with placement
of sutures to evert the lid margin [400]; splitting of the lid in the frontal plane with
interposition of a pedicle of skin, muscle or mucous membrane between the two layers
[400, 401]; destruction of lash follicles by cryotherapy [402-407]; electro-epilation
[390, 406, 407]; X-ray epilation [408]; wholesale removal of the tarsal plate and orbital
septum [409]; tarsal grooving (the Streatfield-Snellen procedure) [410]; eversion
splinting (grey line split) [410,411]; tarsal advance (lid split) [410]; tarsal advance and
rotation (Collin's modification of the Trabut procedure) [407, 410, 412, 413]; tarsal
advance and graft [407]; posterior lamellar tarsal rotation [414, 415]; and bilamellar
tarsal rotation (upper lid Wies or Ballen operation) [407, 410, 416, 417]. Reacher
undertook two randomised clinical trials [407, 410]. He concluded that tarsal plate
rotation (in which a transverse incision is made through the tarsus a few millimetres
from the lid margin, and sutured under moderate tension so as to evert the lashes) was
the superior technique, with an estimated 77% success at twenty-one months after
surgery [407]. Comparable results seem to be obtained regardless of whether the
incision is full thickness (bilamellar tarsal rotation) or spares the skin of the lid
(posterior lamellar tarsal rotation) [414, 415]. Tarsal plate rotation is a simple, rapid
procedure which can be performed effectively by paramedical staff. This is fortunate,
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since in Africa. for example, there is only one ophthalmologist for every million people
[418].
Traditional treatment for trichiasis often consists of mechanical epilation of
ingrowing lashes using home-made forceps. Some control programmes recommend this
to patients with minor trichiasis. Bowman et al., however, suggest that surgery might
be a better strategy, particularly because of the difficulties involved in monitoring
disease progression in patients living in remote communities [419].
Achieving high uptake of surgical services often proves difficult. Programmes in
Malawi [420], Tanzania [421, 422], Egypt [392] and The Gambia [189] have all
reported that less than 50% of those offered correction of trichiasis actually present for
surgery, even when transport to the health facility is provided by the programme and
operations are performed free of charge. Uptake of surgery is lower for women than
men [392]. Village-based surgery, which has been shown to produce good operative
outcomes [414], may improve uptake by saving time for the patient and reducing fear of
the procedure [415].
2.8.2 Antibiotics
Before the introduction of sulphonamides in 1938, infection with the trachoma
agent was thought to be incurable. Unfortunately for patients, this did not prevent
ophthalmologists attempting to inactivate disease by scrubbing the upper fornix and
palpebral conjunctiva with pointed crystals of copper sulphate fixed to the end of
wooden probes. This would be repeated "daily, month after month, year after year, until
the disease (became) quiet" [28](P.1620). This treatment, Duke-Elder remarked, was
"by no means painless" [28](P.1620).
Fortunately. the arrival of antibiotics heralded a new approach. The opportunity
was not ignored. In fact, as Dawson et al. noted, "since the advent of the
sulphonamides, each antimicrobial drug which became available has found some
endorsement for the treatment of clinical trachoma" [423](P.581). In 1950, Freyche
reviewed available evidence supporting the use of tyrothricin, penicillin, streptomycin,
bacitracin, aureomycin, and chJoromycetin. He included 194 references, and alluded to
a further "number of papers so great that even their mere enumeration would be
tedious" [424)(P.523). Since then, the volume of published work, and the number of
ditTerent antiseptics and antibiotics suggested or tested for the management of trachoma
have both continued to grow. The list now includes boric acid [425-429], rifampicin
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[426-428. 430-433]. erythromycin [425, 428, 429], spiramycin [432], chlortetracycline
[425.433-437]. oxytetracycline [432, 434, 438], oxytetracycline/polymixin [245, 439],
tetracycline [182. 247. 426. 427. 429, 434, 435, 437, 440-444], and meclocycline [445],
all used topically; oral preparations of rifampin [446], sulfonamides [185, 423, 424,
436. 440. 441. 444, 447-450], tetracycline [441, 451], doxycycline [444], minocycline
[452, 453], amoxicillin [169], erythromycin [169, 442, 448] and azithromycin; and
intramuscular benzathine penicillin [454] and sulphamethoxypyridazine [454, 455].
New compounds are still being trialed. Recently, studies in Japan have suggested that
tranilast, from the leaves of Nandia domestica (sacred bamboo), and FNQ3, a synthetic
analogue, may have in vitro efficacy against chlamydiae [456].
Most of these compounds have never been formally tested (by today's standards)
against active trachoma. Beginning in the late 1930s, though, mass distribution of
sulphonamides was used for trachoma control in American Indian communities. In the
1960s, these drugs were evaluated against placebo for the treatment of active trachoma,
with mixed results [423]. Though given part of the credit for the dramatic fall in
prevalence seen in indigenous Americans during the twentieth century [457],
sulphonamdes later fell from favour because of the high incidence of adverse reactions
(including erythema multiforme, Stevens Johnson syndrome and renal complications)
associated with their use [334, 446], and are now no longer recommended for active
trachoma. Topical tetracycline and azithromycin are both in current use, and will be
discussed in this review. Erythromycin and amoxicillin are given for the treatment of
TI in some control programmes that do not have access to azithromycin, but neither has
been subjected to a randomised controlled trial. Why, though, are antibiotics used at
all?
In the context of trachoma, antibiotics are used with two overlapping goals. Firstly,
agents that are effective against C. trachomatis are prescribed to individuals with
clinical signs of active disease. The objectives here are to lessen the risk of the patient's
close contacts becoming infected, relieve symptoms, and shorten the period of
conjunctival inflammation [132]. The last of these would have the theoretical
advantage of decreasing the stimulus for the deposition of conjunctival scar. There are
no published data showing that the administration of any antibiotic achieves any of
these things.
Secondly, antibiotics are distributed to subsets of or whole popUlations, to try and
reduce the community load of C. trachomatis, and therefore achieve sustained
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reductions in the prevalence of disease. The ultimate goal is to reduce visual loss due to
trachoma [132, 211]. There is some recent evidence to suggest that mass azithromycin
distribution can lower the community burden of C. trachomatis for at least twelve
months [169], as will be discussed later, but none so far proving that antibiotics can
reduce the incidence of trachoma blindness.
Tetracyclines are active against Chlamydia trachomatis. In the 1950s, mass
treatment campaigns using tetracycline eye ointment were used for trachoma control in
a number of countries [458]. As part of WHO-supported monitoring of the Moroccan
programme in that decade, a large number of schoolchildren were followed to assess
outcome after being given ointment twice- or three-times daily for sixty days. Nearly
80% clinical cure was reported [459]. Results elsewhere were less encouraging [435,
440].
No placebo-controlled trials of topical tetracycline were undertaken until a 1965-67
study by Dawson et al. [180]. This trial was conducted in American Indian children
resident at a boarding school. Topical tetracycline was applied three times daily for six
weeks, and produced a greater reduction in the prevalence of clinical activity than a
topical placebo, both at the conclusion of therapy and one month later. However, the
prevalence of active disease continued to fall in intervention and placebo groups alike,
and there was no significant difference in outcome five months after treatment finished:
this was attributed to the favourable hygienic environment of the school [180]. A
group-randomised trial in Taiwanese schoolchildren concluded that evaluating the
advantage of tetracycline over placebo was made difficult by the high incidence of
"spontaneous cure among the controls, coupled with a high rate of reconversion from
healed to active trachoma among the treated subgroups" [435](P.569). A non-
randomised trial in Tunisia appeared to show that tetracycline was superior to boric acid
(a mild antiseptic, used in that study as a control) in the resolution of both clinical
activity and infection [427]; and a randomised controlled trial by Attiah et al. showed a
statistically insignificant advantage of tetracycline over no treatment [438]. On the
whole, data do not prove that tetracyclines lower the prevalence of disease or infection,
but merely suggest that some benefit might be derived from their use [460]. Two
reasons for this weak effect can be proposed.
First, from the recipients' perspective, ocular tetracycline is not an ideal therapy.
The ointment is irritant to the conjunctiva, difficult and often messy to self-administer,
and for refractive reasons blurs vision for a few minutes after application. Prolonged
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administration is recommended. It is likely that the majority of individuals prescribed
six weeks continuous or six months intermittent treatment do not complete the course,
particularly if they are initially asymptomatic. Most individuals targeted for trachoma
chemotherapy do not feel ill [461]. Second, the presence of C. trachomatis at
extraocular sites such as the nasopharynx and rectum has been demonstrated in several
surveys of trachoma-endemic communities [182, 220, 246]. Instillation of antibiotics
into the conjunctival sac alone is unlikely to clear infection from these areas [446, 462].
Rapid autoinfection from extraocular reservoirs after successful topical treatment then
becomes a theoretical possibility. Whether extraocular chlamydial reservoirs are truly
significant for the epidemiology of trachoma is still unclear.
If topical treatment works, twice daily application may be just as effective as thrice
daily [459], and an intermittent schedule (where ointment is applied, for example, twice
a day for three consecutive days, repeated every four weeks over twenty weeks) may be
more effective in the long term than continuous treatment five days a week for twelve
weeks [459]. Intermittent treatment has the additional advantage of requiring less
ointment [459]. Before the optimal duration and frequency of topical tetracycline
administration could be definitively established, it was realised that attempts to prevent
trachoma blindness using tetracycline would be resource intensive, require prolonged
effort, and might have disappointing results [24, 438]. Community-based tetracycline
distribution programmes were abandoned [24].
The demonstration that a single dose of oral azithromycin is at least as effective as
prolonged courses of topical tetracycline has dramatically altered the approach to
trachoma chemotherapy in a number of endemic countries. Presently, eight countries
are fortunate to receive donations of azithromycin for trachoma control from the
International Trachoma Initiative (ITI); others, like Australia, can afford to provide it
under the national health budget. Elsewhere, despite its imperfections, topical
tetracycline remains the first line treatment for active trachoma, for want of a more
attractive alternative. Azithromycin is discussed under its own heading in Section 2.9
(p.86).
2.8.3 Face washing
Because dirty faces are associated with active trachoma, West et al. undertook a
community-randomised intervention trial to examine the impact of promoting face
washing as an adjunct to mass treatment with tetracycline eye ointment. Three pairs of
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hyperendemic villages matched on maternal education and baseline prevalences of clean
faces and clinical trachoma in young children were enrolled. Every resident of both
intervention and control villages was offered topical tetracycline once daily for thirty
days. In intervention villages, an intensive one-month participatory campaign was
conducted to encourage washing of children's faces [367]. The campaign included a
seminar with village leaders; a series of neighbourhood meetings to build consensus on
the importance of face washing, develop plans, and - subsequently - to review progress;
a school programme to raise awareness of facial cleanliness; seminars with traditional
healers; and presentations (by schoolchildren and the local traditional dance group) of
songs, dramas and drawings related to trachoma and face washing [367, 463].
Antibiotics reduced the prevalence of active trachoma in children in both the
intervention and control groups. The proportion of children with sustained clean faces
at follow-up was higher in the intervention group (35%) than the control group (26%),
and in two of three intervention villages, the return in the prevalence of severe trachoma
(defined by West et al. as fifteen or more follicles or the presence of inflammation that
obscured all the deep tarsal vessels, in the examined eye) towards the baseline level was
slowed. The face washing promotion campaign had no effect on the prevalence of TF
[367]. In the majority of trachoma control programmes, resources to conduct a
campaign of similar intensity are unavailable. The impact of less energetic face
washing education efforts is not known.
2.8.4 Environmental improvement
There is general agreement in the literature that improvements in a community's
standard of living are associated with a decrease in trachoma transmission [346, 364,
462, 464-466]. Socioeconomic development and increased living standards are
believed to be responsible for the disappearance of trachoma from Europe and North
America [211].
Unfortunately, merely waiting for socioeconomic development to take place in
trachoma-endemic areas will not help to prevent trachoma blindness. Some work has
been done to try and identify the actual components of 'development' that reduce the
prevalence of trachoma. Fly control appears promising, but studies have so far failed to
demonstrate effectiveness for an intervention that might prove sustainable. Further
work is required. Improvement in water supply, which is a recommended part of the
SAFE strategy and popular with communities, is yet to be subjected to controlled trials.
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2.9 AZITHROMYCIN
Azithromycin is an azalide macrolide. It is a derivative of erythromycin, differing
only through the addition of a methyl-substituted nitrogen at position 9a of the aglycone
ring. This expands the ring to fifteen members, increases acid stability (and so
increases absorption), enhances tissue penetration, and broadens the antibiotic spectrum,
compared to the parent compound. It is effective against C. trachomatis both in vitro
[467,468] and in vivo [469].
2.9.1 Spectrum of activity
In addition to its activity against Chlamydia, azithromycin has some activity in
vitro against Staphylococcus aureus, Streptococcus pneumoniae, S. pyogenes, and other
Streptococcus spp., Haemophilus influenzae, H. parainjluenzae, and H. ducreyi,
Campylobaeter spp., Branhamella cararrhalis, Escherichia coli and other members of
the Enterobacteriaceae, Bacteroides fragilis, Fusobacterium spp., Neisseria
gonorrhoeae, Bordetella pertussis and B. para pertussis, Mycoplasma pneumoniae and
M hominis, Ureaplasma urealyticum, Leigonella pneumophila, Borrelia burgdorferi,
Mycobacterium avium-intracellulare; Toxoplasma gondii, Treponema pal/idum,
Cryptosporidium, and Plasmodium spp, [470-474].
2.9.2 M«hanism of action
Azithromycin binds to the 50S ribosomal subunit of susceptible organisms, and
thereby interferes with bacterial protein synthesis.
2.9.3 Pharmacokinetics
Azithromycin is absorbed rapidly from the gastrointestinal tract [475] and
distributes widely throughout the body, except to the CSF. Though initial studies
suggested that food in the stomach could dramatically decrease bioavailability [476],
later clinical trials with the commercial fonnulations of azithromycin determined that it
could be given without regard for meals [477]. It has an unusually large volume of
distribution (31Ukg) because of its high level of tissue binding: tissue concentrations
are ten to one hundred times higher than those of serum [478]. Azithromycin is
concentrated intracellularly by a number of cell types [479, 480]. This may help to
explain the drug's extraordinary efficacy against the (intracellular) chlamydiae. Tissue
depletion half life has been estimated at 2-4 days [478].
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Two studies in Saudi Arabia provided information about particular aspects of
azithromycin's pharmacokinetics relevant to its use in trachoma control. Tabbara et al.
obtained the assistance of sixty patients (mean age sixty-six years) undergoing cataract
surgery, each of whom was given a single Ig oral dose of azithromycin at a variable
time prior to surgery. Tear samples and conjunctival biopsy material were obtained at
operation. All tears collected four days or less after azithromycin, and all conjunctival
specimens collected fourteen days or less after azithromycin contained levels of
azithromycin above the MIC90xviii for C. trachomatis [482]. Karcioglu et al. studied
fourteen school-age Saudi children with active trachoma. They gave each child a single
dose of 20mg azithromycin per kilogram bodyweight, and repeatedly sampled subjects'
tears and plasma over the following six days. The concentration of azithromycin in
tears was within or above the MICso range for C. trachomatis (O.03-O.2S#LglmL) at six
days for all 12 patients for whom data were available'" [483].
1.9.4 Indications
The prolonged half life and intracellular concentration of azithromycin make it an
extremely useful therapeutic tool. A single oral dose of l g azithromycin is as effective
as seven days of twice-daily oral doxycycline in the treatment of lower genital tract C.
trachomatis infections [484-486]. Such a dose clears urethral and cervical chlamydial
infection in almost 100% of cases [469]. Since it is also effective against Neisseria
gono"hoeae, single dose azithromycin is now employed in some countries for the
syndromic treatment of sexually transmitted infections. In the West, the drug is also
used for infections of the respiratory tract, middle ear, skin and soft tissue.
In the developing world, the expense of azithromycin tends to exclude it from
routine use in the management of any of these conditions - a one gram dose costs over
£7 in the UK. Only the existence of a donation programme makes azithromycin a
viable option for trachoma control.
1.9.5 Formuladon
ITI currently provides Pfizer-donated azithromycin (Zithromax™, Pfizer, New
York. New York) to trachoma control programmes in Egypt, Ethiopia, Ghana, Nepal,
niii The minimal inhibitory concentration-50 (MICso) is the concentration of ~ti~iotic which produces a 50%
reduction in the inclusion count compared to a drug-free control culture; the minimal inhibitory concentration-90
(MIc,.,) is the c:onc:entrabon which produces a 90810reduction [481].
lilt Two patients failed to complete the study.
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Niger, Mali, Morocco, Sudan, Tanzania, and Vietnam. Zithromax for donation is
manufactured as 250mg tablets and bottles of cherry- or banana-flavoured powder for
suspension (paediatric oral suspension, POS). When reconstituted according to
directions, the concentration of the suspension is 40mglmL.
2.9.6 Efficacy against trachoma
Three trials established the efficacy of azithromycin in the treatment of active
trachoma.
Bailey et al. [182] studied 194 non-pregnant, non-lactating individuals with active
disease (aged nine months to sixty years) in The Gambia. Patients were randomised by
room to a single dose of azithromycin 20mg/kg, or 1% ocular tetracycline ointment
applied twice daily under supervision for six weeks. Those with severe inflammation
(TI) also received oral erythromycin four times a day for four weeks, in line with
Gambian national guidelines. More than 98% of scheduled treatments were witnessed.
No serious adverse reactions were observed. At six months after the commencement of
treatment, active disease was absent in 78% of the azithromycin group and 72% of the
tetracycline group. This difference between the two treatment groups was not
statistically significant.
Tabbara et al. [247] conducted a randomised controlled trial companng
azithromycin and topical tetracycline in sixty-four Saudi children aged between six and
fourteen years, all of whom had active trachoma at baseline. Azithromycin was given as
a single oral dose of 20mg/kg; tetracycline was administered by a school teacher twice
daily, five days weekly, for six weeks. Conjunctival scrapings were collected for
Giemsa staining and DFA at baseline and twenty-four weeks, and masked follow-up
examinations were undertaken at four, eight, twelve and twenty-four weeks. There
were no significant differences, either clinically or microbiologically, between the
treatment groups.
In a study of 168 children with active disease in northern Egypt, Dawson et al.
[245] compared four different treatment strategies. Blocks of eight children were
randomised to (1) application of 1% oxytetracycline / 10,000 units/g polymixin
ointment once daily for five consecutive days in every twenty-eight days for six cycles;
(2) one dose of azithromycin 2Omglkg;(3) azithromycin 20mglkg once-weekly for three
consecutive weeks; or (4) azithromycin 2Omg/kgonce in every twenty-eight days for
six cycles. There were no significant differences in clinical or microbiological cure
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rates between the various groups at any of four follow-up examinations following the
commencement of treatment.
A fourth trial, conducted in a trachoma-endemic area in Turkey by Guzey et al.•
selected ninety-six subjects with active trachoma for treatment with either a three-day
course of IOmglkg azithromycin suspension per day, or eight weeks twice daily 0.5%
oxytetracycline/polymyxin eye ointment. Unfortunately, criteria for diagnosis with
active trachoma were not well defined in this paper [439].
In all of these trials, sample sizes were almost certainly too small to be able to
demonstrate statistically significant differences in the effect of treatment [182].
However, the trials suggest that, under supervised conditions ensuring near-maximal
compliance with prolonged topical treatment courses, single dose oral azithromycin is at
least as effective as topical tetracycline.
When treatment is restricted to individuals with clinical signs, it is probable that not
all ocular chlamydial infections are treated, and re-emergence of disease in the
community is likely to be rapid. The' Azithromycin in Control of Trachoma' (ACT)
trial was therefore undertaken to examine the impact of mass treatment with
azithromycin [169]. The study was a community-randomised trial in trachoma-endemic
areas of The Gambia, Egypt and Tanzania, using pairs of villages matched on the
prevalence of active trachoma in children aged one to ten years. In villages randomised
to tetracycline, supervised once daily topical tetracycline was offered to each village
resident for six weeks. In villages randomised to azithromycin, 20mglkg of that drug
was offered to each resident once weekly for three weeks: three doses were offered to
ensure maximum coverage. Women of childbearing age were given oral erythromycin
or amoxicillin for fourteen days instead of azithromycin. In each country, village-wide
LCR positivity rates at one year were substantially lower than at baseline with both
treatments. The reduction in laboratory positivity was greater with azithromycin than
with tetracycline, though the difference was not significant. Additionally, in each
country and in each disease category, the proportion clinically free of active disease
twelve months after treatment with azithromycin was at least equal to the proportion
free of active disease after treatment with tetracycline [169]. Data from the Egyptian
ann suggest that the effect of either azithromycin or tetracycline on infection was far
greater than the effect on disease at that site [327].
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2.9.7 Is azithromycin the antibiotic of choice?
Is azithromycin actually more effective than tetracycline? Should it be seen as the
antibiotic of choice? For three reasons, the answer to both these questions is: probably
yes.
First, In studies indicating equivalent efficacy of azithromycin and topical
tetracycline, high tetracycline compliance rates were achieved through careful
supervision of antibiotic administration. Mass daily or twice daily directly-observed
application of tetracycline eye ointment is not achievable outside the research setting.
In trachoma control programmes, one or two tubes of tetracycline are generally given to
the individual to be treated, or their parent, with a brief demonstration of the method of
application. For reasons that were outlined above, it is likely that many do not complete
a full six week course. In contrast, azithromycin is simple to take, simple to administer,
and single dose treatment can be directly observed even in large-scale distribution
programmes. Bowman et al. [487] undertook a randomised controlled trial comparing
one directly observed dose of 20mglkg azithromycin against an unsupervised six week
course of twice daily ocular tetracycline, in the treatment of children with active
disease. Children allocated to azithromycin were significantly more likely to be
clinically cured at both ten weeks and six months post randomisation.
Second, because azithromycin is administered systemically, it is likely that it
eliminates infection from both eyes and from extraocular sites [211], and thereby
reduces the likelihood of ocular reinfection by autoinoculation. Topical tetracycline is
unlikely to have a similar effect.
Third, azithromycin is active against other bacterial infections, most notably those
of the genitourinary tract. It also has antiplasmodial action: a significant reduction in
the prevalence of parasitaemia, febrile parasitaemia, and splenomegaly has been
reported in a Gambian community receiving triple dose azithromycin for trachoma
[488]. Goodwill generated by the incidental treatment of such conditions can be of great
benefit in developing community support for trachoma control [489], and should not be
underestimated when considering the value of azithromycin to the SAFE strategy.
2.9.8 Advene effects
Treadway and Pontani collated data from forty-three open randomised controlled
trials conducted on four continents, comparing the incidence of adverse events in 2,655
children treated with azithromycin lOmglkg once daily for three days, with that in 1,844
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children treated with one of nine comparator antibiotics [490]. All children were
between the ages of six months and sixteen years, and all were undergoing treatment for
suspected or confirmed bacterial infections. Adverse events occurred in 232 (8.7%) of
the children treated with azithromycin, and 180 (9.8%) of those treated with
comparator. Most adverse events were mild or only moderately severe, and most were
gastrointestinal. Similarly, phase II and III trial data from fourteen countries presented
by Hopkins [491] showed a 12.0% incidence of side effects amongst 3,995 patients
aged from two to ninety-four years treated with single or multiple dose azithromycin:
significantly lower than that associated with comparators.
In the Gambian ann of the ACT study [169], compliance was over 98% for
azithromycin, while nearly 95% of the villagers randomised to tetracycline received
twenty-eight or more applications. Morbidity surveys of all subjects aged three months
to fourteen years were conducted before treatment commenced, and at weekly intervals
for four weeks thereafter. During follow-up, the azithromycin group had 20% fewer
overall illnesses, fever and headache episodes and 40% fewer diarrhoea and vomiting
episodes than did the tetracycline group [492]. The trial was conducted during a high
malaria transmission season; the fact that fewer episodes of systemic illness were
reported in the azithromycin treated group than in the group treated with eye ointment
was thought to be due to the antimalarial effect of azithromycin [492].
Mass treatment of all children aged one to ten years in far-western Nepal has been
associated with a similar overall beneficial effect, despite a low prevalence of malaria.
In children who had not previously been given azithromycin, the proportion whose
parents reported impetigo, diarrhoea, or abdominal pain was lower ten days after
treatment than at baseline; the proportion of control group children whose parents
reported these symptoms did not change [493]. Other trials of azithromycin against
trachoma also suggest that it is well tolerated in trachoma-endemic communities [182,
247,439].
2.9.9 Issues In the use of azithromycin
<a>Who should it be given to?
Determining who to treat is a priority for research [494]. The poor correlation
between clinical trachoma and chlamydial infection, and uncertainty about the relative
importance of different age and gender groups in transmission, make it difficult to
decide who needs azithromycin and who does not. Various options have been
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proposed, including blanket treatment of all residents of endemic areas [169], mass
treatment of one to ten year-old children [495, 496], targeted treatment of children aged
from one to ten who have clinical evidence of active trachoma, together with treatment
of other members of their households [495, 496], and treatment of children with
trachoma and their household contacts who are children [497, 498]. Only the study by
Holm et al. in Nepal has provided empirical data on the relative effectiveness of
different treatment strategies. That study, which compared treatment of all children
against targeted treatment of children with clinically active disease plus their
households, found no significant difference in the effect of the two strategies on the
prevalence of either active disease or C. trachomatis infection [495].
In previous mass treatment campaigns using topical tetracycline, the formal
recommendation that all children in endemic areas be treated translated to treatment
only of schoolchildren in practice, since such children are easily accessible, while non-
school attenders are not [429]. Unfortunately, the peak prevalence of active disease is
in children below school age. Additionally, schoolchildren are likely to be healthier and
to come from more wealthy families, and may therefore be less likely to have trachoma
than children of the same age who are not at school. It became apparent that treatment
of schoolchildren alone was unlikely to produce a useful impact on the prevalence of
trachoma [435].
There has been a reluctance to consider the use of azitbromycin in pregnant women,
and in children below six months of age. However, a growing body of evidence
suggests that the drug does not harm the developing foetus. Gray et al. conducted a
community randomised trial of presumptive treatment for sexually transmitted diseases
in pregnancy [499], with the principal object of evaluating the effect of such an
intervention on maternal HIV acquisition and perinatal HN transmission [500].
Mothers in the intervention arm, who were at varying stages of gestation, received a
cocktail of antibiotics including a single dose of Ig azitbromycin. Early neonatal
mortality and the incidence of low birth weight were both significantly lower than in the
control ann [499], suggesting that the antibiotics given actually improved pregnancy
outcome. For pregnant women themselves, single dose azitbromycin may produce a
lower incidence of severe side-effects than a seven-day course of erythromycin [501].
Azithromycin has been recommended since January 1998 by the Centres for Disease
Control and Prevention as an alternative regimen for treatment of genital chlamydial
infections in pregnancy [502]. Extensive studies in animals have failed to show any
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evidence of teratogenicity [503]. Based on these data, the ITI's Trachoma Expert
Committee has recently recommended that the prohibition on azithromycin for pregnant
women be lifted.
There are relatively few data on the use of azithromycin in children below six
months of age [503]. In a small study evaluating the drug for use in neonatal
chlamydial conjunctivitis, thirteen infants between six and eighteen days old received
one to three once daily doses of 20mglkg azithromycin. No adverse effects of any kind
were observed [504].
(b) Who should give it?
The problem of ophthalmic understaffing in Africa has already been mentioned. In
trachoma-endemic areas, few ophthalmologists, medical officers or nurses have
sufficient time to devote themselves to a prevention campaign addressing just one of the
many health problems for which they have responsibility. Community health
volunteers have previously been involved in trachoma control activities [102, SOS].
Some of these volunteers are currently contributing to the global Guinea Worm
eradication campaign. As Guinea Worm disappears, the experience and motivation of
volunteers should be harnessed for other health interventions [506]. A pilot study in
Ghana recruited six Guinea Worm volunteers for training in the diagnosis of active
trachoma and its treatment with oral azithromycin [507], with generally positive results.
Attempts to involve these individuals on a larger scale might be worthwhile. True
community-directed distribution, as has been employed in ivermectin distribution for
onchocerciasis [508-511], may be even better.
(c) How should it be given?
Community volunteers recruited to distribute azithromycin are likely to travel by
foot or by bicycle. Weighing scales are typically heavy and bulky. In Ghana, Guinea
Worm volunteers were unfamiliar with the operation of analogue weighing scales, and
required several days' training before they were able to accurately determine subjects'
body weight [507]. Furthermore, scales are relatively expensive, prone to breakage,
frequently lose calibration or perform unreliably when used on dirty uneven surfaces,
and are useful in commerce, so are prone to disappear [507,512].
Mid upper arm circumference (MUAC) [513, 514], various products of height and
MUAC [513]. and physical appearance (estimation of dose without taking any
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measurements) [514, 515] have all been explored as alternative means for determining
drug doses, but height seems to be the best proxy for weight in rural African
populations. Distribution of anti-infectives by height has been successful for the
treatment of onchocerciasis with ivermectin [515] and for the treatment of
schistosomiasis with praziquantel [513]. A height scale can be quickly and cheaply
constructed using any straight length of wood or plastic. Laminated paper tapes (based
on those used in paediatric trauma centres in North America) have been trialed for
general paediatric medicine drug dosing in Malawi, and could provide a lightweight and
compact alternative [512].
(d) Will resistance emerge?
Broad-based distribution of azithromycin in trachoma-endemic communities seems
to provide ideal conditions for the selection of azithromycin-resistant strains in a range
of bacteria, since human population exposure is extensive, one-dose treatment is
employed. the drug has a broad spectrum of activity, and pathogen carriage rates are
likely to be high. Emergence of azithromycin resistance in ocular strains of C.
trachomatis would reduce the effectiveness of this antibiotic in trachoma control
programmes. Emergence of azithromycin resistance in other human pathogens might
make the manufacturer revise its commitment to the whole donation programme.
In vitro studies highlight the ease with which chlamydiae can develop resistance to
some antimicrobials. In 1973, rapid selection of rifampin-resistant mutants of C.
trachomatis was noted when successive isolates were grown in increasing
concentrations of that antibiotic [516]. Four passages of the L2 reference strain through
McCoy cell culture containing subinhibitory concentrations of ofloxacin and
sparfloxacin is sufficient for the selection of mutants highly resistant to
fluoroquinolones [517]. The discovery by Lenart et al. of inclusion vacuoles containing
both C. suis and C. trachomatis L2 (following sequential infections of the same tissue
culture) raises the possibility of inter-species interaction, and - potentially - exchange
of resistance genes through plasmids or chlamydial phages [518].
It is somewhat reassuring that despite decades of tetracycline use in trachoma
control, tetracycline-resistant ocular CT has not yet been identified [519]. However.
Mourad et al. reported partial erythromycin resistance in clinical isolates as early as
1980 [481]. and tetracycline-resistant endocervical and urethral isolates were first
reported by Jones et al. in 1990 [520]. In the latter study. resistance was responsible for
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treatment failure in at least one of the five patients from whom the isolates were
obtained, and tetracycline-resistant strains were also found to be resistant to
doxycycline, erythromycin, sulfamethoxasole, and clindamycin. Most recently,
urogenital C. trachomatis isolates resistant to doxycycline, azithromycin and ofloxacin
causing clinical treatment failure have been reported [521].
Extensive use of azithromycin may also lead to the emergence of resistant strains of
other organisms. Chern et al. studied the effect of azithromycin on the conjunctival
bacterial flora in Nepalese children. Bacterial cultures were taken from the
conjunctivae of 121 children at baseline and two weeks later. Subjects were randomised
to receive a single dose of azithromycin 2Omg/kg either after the baseline or after the
follow-up swabbing. At baseline, all S. pneumoniae isolates recovered from both
groups were sensitive to azithromycin. The proportion of children from whom
pathogenic bacteria were isolated fell significantly in the baseline azithromycin-treated
group, and three of seven strains recovered from this group at follow-up were resistant
to azithromycin. Two of these resistant isolates were from children who had grown
azithromycin-sensitive S.pneumoniae strains prior to antibiotic treatment [522].
In The Gambia, the impact of three once weekly doses of azithromycin 20mg/kg on
carriage of oropharyngeal pathogens in children has been compared to that produced by
daily treatment with tetracycline eye ointment. Oropharyngeal swabs were taken before
treatment and twenty-eight days later. There was a significant reduction in carriage of
S.pneumoniae in the azithromycin group, but no effect on the carriage of H. influenzae;
antibiotic susceptibilities were not reported [523]. In German children with respiratory
tract infections, azithromycin seems more likely than other macrolides to select for
resistant strains of oral microflora [524].
Two published studies have examined the effect of azithromycin used for trachoma
control on the prevalence of antibiotic resistance in non-ocular pneumococci. Working
with Aboriginal children in the Northern Territory of Australia, Leach et al. examined
the effect of azithromycin on nasopharyngeal carriage and antibiotic resistance of
Streptococcus pneumoniae [497]. A total of 130 children with trachoma and their
household contacts who were children were given a single dose of azithromycin
2Omglkg. Seventy nasopharyngeal swabs were taken from cases before treatment, and
up to thirty-nine were taken at two weeks, two months and six months after
azithromycin. Carriage rates were 68%, 29%, 78% and 87% at baseline and these three
follow-up points respectively. The prevalence of azithromycin resistance in strains
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from carriage positive children was higher at two weeks than at baseline, and higher
again at two months, then fell between two months and six months [497]. However, the
formulation of azithromycin used was unusual", follow-up was limited by the terms of
the ethical approval obtained, and there was no control group: the observed change
could have been produced by a number of confounding factors, such as the use of other
antibiotics by cohort individuals [525].
Fry et al. examined antimicrobial resistance profiles of nasopharyngeal
pneumococcal isolates before and after a mass azithromycin distribution campaign in
far-western Nepal [493]. A total of 458 children were followed, divided amongst three
groups: the 'current treatment' group, living in villages in which azithromycin 20mglkg
was given to each one to ten year-old child shortly after baseline swabbing, and in
which azithromycin had not previously been offered; the 'one previous exposure'
group, who had received azithromycin six months prior to baseline; and the 'two
previous exposures' group, who had received azithromycin on two separate occasions,
six months and eighteen months prior to baseline. Neither the one nor two previous
exposures groups were given azithromycin between baseline and the follow-up swabs.
No azithromycin resistant isolates were obtained from the current treatment or one
previous exposure groups, either before treatment, or ten or 180 days afterwards. In the
two previous exposures group, two of ninety-two (2%) of isolates were azithromycin
resistant at baseline, and four (5%) of eighty-eight isolates were resistant at 180 days
post baseline; this change was not significant [493]. This may indicate that, when the
pre-existing prevalence of macrolide resistance is low, multiple courses of azithromycin
are required to produce resistance in pneumococci [493].
Though it is true that azithromycin is not commonly used against S. pneumoniae in
most trachoma-endemic countries [519], microorganisms do not respect international
boundaries. Both additional specific studies and ongoing surveillance are warranted.
(e) How often should it be given?
Using a mathematical model, Lietman et al. estimated the required frequency of
azithromycin dosing to be every six to twelve months in hyperendemic areas xxi and
every twelve to twenty-four months in moderately trachoma-endemic areasxxii•
Calculations, though, were based on data for prevalence of disease rather than infection:
xx a suspension of crushed azithromycin tablets
oj defined by Lietman et al. as a prevalence of active disease in children at baseline of greater than 50%
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given the poor correlation between the two, analysis with the latter might generate more
useful output. In addition, the model assumed universal treatment coverage, 95%
treatment efficacy, structured mixing patterns of residents, homogeneous distribution of
cases, and no inward migration [526]. There remains a need for empirical data on rates
and routes of reinfection following azithromycin treatment for trachoma control.
2.10 SUMMARY
Repeated ocular infection with Chlamydia trachomatis is an important cause of
blindness. Some details of the biology of the organism, the pathogenesis of disease and
the mechanisms of human immunity have proven difficult to unravel, but sufficient
information is available to permit a rational approach to diagnosis. Because clinical
signs correlate poorly with the presence or absence of ocular CT, research into the
epidemiology of trachoma and the effect of control interventions should be based on
tests of infection status. A number of kinds of laboratory assay are available. The
sensitivities of the nucleic acid amplification tests are probably at least as high as those
of other assays, and their specificities are probably close to 100%. Additionally, the
ability of kinetic quantitative PCR to rapidly and accurately quantify the number of
copies of a DNA sequence present in a sample makes it an ideal research tool for
investigating the epidemiology of this disease.
The strategy used for the control of trachoma has the acronym SAFE: §urgery for
trichiasis and entropion, Antibiotics for active disease, and lace washing and
Environmental improvement to reduce transmission. The antibiotic most commonly
used for trachoma is topical tetracycline ointment, which needs to be applied daily or
twice daily for six weeks. There is evidence that single dose oral azithromycin is more
effective than topical tetracycline in clearing ocular C. trachomatis infection. However,
more research is needed to establish optimal target groups and dosing frequency for
azithromycin, and to improve strategies for delivery of the drug to endemic
communities. Studies with kinetic quantitative PCR and investigation of weight-based
dosing could make useful contributions.
uii defined by Lierman et al. as a prevalence of active disease in children at baseline of less than 35%
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3. AIM AND OBJECTIVES
The aim of this thesis is to provide evidence to assist the development of rational
strategies for the use of azithromycin in trachoma control.
Specifically, the objectives are:
(I) To determine, using quantitative peR, the infective load of Chlamydia trachomatis
in different age and gender groups in a community of approximately 1000
individuals before antibiotic treatment.
(2) To measure, using quantitative methods, the effect of community-wide mass
treatment with oral azithromycin 20mglkg on the infective load of C. trachomatis in
different age and gender groups.
(3) To measure, using quantitative methods, the rate at which infection is re-introduced
following community-wide mass treatment with azithromycin.
(4) To determine the relative importance of different risk factors in predicting re-
emergent infection following community-wide mass treatment with azithromycin.
(5) To trace sources and routes of reinfection with C. trachoma tis following
community-wide mass treatment with azithromycin.
(6) To determine the relationship between height and weight in a trachoma-endemic
community in Tanzania, to investigate the feasibility of using height to guide the
dose of azithromycin there.
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4. RESEARCH BACKGROUND
4.1 SETTING
Tanganyika became independent from Britain in 1961, and joined the Indian Ocean
islands of Zanzibar and Pemba two years later to form the United Republic of Tanzania.
Despite a radical programme of economic and social reform introduced by Julius
Nyerere, the first president, Tanzania languishes near the bottom of the league table in
indices of human development. In GDP terms, the country is the second poorest of the
173 for which data are available, with a per capita annual income of just pppniii
US$523 in 2002 [527].
The mainland of Tanzania is divided into twenty regions, each of which is
subdivided into districts. Rombo is an arid district of the Kilimanjaro region, lying just
below Tanzania's northern border, on the eastern and northern slopes ofMt Kilimanjaro
(Figure 4.1, p.lOO). In 2001, the total population ofRombo was estimated to be nearly
250,000 [528]. There are sixty-four villages, each of which has between 3,000 and
8,000 residents spread over a few square kilometres. Current sociopolitical structures
are a legacy ofujarnaa (socialism) and the 'villagisation' movement of the early 1970s
[529]. Groups of approximately ten families living adjacent to each other are formed
into a collective known as a balozi (Plural: mabalozi), a word also used for the man (or,
less commonly, woman) who represents the group at village meetings. A group of
seven to twenty mabalozi creates a kitongoji, or sub-village, headed by a sub-village
chairman. The village is more or less a product of map-making whim, with the nearest
neighbours of a family living on the outskirts of a village just as likely to be in the next
village as the home one. Villages are administered by a chairman, who is himself a
balozi leader, and by an executive officer, a full-time employee of the government.
Rombo lies in the rain shadow of Mt Kilimanjaro. During the dry season, flow
ceases in all the rivers whose courses wind down the northern slopes of the mountain.
In all locations investigated in a 2002 hydrogeological survey of the district, substantial
aquifers were only located more than a hundred metres underground, below a thick
basaltic lava crust [530]. As a result, it is difficult and expensive to drill boreholes.
Many villages therefore have no close water source. For some households, water
collection during the dry season may involve a round trip of up to six hours.
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Figure 4.1: Map of The United Republic of Tanzania. The location of Rombo District is
indicated by the yellow arrow.
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Villages are served by dirt roads, many of which are in a poor state of repair.
Agriculture is the primary activity. Maize, beans and bananas are the staples, while
bananas, sunflowers and coffee are commonly grown as cash crops. Most families keep
small numbers of a variety of livestock. The typical house has walls constructed from a
wo en stick frame and mud, or roughly milled timber. Corrugated iron roofs are now
mar commonly seen than the traditional thatch.
xxtu In theory, at the PPP (Purchasing Power Parity) rate, PPP US$I has the same purchasing power in Tanzania as
US$I has in the USA. It therefore represents a common currency through which economic indicators can be
compared across countries [527).
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4.2 ETHNICITY, CULTURE, EDUCATION, AND LANGUAGE
The Chagga are the predominant ethnic group in Rombo. Despite being the first
Tanzanian tribe to embrace the western economic and monetary systems after European
colonisation, animal - and particularly cattle - ownership is still regarded as a symbol
of wealth in Chagga society. An awareness of the risks posed by wachawi (sorcerers),
combined with a fear of cattle thieves induces many to continue the traditional practice
of keeping livestock inside the house overnight. In addition to the Chagga, there are
small numbers of Masai, Kamba and Kikuyu living in Rombo. Most Rombo residents
are regular attendees at a church of one of the Christian denominations active in the
district. Many simultaneously maintain animist beliefs.
In Rombo, most residents speak one of a number of dialects of KiChagga as their
mother tongue. However, the language of teaching in Tanzanian public primary schools
is Swahili. Universal free primary education was introduced soon after independence
[531], and despite the later re-introduction of and progressive increase in fees made
necessary by low government revenues and high national debt repayments [532], most
parents make determined efforts to ensure their children attend school. As a result,
Swahili - originally a coastal language - is almost universally spoken by Tanzanians
aged fifty years or less. Only a small proportion of people in the district know more
than a few words of English.
4.3 HEALTH AND HEALTH SERVICES
Basic health indicators for the Tanzanian population reflect the country's economic
woes. In 2000, the national infant and under-five mortality rates were estimated at 104
and 165 per 1,000 live births respectively [533, 534], and the maternal mortality rate a
frightening 1,100 per 100,000 live births [535]. UNAIDS estimate that up to 4.25% of
men and 9.67% of women aged between 15 and 24 may be infected with HN [536,
537]. Forty-seven percent of all Tanzanians are undemourished=" [538].
The medical services for Rombo District are provided by Huruma District
Designated Hospital, which is managed and largely staffed by the Sisters of Our Lady
of Kilimanjaro. Complications of malaria and HN, lower respiratory tract infections,
diarrhoeal disease, tuberculosis, malnutrition, trauma, and interventional obstetrics all
make significant contributions to the case load. The hospital includes a respected eye
uiv Persons whose food intake continually falls below the minimum requirement, or whose food intake is continuaIly
insufficient to meet their energy requirements.
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clinic staffed by up to four ophthalmic nurses. Huruma Hospital is about ninety minutes
drive away from the Kilimanjaro Christian Medical Centre (KCMC) at Moshi, which
includes a medical school (the second in Tanzania), and which functions as the zonal
referral hospital for five northern regions of Tanzania. Specialist ophthalmologists from
KCMC visit Huruma on a regular basis.
4.4 TRACHOMA IN TANZANIA
Trachoma has been reported in ten of mainland Tanzania's twenty regions. An
estimated twelve million people live in endemic areas [539]. Some places are
particularly badly affected: a survey in Kongwa District of central Tanzania in 1990, for
example, found the prevalence of active inflammatory trachoma to be 60% in a sample
of 3853 pre-school children. Eight percent of 484 individuals aged fifty-five or older in
that survey had trichiasis and / or entropion [331].
A focus of trachoma is also found in Rombo, affecting perhaps 90,000 people. An
informal survey conducted by Christoffel Blindenmission (CBM) in 1998 estimated the
prevalence of active disease amongst Rombo schoolchildren to be approximately 20%.
4.5 KAHE VILLAGE
Kahe village was selected as the location to conduct the studies detailed in this
thesis on the basis of its accessibility, relatively high prevalence of active trachoma
identified during the CBM survey, and enthusiasm of village opinion leaders for their
community's participation. It is reasonably typical of Rombo villages. It lies between
latitude 3° 03' OO"Sto 3° 04' OO"Sand longitude 37° 36' 30"E to 37° 39' 20"E [530].
Its northern boundary is within a few kilometres of Tanzania's border with Kenya.
4.6 COLLABORATING INSTITUTIONS
This thesis was linked to a programme of trachoma research entitled 'Strategies for
the control of blinding trachoma', which included studies in Rombo, in Kongwa District
of Tanzania, and in The Gambia. The London School of Hygiene & Tropical Medicine
(LSHTM) has responsibility for Rombo and The Gambia, while Johns Hopkins
University, Baltimore, administers the Kongwa centre, within the structure of the long-
running Kongwa Trachoma Project.
Huruma Hospital assisted the project by seconding to us a local ophthalmic nurse
experienced in community eye work, by providing office and living space, and by
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assisting with the recruitment and training of field staff. The Principal Medical Officer
of Huruma and the author of this thesis were the joint local principal investigators for
the research.
KCMC personnel were involved in formulating the research questions and
preparing the original grant application, and assisted with project steering and
administration. In addition, the freezers of the KCMC clinical laboratory were used for
interim storage of samples prior to their shipment to the UK for analysis.
The many contributions made by individual collaborators, both from within these
institutions and elsewhere, have been described in the Acknowledgements (p.ll).
4.7 FUNDING
Work at all three sites of the 'Strategies for the control of blinding trachoma'
programme is supported by programme grant number 059134 from the Wellcome Trust
/ Burroughs Wellcome Fund. In addition, the Edna McConnell Clark Foundation
provided funds through its grant number 99100 for the initial phase of map-making,
enumeration of the study population, and collection of baseline clinical samples in
Rombo. From May 2002 until submission of this thesis in July 2003, the author's salary
was supported through grant number 01-034 from the International Trachoma Initiative.
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5. METHODS
5.1 COMMUNITY CONSULTATION
Preliminary discussions were held with the Kahe village chairman and executive
officer. A meeting of the village mabalozi and waganga (traditional healers) was then
called, where opinions about priority community problems were sought, and possible
participation in a trachoma research programme discussed. It was agreed that kikope
(problems of the eyelashes) were a major cause of disability for the elderly, and a shared
understanding was reached of how the proposed study might impact on this problem in
Kahe and elsewhere. Enthusiasm for the study was expressed, and at a second meeting,
community consent was given for the work to go ahead. Opinion leaders were asked to
identify any potential shortcomings of the suggested conduct of the study, and to offer
possible solutions.
5.2 MAPPING
During April and May 2000, field assistants visited each of the 1108 households in
Kahe. Each kaya (house) was assigned a four-digit identity code. The first two digits in
this code indicate the number of the balozi (01-90, pre-assigned on a list of the ninety
Kahe mabalozi); the second two (01-99) indicate the arbitrary numbers assigned to each
kaya. Kaya numbers were allocated sequentially as households were visited. The
balozi I kaya (BIK) number of the house was recorded on an individual form for that
house (Appendix 2, Survey form (a». To prevent assignment of the same number to
more than one household, all the households comprising anyone balozi were mapped
by a single field assistant. Each field assistant carried a list of all possible BIK numbers
for their mabalozi, crossing off each number as it was used. Because the balozi leader's
house was always the first visited in each balozi, that house always took kaya number
01.
On the same household form (Survey form (a», a map of the compound was drawn
showing the position of all rooms and other permanent structures. Each structure was
assigned a code. Rooms in which people slept were given numbers. Store rooms,
kitchens, bathrooms, latrines and animal enclosures had letter and number codes. The
roof type (tinlstraw/other/none) of each numbered room was recorded.
The field assistant then asked permission from the head of the household to paint
the BIK number in a prominent position on the door of room one of the kaya. If
104
permitted, the room number was also painted on the external door of each sleeping
room. Spray paint and a stencil were used to ensure that marking the doors for study
purposes was not unsightly. Painted code numbers were maintained throughout the
study by a field assistant who was resident in the village.
In July 2002, each household was re-visited to determine the location of the
structures shown on the Survey form (a) for that kaya. A handheld Trimble
GeoExplorer 3 GPS unit (Trimble Navigation Limited, Sunnyvale, CA, USA) was used.
To allow later differential correction of field data, throughout the duration of fieldwork,
reference satellite data were continuously recorded by a Trimble Pro XR receiver,
located at KCMC in Moshi, using Trimble Reference Station software. All household-
level spatial data were collected as points. The position of each room was recorded by
taking readings in front of its external door, and of latrines and animal enclosures by
taking readings in front of the door or entrance point. The location of each household as
a whole was determined by taking readings at the approximate centre of the compound,
determined by eye. For each point of interest, at least six readings were taken and
automatically averaged within the GPS unit to yield a single northing and easting.
Because two years had elapsed since the original hand-drawn mapping exercise, there
were occasional discrepancies between the compound maps and the location of
structures on the ground at the time of GPS data collection. In most cases, the
discrepancies involved the addition of extra rooms or structures. When features had
been moved or demolished, it was often possible to determine their original locations: in
these instances spatial data was recorded at those points [540]. Data for features where
this was not possible were excluded from geographical analyses.
All GPS data were uploaded daily onto a laptop computer, using GPS Pathfinder
Office 2.80 software (Trimble). Differential post-processing of the GPS field data
against base station data was performed in Pathfinder Office.
S.J SURVEY
A house-to-house survey was performed, covering each household in Kahe. The
purposes of this exercise were to compile a census list of all residents of Kahe village,
and to collect village-wide data on clinical signs of trachoma and known and candidate
risk factors for the disease. Personnel were divided into two survey teams, each
comprising three field assistants, one examiner (patrick Massae (an ophthalmic nurse),
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or the current author), and a guide, who was either the village chairman or another
senior balozi.
Participation in the survey was voluntary. Household heads and individual village
residents were each given the opportunity to decide whether or not they wished to take
part. They were assured that this would not affect their ability either to enter the study
at a later date or to receive treatment for trachoma.
Balozi leaders were requested to notify household heads several days before the
first scheduled visit of the survey team. Householders were asked to remain at home if
this would not interfere with attendance at school or work. The village chairman's
household was the first visited. Subsequently, the balozi leader's household was the
first to be visited in each balozi.
The three field assistants in each team were responsible for household mobilisation
and the collection of demographic information. One field assistant went to each kaya,
informed all those present of the nature and aims of the study, answered questions, and
invited householders to make themselves available for enumeration and examination.
They then listed the members of the household (see below), obtained consent, and
recorded data on household-level risk factors.
S.3.1 Definition of a household
For the purposes of the study, a household was defined as the group of individuals
sharing a building or group of buildings within a single shamba (plot of cultivated
ground). In almost all cases this comprised a husband and wife, their dependant
children, and any relatives, friends or household workers living with them. Where there
was doubt, the balozi leader was asked to determine if a given group of individuals
constituted one or more households.
S.3.2 Inclusion criteria for a household
All individuals resident within the household were eligible for inclusion in the
survey. Residency was defined as overnight stay for at least fifteen nights in the
previous month, or recent arrival and intention to remain. Both males and females of all
ages were invited to participate. Temporary visitors to a household were not included in
the survey for that household.
In the case of individuals who divided their time between two or more
households. the individual was asked to state in which household they had spent most
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nights during the preceding month. This household was the one to which they were
considered to belong. An exception to this rule was made for men who had more than
one wife. The usual arrangement in Kahe is for each woman to live in her own
household, with the husband regarded as the head of each of the households. To avoid
duplicating data on these men, demographic details were recorded for them in each
household in which they were the nominated head, but examination findings only for
the house in which they were first seen. To ensure that this happened, the head of each
household was asked before examination whether he had already had his eyes examined
by a member of the trachoma survey team. If he had already been examined, the boxes
for clinical findings were filled with the code '7', to simplify the identification of
'duplicate' individuals (see Table 5.1, p.l 09).
5.3.J Consent
Informed consent was obtained from each participating individual. Information
sheets and consent forms were prepared in Swahili. One piece of paper was used to
record consent for up to ten members of a household in tabular format (Appendix 2,
Survey form (bj). Each individual was asked to sign his or her name in ink, or place
their right thumb-print on the page against their name. For those aged under eighteen
years, the consent of their parent or guardian was obtained.
5.3.4 Information recorded for each individual
The first and last names, any aliases, date of birth, gender, ethnic group, room
number slept in, highest level of formal education completed, and - if still at school -
the current school attended, were recorded for each individual resident in the household.
Details for up to ten householders were recorded on a single sheet (Appendix 2, Survey
form (c); if more than ten individuals were resident in the house, additional sheets were
used and marked with the same household number. Table A3.1 (Appendix 3, p.209)
contains the abbreviations and codes used on this form. Because these data represented
our village census, demographic details were recorded to the fullest extent possible even
for individuals who did not consent to examination, as well as for those who were not
present at the time of the household visit.
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5.3.5 Information recorded for each household
In each kaya, an adult was asked to provide information about the household. A
field assistant recorded answers to questions using a separate household form for each
kaya (Appendix 2, Survey form (dj), Questions on this form sought data on the number
of cattle, sheep, goats, pigs, ducks, chickens, dogs, pigs, rabbits and pigeons the family
owned, and the number of cattle kept in the house or in the shamba that surrounded it.
The time taken to walk from the house to the place from which water was collected in
the wet season and in the dry season was recorded, as well as the number of times per
week it was permitted to collect water in each season. Additionally, the informant was
asked about the family'S access to a latrine. Those that said that they had access were
asked if the latrine was for the exclusive use of the family, or shared with another
family. Because local government regulations require each family to maintain a latrine,
respondents were reassured that our visit did not constitute a heath inspection, and that
all information given would be held in the strictest confidence.
If the family did claim access to a latrine, a field assistant asked permission to see
it. He or she would then record (I) whether there was a beaten path to the door of the
latrine; (2) whether the latrine was sufficiently well screened to ensure that the identity
of a person inside the latrine could not be determined by a person walking along the
nearest path that passed it; (3) whether there were flies (two or more v less than two)
within the enclosure that surrounded the latrine; (4) the type of floor; and (5) using a
torch, whether faeces were visible within the pit {Appendix 2, Survey form (d».
5.3.6 Examination for facial cleanliness
While preparing to examine each consenting individual for clinical evidence of
trachoma, the examiner assessed the subject's face for the presence or absence of three
signs of a 'dirty' face: eye discharge, nose discharge and fly-eye contact. Eye discharge
was defined as pus or dried secretions around one or both eyes; nose discharge as
discharge from the nose visible outside the margin of the external nare; and fly-eye
contact as direct observation of one or more flies making contact with the lid margin (or
tissue internal to the lid margin) during the time required to prepare for eye examination
and examine the subject. Information about the face was recorded {Appendix 2, Survey
form (c», using the codes found in Appendix 3 (Table A3.2, p.2ll).
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Villagers were not told in advance that facial cleanliness would be graded.
Permission to withhold this information was obtained from the village chairman prior to
the start of the survey.
5.3.7 Examination for trachoma
Both everted upper eyelids of each individual were examined using 2.5x binocular
magnifying loupes and handheld torch. The WHO simplified trachoma grading scheme
[200] was used, with three refinements.
'P' - in the context of trichiasis - was used to label cases in which five or more
lashes touched the globe, distinguishing them from less severe trichiasis. This was to
maintain consistency in notation between the three arms of the Wellcome Trust /
Burroughs Wellcome Fund-supported 'Strategies for the control of blinding trachoma'
study (see Section 4.6, p.l 02).
'M', for mild active trachoma, was added to protect the integrity of the diagnosis of
TF. It reduces the temptation to classify fewer than five follicles, or small follicles, as
TF, even though they do not quite meet the WHO simplified scheme criteria.
'E' was similarly created to protect the diagnosis of TS. The concept of "easily
visible" [200] scarring is difficult to assess objectively, particularly in the blanched
conjunctivae seen in many elderly subjects.
The full grading system used, including these additions, is presented in Table 5.1.
(Final analysis was performed using the strict WHO simplified system definitions.)
Table 5.1: Trachoma grading scheme used (after Thyle ors et al. 200])
Sign Definition Code
TT Trachomatous trichiasis - at least one eyelash rubs Absent=O
on the eyeball, or evidence of recent removal of in- One to four lashes= 1
turned eyelashes. Five or more lashes=P
Refused exam=5
Already examined
elsewhere=7
Not recorded=9
CO Corneal opacity - easily visible corneal opacity over Absent=O
the pupil, so dense that at least part of the pupil margin Present=l
is blurred when viewed through the opacity. Refused exam=5
Already examined
elsewhere=7
Not recorded=9
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Table 5.1 (continued from previous page)
TF Trachomatous inflammation - follicular - the Absent=O
presence of five or more follicles at least O.5mm in Present=l
diameter, in the central part of the upper tarsal Unable to evert=4
conjunctiva. Refused exam=5
Already examined
elsewhere=7
Not recorded=9
One to four follicles (mild active trachoma, not 'TF') Mild=M
TI Trachomatous inflammation - intense - pronounced Absent=O
inflammatory thickening of the upper tarsal Present=l
conjunctiva obscuring more than half the normal deep Unable to evert=4
tarsal vessels. Refused exam=5
Already examined
elsewhere=7
Not recorded=9
TS Trachomatous scarring - the presence of easily Absent=O
visible scars in the tarsal conjunctiva. Present=l
Unable to evert=4
Refused exam=5
Already examined
elsewhere=7
Not recorded=9
White patches that do not change with altered pressure
but that are not 'easily visible' - presumed early Early=E
scarril!&
5.3.8 Mopping up
Following completion of the first round of house- to-house visits, local schools were
visited to see children who had not been present at their homes. Households from
which demographic or examination data were still incomplete were then visited again,
after notification of household heads. Lists of individuals still not examined were then
compiled and given to mabalozi, who were asked to encourage listed people to attend
one of a series of centralised examination sessions, or to bring word that the individuals
concerned did not wish to participate. Balozi leaders able to account for all individuals
(examined, refused, absent) listed as resident in their balozi were given a small cash
sum (approximately £1).
5.3.9 IncldeDta) fiadiags
Upon identification of non-trachomatous eye pathology or non-ocular disease in
study subjects (during fieldwork for the survey and the subsequent longitudinal study),
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treatment or referral was offered to the patient whenever possible. In emergency cases,
and for elective procedures booked at Huruma Hospital, patients were collected from
Kahe and taken to hospital in the project vehicle.
5.4 LONGITUDINAL STUDY: BASELINE
5.4.1 Selection of cohort
Following completion of the survey, the kitongoji with the highest prevalence of
active trachoma (Kahe Mpya - 'New Kahe'; results by kitongoji are presented in Table
6.6, p.134) was invited to take part in the longitudinal study. This involved examination
and conjunctival swab collection from all consenting sub-village residents before, and
two, six, twelve, and eighteen months after, treatment of the entire village with
azithromycin. The invitation to participate was accepted with enthusiasm by the
kitongoji chairman and mabalozi of Kahe Mpya. The residents of Kahe Mpya are
referred to hereafter as 'the cohort'.
5.4.2 Numbering of individuals in the cohort
Each individual registered at the survey as living in Kahe Mpya was assigned a
unique six-digit identity (ID) number. All ID numbers used were multiples of eleven.
Such numbers have the property that when anyone digit is changed, or when two
adjacent digits are transposed, the resulting number is no longer a multiple of eleven.
This facilitated a simple check on the accuracy of data entry.
5.4.3 Sample labels
Self-adhesive labels tolerant of high humidity and temperatures between -80 and
+400C (Tough-Tags™, Diversified Biotech, Boston, MA, USA) were used. The labels
were laser-printed with sample codes prior to the commencement of fieldwork. A
different code was used for each sample from each individual at each household visit.
Seven digit numbers divisible by eleven were used. Each sample number was printed
on two adjacent labels: in the field, one copy was fixed to the sample tube, the other to
an individual data collection sheet on which the name and ID number of the study
subject had been pre-printed (Appendix 2, Cohort fonnlOO).
Any possible sample number was printed on a pair of ToughTags only once - no
two pairs used at any stage of the study had the same number. The sample number was
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therefore able to identify the individual from whom, the date on which, and the
anatomical site from which the sample was taken.
5.4.4 Database
Demographic data obtained in the village survey were entered into a database
purpose-built using Microsoft Access 97 SR-2. The report capability of Access was
then used to pre-print subject ID cards, as well as individual forms for each of the
baseline and follow-up visits of the longitudinal study.
5.4.5 Baseline examination, swabbing, and treatment
Baseline examinations for the longitudinal study were undertaken in July 2000.
Everyone living within the cohort kitongoji was invited for examination, conjunctival
swabbing, and treatment. Because of the number of personnel and volume of
equipment required, a house-to-house strategy was not employed. Rather, permission
was sought from Kahe Mpya mabalozi to see all individuals resident within their balozi,
at their house, on designated days. Mabalozi were asked for assistance in mobilising
the residents of their balozi. They were offered a small cash incentive (£2) to be
awarded once each individual living in their balozi had been accounted for.
(a) Baseline census update
As indicated in Section 5.4.4, the forms used for the baseline cohort visit were pre-
printed with the demographic data from the whole-village survey. Residence details
were checked at the time of baseline cohort examination to ensure that they were still
accurate. For individuals who had moved kaya or room since the survey, new details
were recorded; a field assistant later visited them at home to confirm the BIK.and room
number of their new homes.
Any person living in Kahe Mpya at the time of the baseline round who had not
been registered as being resident there in the survey had their details recorded on a
blank form. Temporary visitors were not included. The household inclusion criteria for
the longitudinal study were the same as those used for the whole-village survey.
(b) Consent
After reading the information sheet for the longitudinal study, answering questions,
and checking the demographic data previously recorded for the individual, informed
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consent for ongoing participation in the longitudinal study was requested. To confirm
enrolment, written consent (in addition to the form that had been completed during the
survey round) was obtained from each individual, or their parent or guardian.
(c) Examination and swabbing procedure
Each consenting individual had a face photograph taken for ID card purposes (see
below), and their face assessed for eye discharge, nose discharge, and fly-eye contact, as
in the survey. The upper tarsal conjunctivae of both eyes was re-examined, using the
same grading scheme (Table 5.1, p.109) that had been used for the survey. A sample
was then taken from the upper tarsal conjunctiva of the right eye for C. trachomatis
PCR, using a dry, sterile, Dacron polyester-tipped swab ("Puritan", Hardwood Products
Company, Guilford, Maine, USA). In testing endocervical specimens for C.
trachomatis DNA by Amplicor PCR, dry Dacron swabs provide higher diagnostic
sensitivity than do Dacron swabs swirled in specimen transport medium [282]. A
standardised collection technique was employed, designed to minimise variations
between individuals in the amount of material collected: the swab was held horizontally,
and rubbed along the length of the conjunctiva four times, rotating it a quarter turn on
each pass.
Individuals with nasal exudate visible outside the margin of one or both nares had a
separate swab taken of this material for C. trachomatis quantitative PCR.
The same examiner (patrick Massae) assessed and swabbed all subjects. In an
effort to minimise cross-contamination of samples for peR, and to prevent carry-over
transmission of ocular pathogens from one subject to the next, he wore two pairs of
latex medical examination gloves. The outer pair was removed and discarded after each
subject had been seen, and the inner pair sprayed with isopropyl alcohol and allowed to
air dry. A new pair of outer gloves was then donned. A new clean cotton-tip was used
to evert the eyelid of each individual.
(d) Azithromycin
Azithromycin was distributed to all consenting householders in Kahe Mpya during
this visit, as described in Section 5.5 (p.114).
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5.4.6 Duplicate conjunctival swabs
Prior to baseline swabbing, forty-seven individuals living in Kahe Mpya (5% of the
978 listed as being resident at the time of the survey) were selected at random (using a
random number generator). Two eye swabs were to be taken from each of these
individuals, if they were seen at baseline: the first for analysis with the rest of the
cohort, and the second as a duplicate specimen to determine the reproducibility of the
swabbing and laboratory techniques.
5.4.7 Identity cards
Face photos were taken of each individual recruited to the cohort. Each individual
was asked to hold their consent/data form in front of their chest for the photo. The six-
digit ID number of the individual was printed in large type on the top of this form. Film
was developed in Moshi and printed as passport photos. ID cards were then prepared,
displaying, in addition to the photo, the name, aliases, ID number, date of birth, and
gender of the individual. Cards were printed using Microsoft Access.
Two laminated copies of each card were prepared. One was given to the individual
at the two-month follow-up round in September 2000. The second copy was kept as a
spare.
5.4.8 Handling of samples collected during fieldwork
Each swab taken was labelled with an adhesive sample label bearing a sample code,
as described above, and placed on ice in a cold box in the field (4°C). At the end of
each day swabs were put into a -20°C freezer at Huruma Hospital. After interim
storage at KCMC, they were shipped to London on ice or dry ice. Details of the
laboratory protocols appear in Section 5.7 (p.l19).
5.S TREATMENT
In the cohort, antibiotics were offered at the baseline visit. After the baseline
cohort visit, all non-cohort households in Kahe were revisited. For both groups, a single
oral dose of approximately 20mglkg azithromycin (to a maximum of lg) was offered to
every non-pregnant resident individual over one year old. In non-cohort mabalozi,
distributors performed an initial round of balozi-to-balozi visits, after giving notice to
residents that antibiotic would be available at their balozi leader's house on a specified
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day. Several mop-up exercises were then undertaken in an attempt to make sure that
no-one who wanted treatment missed out.
In accordance with national treatment guidelines, two tubes of 1% tetracycline eye
ointment were given to children under the age of twelve months and to women who said
they were pregnant, in place of azithromycin. Ointment was self-administered at home
by the recipient or their carer. Recipients were taught the method of application, and
instructed to apply the ointment twice a day for six weeks. Compliance with topical
treatment was not monitored.
Azithromycin treatment was directly observed in every instance: drug was not
given to third parties for onward distribution to family or friends. For village residents
requesting treatment but unable to present themselves to receive it (the elderly, the ill,
mothers with newborn children), home visits were made.
Those who refused clinical examination in the surveyor enrolment in the cohort
were still offered treatment. No charge was levied for azithromycin, tetracycline, or any
other treatment.
5.5.1 Weight measurement
Subjects were first asked to remove their shoes and any heavy items that they
carried in their pockets. Most were weighed to the nearest O.lkg using electronic
scales. Children unable to stand unsupported on the scales were weighed using spring
scales. Individuals unable to be weighed (refused, too ill, too frail) had their weight
recorded as '000.0' kg.
5.5.2 Height measurement
For adults and most children, height was determined to the nearest centimetre by
asking the individual to stand erect and without shoes on a hard flat surface; a two-
metre long wooden measuring stick marked from the base in centimetre increments was
placed vertically at their back. A ruler held horizontally was used to bridge the distance
between the subject's crown and the appropriate mark on the measuring stick. For
children not yet able to stand, length from heels to crown was measured to the nearest
centimetre by lying the child adjacent to the measuring stick. Adults or children with
biomechanical disorders that prevented full extension, who refused, or who were too ill
to be measured, had their height recorded as '000' cm.
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5.5.3 Calculation of azithromycin dose
Pre-prepared reference tables indicating required azithromycin dose-for-weight
were used, to reduce the risk of errors in dose calculation. English and Swahili versions
of these tables form Appendix 4 (p.212). For the small number of individuals who were
unable to be weighed, a dose equal to that given to someone of similar age and
appearance from the same balozi was dispensed.
5.5.4 Treatment records
For treated individuals living in cohort mabalozi, details of body weight, height,
planned dose, and administered dose were recorded in spaces on the baseline visit form
(Appendix 2, Cohort formlOO). For treated individuals living in non-cohort mabalozi,
this information was recorded in boxes printed on the reverse side of the form used to
gather demographic and clinical information during the whole-village survey (Appendix
2, Survey form (c)(back». The codes used to record planned treatment and its success
are shown in Table A3.3, Appendix 3, p.211). To avoid treating people more than once,
to qualify for treatment, individuals had either to have been listed during the whole
village census or baseline cohort round, or have their residence status confirmed by their
balozi leader.
5.5.5 Trichiasis surgery
Individuals identified as having trichiasis and/or entropion in one or both eyes were
offered tarsal plate rotation procedures. Operations were performed by Patrick Massae,
an experienced trichiasis surgeon well known to village residents, in the village
dispensary, free of charge, and guides were available to assist patients to walk to the
dispensary. Very frail patients were collected and returned in the project vehicle.
5.6 LONGITUDINAL STUDY: FOLLOW-UP
5.6.1 Monthly census review
Beginning thirty days after the first day of baseline examinations, a review of the
cohort population was undertaken each month. Field assistants went house-to-house.
At each household, one or more informants deemed to be reliable were asked to give
information. For each person who had been registered as being resident in that
household at the previous examination or review, confirmation was sought that the
individual was still resident there, using the same criteria used for the original census in
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the survey. Current sleeping room and current school attended were checked. The
destination of those who had moved out of the house was recorded whenever this was
known. Lastly, the informant was asked whether any new individuals were now living
at that address.
At a subsequent face-to-face meeting, new arrivals to Kahe Mpya (from non-cohort
households in Kahe, or from outside the village) and newborns were invited to enrol in
the cohort. Demographic details were recorded, informed consent obtained, a face
photograph taken for the preparation of an ID card, and a single swab collected from the
everted upper tarsal conjunctiva of the right eye, for C. trachomatis PCR. A history
was also taken to determine whether the individual had ever received azithromycin or
topical tetracycline eye ointment, and if so, when. For those moving in from other
mabalozi within the village, records from the treatment round were examined to help
check the accuracy of this history. Ocular examination was not performed; nor was
treatment for trachoma offered, with the following exception. At the time of the one-
month census review in August 2000, treatment of non-cohort mabalozi in Kahe was
just being completed (see Section 6.3, p.145). Individuals moving from non-cohort
Kahe households to Kahe Mpya during the first month of the longitudinal study would
therefore be unusually placed: had they stayed at their old residence, they would have
been offered treatment. To avoid disadvantaging these people, all new arrivals to Kahe
Mpya registered at the one-month census review were offered treatment, provided they
had not already received it elsewhere.
The monthly visits were also used as a means of obtaining feedback from mabalozi
and household leaders and enrolled individuals. In particular, the informant at each
household was given the opportunity to identify concerns over any aspect of the conduct
of the study.
When necessary, the Kahe Mpya sub-village map was updated. For newly formed
households and newly constructed rooms added to existing households, BIK and room
numbers were assigned. GPS readings were taken at a later date, as described in
Section 5.2 (p.l04).
5.6.2 FoUow-up examination and swabbing
Follow-up visits were undertaken at two, six, twelve, and eighteen months. At each
of these time points, all available enrolled individuals then resident in Kahe Mpya were
seen. Follow-up involved assessment of the face for eye discharge, nose discharge, and
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fly-eye contact; examination of the everted upper tarsal conjunctivae of both eyes;
collection of a swab of the upper tarsal conjunctiva of the right eye, using the standard
technique; and collection of a swab of visible nasal exudates, if present.
Individuals who were registered as part of the cohort but who moved out of Kahe
Mpya during the period of follow-up were deemed to be not part of the cohort for such
time as they were living elsewhere. If such individuals subsequently returned to live in
Kahe Mpya, they rejoined the cohort as 'old' individuals.
As at baseline, mabalozi leaders were offered small cash rewards for assistance in
mobilising the population and the work involved in helping the field team account for
each individual in their balozi.
5.6.3 Risk factors for re-emergent infection following treatment
At the six, twelve, and eighteen month follow-up points, in addition to examination
and swabbing as described above, each cohort individual who presented to be seen was
asked to provide answers to the four questions:
1. In addition to working in your shamba, what sort of work do you do?
2. Where do you do this work?
3. Where have you travelled in the last six months?
4. Where have you travelled in the last month?
The same two interviewers, each of whom spoke both Swahili and the local
Kichagga dialect (Kiusseri), undertook the task of asking these questions at all three of
these follow-up points. Questions were read as written above, but further explanations
and examples ("For example, have you been to a church outside the village recently?
When?'') were provided as necessary. Respondents were able to give an unlimited
number of answers to each of the four questions. Family members were asked to
provide information for young children and other individuals unable to speak for
themselves. Job types and locations had pre-assigned numerical codes.
5.6.4 Re-treatment
At the six, twelve, and eighteen month visits, individuals who had clinical evidence
of active trachoma were offered two tubes of topical tetracycline eye ointment. As at
baseline, treatment was given without charge. Compliance with tetracycline was not
monitored. Treatment was not offered at the two-month visit, since it was felt likely
that clinical signs present at that time were evidence of resolving rather than new
118
infection. Repeat administration of azithromycin was scheduled for twenty-four
months.
5.7 LABORATORY METHODS
5.7.1 Blinding
All samples were tested blind to clinical assessment and to demographic
information.
5.7.2 Qualitative peR
The Arnplicor Chlamydia trachomatis qualitative PCR assay (Roche Molecular
Systems, Branchburg, NJ, USA) was used for the first stage of sample analysis, as a
screening test to select samples for quantification. Standard precautions against cross-
contamination were employed. Benches, hoods and discard bins were cleaned with 5%
Chloros (sodium hypochloride solution, Hays Chemical Distribution Ltd, Leeds, UK;
stock contains >5% but <16% available chlorine) and 70% alcohol before and after each
laboratory session. Sample racks, pipettes and other materials were similarly cleaned
with 2% Chloros and 70% alcohol. All sample pipetting was performed in a class II
negative pressure isolation hood, using aerosol barrier tips. The amplification and
detection areas were distinct, and separated from the sample preparation area by a self-
closing door. PCR master mix was prepared in a second class II hood that was
dedicated to this purpose.
Each swab was eluted by vortexing for ten seconds in 0.5mL Arnplicor CTING
lysis buffer in a 2mL polypropylene tube. Excess liquid was expressed from the swab
against the inside of the tube, and 0.3mL Amplicor specimen diluent added. The lysed
sample was held at room temperature for ten minutes, incubated at 95°C for ten minutes
to inactivate inhibitors, and refrigerated overnight at 4°C. Heating and overnight
refrigeration prior to amplification reduced the proportion of samples in which PCR was
inhibited, and therefore the number of samples that needed two or more tests to obtain a
result.
Amplicor CTING working master mix (MMX) was prepared by adding 100p.Lof
CTING internal control to one vial of CTING master mix, recapping, and inverting the
vial fifteen times. Working positive and negative controls were prepared freshly for
each day, according to the manufacturer's instructions. The Amplicor NG-positive
control (plasmid DNA containing N. gonorrhoeae sequences) served as the CT-negative
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control. PCR was performed according to the manufacturer's instructions. The
principles of this assay are described in Section 2.6.7 (p.53). In each well of the ninety-
six well plate, 50p.L of sample, working positive control or working negative control,
and SOILL of MMX underwent thirty-five cycles of amplification on a GeneAmp 9700
thermal cycler (Applied Biosystems, Foster City, USA). Two positive and two negative
controls were included in each plate. The final cycle had the same denaturation and
annealing steps as the earlier cycles, but was held at 72°C for five minutes to ensure
completion of chain extension.
In order to identify samples in which PCR was inhibited, we tested for
amplification of both target (PCT) DNA and the MMX internal control (IC) sequence.
Separate aliquots of the amplicon from each sample were added to two microwell
plates, one of which contained a probe for the Ie, and one of which contained a probe
for the pCT target sequence. The protocol for ELISA and detection followed the
manufacturer's instructions. Optical density (Ou) was read at 4S0nm on an MRX
microplate reader (Dynex Technologies, Chantilly, Virginia, USA). An aD of less than
0.200 in the internal control well was taken as evidence of inhibition of PCR. In these
cases, an aliquot of the original lysed sample was diluted 1:5 with a 50150 mixture of
Amplicor CTING lysis ButTer and specimen diluent, then retested. If PCR was still
inhibited at 1:5 dilution, a 1:10 dilution was prepared and amplified.
5.7.3 Selection and purification of samples for quantification
All positive (optical density (OD)~.8 from the CT microwell plate) and equivocal
(0.2<0D<0.8 on two successive tests) samples were quantified. For each of these
samples, 360ILL of Amplicor preparation was processed through a QIAamp DNA Mini
Kit (Qiagen Ltd, Crawley, UK), to purify and concentrate sample DNA, because the
Amplicor butTers were not compatible with the quantitative peR assay. QIAamp
columns were used according to the manufacturer's instructions. QIAamp-purified
DNA was resuspended in 50ILLQIAamp AE elution butTer.
5.7.4 Quantitative PCR
Real-time quantitative PCR was performed using the Lightffycler (Roche
Molecular Systems). The target for quantitative PCR amplification was a 123 base-pair
fragment within the highly conserved constant domain 3 of omp l . Primer sequences
(with melting temperatures, Tm)were as follows:
120
CT 1 - 5' -GCTGTGGTTGAGCTTT ATACAGACAC-3'
CT2 - 5'-TTTAGGTTTAGATTGAGCATATTGGA-3'
rr, 65°C)
rr, 62°C)
To prepare standards for quantification, the target sequence was amplified and gel
purified. Accurate estimation of the concentration of the stock so obtained was
undertaken using PicoGreen® (Molecular Probes, Eugene, OR, USA) read at 5021523
run in a SpectraMax spectrophotometer (Molecular Devices, Sunnyvale, CA, USA),
analysed with SoftMax Pro (Molecular Devices). Absolute copy number of the stock
was estimated according to the formula:
number of'rnolecules/al, = (fragment concentration (gluL)
fragment size(123 base pairs) x 660 x 6.022xI023
Stock was serially diluted in sterile water containing 2 ng!JLLHerring sperm DNA
(Sigma, Poole, Dorset, UK) so that 4JLL contained the required copy number of
standard.
PCR master-mix was freshly prepared prior to the start of each run [238] by
combining (per sample tested): 10JLLQuantiTect™ SYBR Green PCR Master Mix
(Qiagen; contains HotStarTaqTM DNA polymerase, QuantiTect SYBR Green PCR
buffer, dNTP mix, SYBR Green I, ROX passive reference dye, and MgCh), IJLLof
IJ.LM solutions of each of the 3' and 5' primers and 4JLLDNAIRNA-free water. 4JLLof
standard or re-suspended DNA from the QIAamp column was added to a glass capillary
containing 16JLL prepared PCR master-mix. For all but twenty of the quantified
samples (see below), quantification was performed twice, on two independent 4JLL
aliquots, amplified on separate runs. Each run included six concentrations of standard
(ten-fold dilutions of the stock solution from 105 to a single copy per capillary) and a
negative or zero control. The profiles of fluorescence against cycle number of these
seven capillaries were used to generate a standard curve. Thermal cycling was initiated
with a fifteen minute, 95°C incubation step to activate the HotStarTaq polymerase.
The starting copy number present in each sample capillary was determined by
comparison with the standard curve, using LightCycler Software v3 (Idaho Technology,
Salt Lake City, Utah, USA).
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5.7.5 Interpretation of peR results
The sensitivity of the LightCycler assay was optimised so that it could amplify one
copy of omp l per capillary (see Section 6.2.4, p.137). In spite of this level of
sensitivity, Amplicor should be still more sensitive, for two reasons. Firstly, the 4#J.Lof
post-QIAamp resuspended DNA used for quantification is equivalent to 28.8#J.Lof the
original Amplicor preparation?", whereas 50J.1Lof that preparation is used in the
AmpJicor assay. Secondly, Amplicor detects a multicopy plasmid rather than a single
copy chromosomal gene, multiplying the volume advantage. Amplicor positive
samples could therefore test negative in the LightCycler simply due to sampling
variability. On this basis, a probabilistic estimate was obtained of the number of copies
of ompl in Amplicor positive, LightCycler negative samples, as follows:
The volume of Amplicor preparation used in each Amplicor assay was vA=50J.1L.
The Amplicor-preparation-equivalent volume used in each LightCycler capillary was
vL=28.8J.1L. It is assumed that (1) the number of plasmids per organism was k=4 [127];
(2) that samples were mixed homogeneously, and therefore that the number of copies of
target DNA in each sub-sample would have a Poisson distribution; and (3) that both
Amplicor and the LightCycler assay were 100% sensitive ([276] and Section 6.2.4(b)
(p.137) respectively), so that if there were one or more copies of the target in the sub-
sample, they would be reliably amplified and detected. With these assumptions, if the
actual concentration of omp l in the Amplicor preparation is A copies per J.1L,the
probability of having zero copies of ompl in a LightCycler capillary is
-vUe .
The probability of at least one plasmid in an Amplicor well is
The likelihood for an Amplicor positive, LightCycler negative sample is therefore
L = (1- e-tvAA )e-VU •
To obtain i, the maximum likelihood estimate of A., the equation is differentiated,
and A. set equal to zero, obtaining
i = _1_101 kvA + VL).
kvA , vL
DV For q~tificd ~I~ 360,u. of the original Amplic~r p~ion is ~en and concentrated (by purification and
re-SUspenllon) to SO,u. In the QIAamp; 41'1- of the SO"L IS used In each LlghtCycJer capillary. This is equivalent to
using (4/50)·360 - 28.81'1- of the Amplicor preparation
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To obtain the estimated number of copies of ompl per swab, this is multiplied by
550J.L1.For the above values of vA, vL and k, this yields 5.70 organisms per swab (or
0.30 per capillary).
If two capillaries are done, the probability of both testing negative is
so vL is replaced by 2vL in the calculations. For such samples, the estimate is 4.12
organisms per swab (0.22 per capillary).
Two separate aliquots of most quantified samples were tested. When one or both
aliquots were LightCycler positive, the geometric mean of the two replicates is
presented here (including some with the value of 5.7 inferred for one of the replicates).
Of all samples tested in the LightCycler, twenty (fifteen from the baseline round and
five from the two-month follow-up) could only be tested once, due to low volumes of
residual sample following optimisation of the assay.
5.7.6 Culture
Eye swabs collected in 2-SP medium were shipped on dry ice from London to the
National Microbiology Laboratory, Health Canada, Winnipeg, Canada. HeLa 229 cells
were grown in twelve-well tissue culture plates. Confluent twenty-four-hour old
monolayers were treated for twenty minutes with 30.uglml DEAE-dextran. Each
conjunctival swab was vortexed for fifteen seconds with sterile glass beads and
inoculated, in triplicate, onto the pre-treated HeLa cell monolayers. The inoculated
cultures were incubated at 35°C in 5% C02 for one hour. Isolation medium, containing
Minimal Essential Media, lO% fetal calf serum, 100mM glutamine and l.uglml
cycloheximide, was then added to each well and the cultures were centrifuged at
1240xgravity for sixty minutes at 25°C. An additional ImL of isolation medium was
added to each well after centrifugation and the cultures were incubated at 35°C in 5%
C02 for seventy-two hours. One monolayer culture from each specimen was stained for
the presence of chlamydial inclusions using a fluorescein-conjugated monoclonal
antibody specific for C. trachomatis (c. trachomatis culture confirmation kit, Syva Co.,
Palo Alto, USA). The remaining two monolayers were blindly passaged onto fresh
HeLa cell monolayers. A specimen was considered negative if no inclusions were
detected after ten blind passages.
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5.8 DATAHANDLING
A number of field assistants were given training in basic computer skills, and
shown how to enter data using purpose-built 'forms' (data entry screens) that were
constructed in a Microsoft Access database. Field assistants and the author undertook
data entry during breaks between fieldwork.
Data collected on paper forms were double-entered into the database. Two versions
of each base table and data entry form were constructed. The first-entry form directed
the information to a first-entry table, and the second-entry form to a second-entry table.
When a particular data set was complete, cross-checking Access 'queries' were run,
matching corresponding entries in the two tables using 'primary key' field(s), and
comparing the contents of other fields for mismatches between first and second entry.
Lists of discrepancies were automatically entered into an errors table. Another query
was used to create a table of records that had only been entered once, in either the first
or second entry table. All errors were checked by hand by the current author, referring
to the original paper data collection forms. Corrections were made to first or second
entry base tables as necessary.
5.9 DATA ANALYSIS
Analyses were performed using Stata 7.0 (Stata, College Station, TX, USA),
Microsoft Access 2002 SP-2, and Microsoft Excel 2002 SP-2. Datasets were converted
between the various formats required by these packages using StatiTransfer 6.1 (Circle
Systems, Seattle, WA, USA). Graphs were drawn in Stata and Microsoft Powerpoint
2002 SP-2. Maps showing the distribution of infected individuals by household at each
time point were constructed in ArcView GIS 3.1 (Environmental Systems Research
Institute, Redlands, CA, USA).
5.9.1 Analysis of clustering
Analyses for spatial clustering of infected individuals were undertaken in SaTScan
v3.0.4 (National Cancer Institute, Bethesda, MD, USA [541]). For each time point,
case and population counts for each location and the geographical coordinates of these
locations were the inputs. In each analysis, every household was considered as a
possible location for the centre of a focus of elevated infection prevalence; a circular
window was positioned at the geographical location of each house in tum, and its radius
varied continuously from zero to that sufficient for the circle to enclose half the total
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population examined at that time point. For each location and size of the scanning
window, the number of cases within the window was compared to the expected number
using a Poisson model, with adjustment for the uneven background population density
[542]. For windows containing more cases than expected, the statistical significance of
the departure from the model was evaluated in a Monte Carlo simulation with 999
replications [541].
5.9.2 An index Cor the average ompJ load
A summary statistic relating to the average load of infection was needed. For
onchocerciasis, the community microfilarial load (CMFL) is used. It is calculated by
taking skin snip microfilarial counts from all individual for whom the index is to be
determined, adding I to each, calculating the geometric mean, then subtracting 1 from
the result. Adding 1 to each value before calculating the geometric mean prevents the
CMFL from being 0 whenever one or more of the microfilarial counts is O. An
analogous index could be used for ocular chlamydial load, but the method has a
fundamental mathematical flaw: the value of the index is highly dependent on the units
of the raw data. For example, the CMFL calculated using microfilariae per skin snip is
markedly different from the CMFL for the same group of people calculated using
microfilariae per milligram of skin. After investigating several alternative measures of
central tendency, the CMFL approach was adapted by substituting the arbitrary value of
1 with the (equally arbitrary) smallest possible assay value, which at least has the
advantage of removing the scale dependence of the index. As discussed in Section 5.7.5
(p.122), the smallest possible number of copies of ompl that can be determined using
our laboratory methods is 4.12 per swab, or 0.22 per capillary. Throughout this thesis,
the index, which will be referred to as the community ocular C. trachomatis load, or
COCTL, has been quoted in copies of ompl per swab. Its confidence intervals were
estimated in Stata, by bootstrap, with 10,000 replicates [543].
5.9.3 Risk Cacton Cor inCection post-treatment
Risk factors for infection at two, six, twelve and eighteen months after treatment
were evaluated in separate logistic regression models for each time point. The
dependent variable measuring infection was Amplicor status. As will be discussed in
Section 6.5.3 (p.l SS), there were only nineteen Kahe Mpya residents who were
Amplicor positive at two months, and progressively fewer positive individuals at six,
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twelve and eighteen months. This meant that the number of explanatory variables
which could be included in the analyses had to be restricted. Two confounders were
included: age in years, measured as a continuous variable, and gender.
For the two and six month analyses, four sets of exposure variables were evaluated,
chosen for their potential value in providing evidence for the A, F and E components of
the SAFE strategy:
( 1) Treatment status. Treatment codes entered on treatment record cards at baseline
or one month (see Section 6.3, p.145) were summarised to create one binary variable for
azithromycin and one for tetracycline eye ointment, each showing whether or not any of
the corresponding treatment had been received at either time point.
(2) Presence or absence of eye discharge, nose discharge and fly-eye contact at the
time of examination (one variable for each).
(3) Straight-line distance of the subject's residence (at the time of follow-up) to the
Kahe Mpya standpipe, based on the northings and eastings determined by differentially-
corrected GPS data.
(4) Access to a household latrine. This was used as a binary variable, disregarding
whether or not the family had exclusive access to the latrine.
Logistic regression was undertaken using a step-up approach, beginning with an
empty model. Each of the variables was fitted in tum; the most significant (determined
by the likelihood ratio test) was added if its significance level was less than 0.05. This
was then repeated, and the next most significant variable added if its significance level
was less than 0.05. This process proceeded iteratively until the next most significant
variable had a significance level of 0.05 or greater.
In fitting models for risks of being infected at twelve and eighteen months after
treatment, the same method was used, but in addition, the effect of receiving
tetracycline eye ointment at the previous round of examinations (see Section 5.6.4,
p.IIS) was estimated.
5.10 ETHICS
Research was conducted in accordance with the provisions of the World Medical
Association Declaration of Helsinki, as revised at the 520d General assembly,
Edinburgh, Scotland, October 2000 [544].
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5.10.1 Etbical considerations
(a>Equitable selection of subjects
Kahe was chosen as the site for study because of its accessibility, relatively high
prevalence of active trachoma, and proximity to trained local personnel and support
facilities. Kahe Mpya was invited to become the cohort kitongoji because it was the
sub-village of Kahe with the highest prevalence of active disease in the village survey.
Regardless of cohort enrolment, all non-pregnant individuals over the age of six months
in Kahe were offered antibiotic treatment according to national guidelines (Section 5.5,
p.114), and, where appropriate, surgery for trichiasis (Section 5.5.5, p.116).
(b) Potential benefit and the risk of harm
Prior to the commencement of fieldwork, adult and child volunteers were asked to
undergo eye examination and conjunctival swabbing in the manner described in Section
S.4.S(c} (p.112), to ensure that it would be tolerated. These volunteers reported that the
swabbing procedure was mildly uncomfortable, but not painful.
Azithromycin was donated by the International Trachoma Initiative through the
Tanzanian National Trachoma Control Programme, and was provided free of charge to
recipients. Mass treatment was expected to dramatically reduce the prevalence of both
ocular CT infection and clinical active trachoma in Kahe for some months after the
intervention. The likely duration of this effect was difficult to estimate: this study was
expected to be of value in providing data on which to base such predictions. Based on
safety data and previous experience in its use on a community-wide basis in trachoma-
endemic communities, a low incidence of serious adverse reactions was anticipated.
Mass single dose antibiotic treatment poses potential risks for the selection of antibiotic-
resistant bacterial strains; though the data do not appear in this thesis, studies conducted
in Rombo in conjunction with those described here involved collection of data to
monitor antibiotic resistance in C. trachomatis and S.pneumoniae.
Case-finding and subsequent treatment of individuals with trichiasis was expected
to reduce the prevalence of trichiasis in Kahe to a very low level. Additionally, eye and
systemic pathology detected as incidental findings during fieldwork were treated or
referred as appropriate.
Training and experience in research methods and data entry was provided to a
number of individuals in connection with their work on the study. Up to ten field
workers were employed at various stages of the project.
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Every effort will be made to ensure that the results of this work are published in
peer-reviewed journals and used, where appropriate, to inform trachoma control policy.
The research is therefore likely to benefit trachoma-endemic communities in the long
term, including the one in which the investigations were conducted.
(c) Consent
Free and informed written consent was obtained from each participating individual,
or their parent or guardian (Section 5.3.3, p.107; Section 5.4.5(b), p.112).
(d) Confidentiality
The confidentiality of personal information gathered in the course of the study has
been maintained. Personal data will only released to third parties with the express
consent of the individuals concerned. When not being used for fieldwork, consent and
data collection forms from the study are kept in secure locations in Rombo and London.
Paperwork will be securely kept for five years following publication, and then
destroyed.
Informed verbal permission to identify the study village in reports and published
papers was granted without reservation by the Kahe village chairman and vitongoji
leaders, on 30th March 2000.
5.10.2 Ethical approval
Ethical approval for these studies was obtained from both the LSHTM Ethics
Committee (reference number 597 / 1999)and the KCMC Research and Ethical
Clearance Committee.
A time line for the studies comprises Figure 5.1 (p.129).
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6. RESULTS
6.1 SURVEY
6.1.1 Census
As outlined in Section 5.3 (p.l05), the population of Kahe village was enumerated
as part of the survey, which was conducted between 11th April and 26th June 2000. At
that time, field assistants listed a total of 5748 residents of Kahe village. Forty-five of
these were identified as duplicate listings by examiners. The age and gender
distribution of the 5703 'unique' village residents is shown in Table 6.1. Children aged
fifteen years and under accounted for 54.2% of the village population. There were 2542
(44.6%) males and 3161 (55.4%) females. The preponderance of females over males
was mainly found amongst sixteen to sixty year-olds, which probably reflects the
tendency of men in this age bracket to leave the village to seek paid work.
Table 6.1: Age and gender distribution of the resident population, Kahe village, April-
June 2000
Age (years) Males (% of total Females (% of total Total (% of totalvillage~pulation)_ village population) village population)
0- 92_(1.61 91 (1.6) 183(3.2)
1-2 207 (3.6) 206 (3.6) 413 (7.~
3-4 206J3.~ 213 (3.7) 419 (7.~
5-6 213 (3.7) 221 (3.9) 434J7.~
7-8 187J3.:n 189 (3.3) 376J6.~
9-10 216J3.81 214 (3.8) 430J7.51
11-15 406 (7.1) 428 (7.5) 834JI4.~
16-30 268 (4.7) 565 (9.9) 833 (14.61
31-60 51719.11 786 (13.8) 1303i22.81
61+ 230 (4.0) 248 (4.3) 478 (8.4)
All 2542 (44.6) 3161 (55.4) 5703_{l001
The predominant ethnic group in Kahe is Chagga: 5674 (99.5%) of the 5703
residents identified themselves as belonging to this tribe. Seven (0.1%) said that they
were Masai, six (0.1%) Kamba, and three (0.05%) Waimeru; the remaining thirteen
(0.2%) belonged to a variety of other ethnic groups.
Of 4254 Kahe residents aged seven or more years (i.e., excluding pre-school age
children), 1497 (35%) had received less than one year of formal education. The level of
education completed is presented by age group in Table 6.2 (p.131) for males and in
Table 6.3 (p.131) for females. Males over the age of thirty living in Kahe were
significantly more likely than females over thirty to have completed at least one year of
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school. In the 31-60 years age group, 406 of 481 males (84%), and 417 of 758 females
(55%) had finished one or more years of primary school (i=114, P < 0.00005). In the
61+ years age group, the proportions were 59/224 (26%) and 71243(3%) for males and
females respectively (i=53, P < 0.00005). In younger age groups, the proportions of
males and females who had received at least some formal education were approximately
equal (Table 6.2 and Table 6.3). Gender differences in successful completion of post-
primary education were not significant.
Table 6.2: Level 0 onnal e ucation comp. et ,>Y age group, rna es, Kahe village
Age
Level of formal education completed (number, (%»
Any Standard Any Form Not(years) None primary sevenxxvi secondary sixxxvii known Total
0- 92 (lOO) 0(0) 0(0) 0(0) 0(0) 0(0) 92
1-2 207 (100) 0(0) 0(0) 0(0) 0(0) 0(0) 207
3-4 206 (lOO) 0(0) 0(0) 0(0) 0(0) 0(0) 206
5-6 213 (lOO) 0(0) 0(0) 0(0) 0(0) 0(0) 213
7-8 170 (91) 17 (9) 0(0) 0(0) 0(0) 0(0) 187
9-10 115(53) 101 (47) 0(0) 0(0) 0(0) 0(6) 216
11-15 24 (6) 382 (94) 13 (3) 2 (1) 0(0) 0(0) 406
16-30 9 (3) 259 (97) 172 (64) 15 (7) 0(0)- 0(0) 268
31-60 83 (16) 433 (84) 266 (51) 9 (2) 4 (1) 1 (0) 517
61+ 166 (72) 62 (27) 17 (7) 2 (1) 0(0) 2 (1) 230
All 1285 (51) 1254 (49) 468 (18) 28 (1) 4 (0) 3 (0) 2542
ff4 d l db I
Table 6.3: Level of formal education complet ,)Y age grOUP, females, Kahe village
Age
Level of formal education completed (number, (%»
Any Standard Any Fonn Not(years) None primary sevenxxvi secondary sixxxvii known
Total
0- 91 (lOO) 0(0) 0(0) 0(0) 0(0) 0(0) 91
1-2 206 (lOO) 0(0) 0(0) 0(0) 0(0) 0(0) 206
3-4 213 (100) 0(0) 0(0) 0-(0) 0(0) 0(0) 213
5-6 219 (99) 2 (1) 0(0) 0(0) 0(0) 0(0) 221
7-8 175 (93) 14 (7) 0(0) 0(0) 0(0) 0(0) 189
9-10 107 (50) 107 (50) 1 (0) 0(0) 0(0) 0(0) 214
11-15 29 (7) 399 (93) 21 (5) 0(0) 0(6) 0(0) 428
16-30 26 (5) 539 (95) 466 (82) 21 (4) 1 (0) 0(0) 565
31-60 352 (45) 433 (55) 296 (37) 6 (1) 1 (0) 1 (0) 786
61+ 241 (97) 7 (3) 2 (1) 0(0) 0(0) 0(0) 248
All 1659 (52) 1501 (47) 786 (25) 27 (1) 2 (0) 1(0) 3161
edb
At the time of the census, there were 1103 households. Some or all of the residents
of 1099 were examined. No household-level data were available from four kayas in
uvi The final year of primary education in the Tanzanian school system.
_. The final year of secondary education in the Tanzanian school system.
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which people were examined. Together, these four were home to eleven individuals;
for the other 1095 kayas, household details were complete. Residents in thirty (2.7%)
of these 1095 had no access to a latrine, while 103 (9.4%) households shared a latrine
with one or more other households, and 962 (87.9%) households had their own latrine.
Only 300 (27.4%) households owned one or more cows. Given the importance that the
Chagga attach to cattle ownership, the fact that less than a third of all households owned
a cow can be interpreted as an indication of the poverty of the village. The mean
reported time required to collect water in the dry season was 168 minutes (range 0-
480).
6.1.2 Enrolment
Of 5703 resident individuals, 5527 (96.9%) consented to enrolment in the survey,
and were examined. Thirty-two people (0.6%) explicitly refused to participate. The
remaining 144 (2.5%) were not seen at either the initial or follow-up house-to-house
examination rounds, and did not attend the subsequent 'special invitation' examination
sessions. Some of the 144 may have been working outside the village or had other
commitments that prevented attendance for the entire three month duration of survey
fieldwork, but most probably did not want to participate, and should therefore be
considered refusals. The characteristics of individuals who were seen, who refused, and
who did not attend is presented in Table 6.4 (p.133). Persons who did not attend
(without explicitly refusing) had a significantly older mean age (z=4.38, P<O.OOOl), and
were significantly more likely to have received secondary education (i=19.38,
P<O.OOOl) compared to attendees. The other differences between the three groups in
Table 6.4 were not statistically significant.
Of the 5527 people who presented, neither eyelid could be everted to permit
examination of the upper tarsal conjunctiva in twelve (0.2%), because of short lashes,
excessive tearing, inflexible tarsal plates, patient intolerance, or some combination of
these factors. In a further fifteen individuals (0.3%), one upper tarsal conjunctiva could
not be examined. Complete information on the presence or absence of conjunctival
signs (TF, TI and TS) in both eyes is therefore available for 5500 people (99.5% of
those enrolled in the survey; 96.4% of residents). Enrolment and examination data by
kitongoji, including this information, is shown in Table 6.5 (p.133).
132
Table 6.4: Comparison of people seen and not seen in the survey, Kahe village, April-
June 2000
Variable Explicitly Did not attend Attendedrefused (n=32) (n=I44) (n=5527XXviii)
Mean age 28 years 29 years 23 years
Gender 69%male 54%male 44%male
Secondary education 0(0%) 7 (5%) 55 (1%)
Household owns one or more cows 6 (19%) 36 (25%) 1710 (31%)
Household has own latrine 28 (88%) 130 (90%) 5020 (91%)
Mean reported time from 172 minutes 162 minutes 168 minuteshousehold to water, dry season
Table 6.5: Number of residents, number examined, and number refused by kitongoji,
Kah'11 Anril J 2000survey, e vi age, ~pn - une
Examined FullyforTT and
Kitongoji Explicitly Did not CO; unable
examined Total
refused attend to evert one (% of total residents
or both lids residents)
KaheZamani 5 19 5 594 (95.3) 623
Ndong'e 'A' 3 27 5 773{95.7J 808
Ndong'e 'B' 12 10 4 715.{96.5J 741
Kiura 0 7 3 581 (98.3) 591
KaheMpya 5 21 1 951 (97.2) 978
Ussarangei 5 39 4 927 (95.1) 975
Ture 2 21 5 959 (97.2) 987
Totals 32 144 27 5500 (96.4) 5703
6.1.3 Findings
The prevalence of active trachoma (TF and/or TI) is presented by kitongoji in Table
6.6 (p.134). Signs were considered present if seen in either the right eye or the left eye
or both. In the analyses here, as elsewhere in this thesis, the strict WHO definition
(TF=1 in Table 5.1, p.l09) was used when classifying eyelids as showing 'TF' or 'no
TF'. The prevalence of active disease ranged from 13.6% in Ndong'e 'A', to 27.6% in
Kahe Mpya. Such heterogeneous distribution of disease is typical of trachoma, as was
noted in Section 2.7.2 (p.70).
The main purposes of conducting the survey were (i) to identify the sub-village
with the highest prevalence of active disease, and (ii) to obtain information about the
prevalence and determinants of trachoma in Kahe. Only the first of these has relevance
to the focus of this thesis: the study of ocular CT loads before and at intervals after mass
_.. For secondary education, n=5523 (educational status not known for four individuals); for cattle ownership and
latrine access, n=SS 16
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antibiotic treatment. Further analyses of data collected in the survey are therefore not
presented here.
Table 6.6: Prevalence of active disease in either or both eyes, by kitongoji, Kahe village,
A '} t J 2000ipn 0 une
Kitongoji No. examined Prevalence of active disease (%)
KaheZamani 594 102 (17.2)
Ndong'e 'A' 773 105 (13.6)
Ndong'e 'B' 715 146 (20.4)-
Kiura 581 93 (16.0)
KaheMpya 951 260 (27.3)
Ussarangei 927 167 (18)
Ture 959 219 (22.8)
Totals 5500 1092 (19.9)
6.2 LONGITUDINAL STUDY: BASELINE
6.2.1 Enrolment
Of the seven vitongoji in Kahe, Kahe Mpya had the highest prevalence of active disease
in the survey (Table 6.6), and was invited to take part in the longitudinal study. At the
time of the survey, 978 people were resident in that subvillage (Table 6.5, p.133). The
first survey visit to each Kahe Mpya household (at which time the data for that original
census were collected) was made at some time (varying between households) between
10th May and 7th June 2000. For the longitudinal study, the baseline round of eye
swabbing was undertaken between 11th and 24th July 2000. During the intervening
period, three Kahe Mpya residents moved out to other vitongoji of Kahe, thirty-two
moved out of the village altogether, two died, and the whereabouts of another became
unknown to his family members. At the same time, thirty-eight new individuals were
born or moved into Kahe Mpya (see Figure 6.8, p.153). Therefore, at the time of the
baseline round, there were still a total of 978 (=978-3-32-2-1 +38) individuals living in
Kahe Mpya ('the cohort'). Of the 978, 956 (97.8%) were seen and examined at
baseline, two (0.2%) were temporarily absent from the Village, five (0.5%) explicitly
refused, and fifteen (1.5%) did not attend for examination.
6.2.2 CUnical findings
The prevalence of clinical signs of active disease by age in the cohort at baseline is
presented in Table 6.7 (p.136), and graphed in Figure 6.1 panel (a). The overall
prevalence of active disease (TF and/or TI) in one or both eyes was 195/956 (20%). In
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{continued from end p.134} one to nine year-old children, the prevalence of active
disease at baseline was 140/325 (43%) - more than double the WHO threshold for
community mass antibiotic treatment. As expected, the prevalence ofTF was highest in
young children. peaking in the one to two year-old age group. TF became much less
common with increasing age. The prevalence of conjunctival scarring, trichiasis and
corneal opacity by age at baseline is shown in Table 6.8. Again as expected, and in
contrast to active disease, TS, TT and CO were more frequently seen with increasing
age. A five year-old boy was the youngest individual with TS; 45% of those aged sixty-
one years or older had this sign. A total of fourteen of 956 individuals examined (nearly
1.5%) had TT. All fourteen were offered tarsal plate rotation procedures during August
2000 (see Section 5.5.5, p.116). as were sixty-two individuals with TT from the other
six vitongoji. Forty-nine (64%) of the seventy-six patients presented for operation.
Table 6.7: Prevalence ofTF, TI and active disease (TF and/or TI) in either or both eyes,
b KahM b riy age, e Ipya, ase me.
Age (y_earsl No. examined TF(%) TI(%) Active disease (%
0- 35 9 (26) 9 (26) 13 (37)
1-2 66 31 (47) 32 (49) 42 (641
3-4 77 33 (43) 21 (27} 37 (48)
5-6 83 28 (34) 17 (20) 34 (41)
7-8 69 17(25) 8 (12) 19 (28)
9-10 67 14(21) 9 (13) 16 (24)
11-15 155 5 (3) 8 (5) 12 (8)
16-30 129 I (1) 2 (2) 3 (2)
31-60 208 2 (1) 9 (4) 10 (5)
61+ 67 0(0) 9 (13) 9 (13)
All 956 140 (15) 124 (13) 195(20J
Table 6.8: Prevalence of late stages of trachoma (TS, TT, CO) in either or both eyes, by
Kah M b rage, e tpya, ase me.
Age (years) No. examined TS(%) TT(%) CO(%)
0- 35 0(0) 0(0) 0(0)
1-2 66 0(0) 0(0) 0(0)
3-4 77 0(0) 0(0) 0(0)
5-6 83 1 (1) 0(0) 0(0)
7-8 69 3 (4) 0(0) 0(0)
9-10 67 2 (3) 1 (1) 0(0)
11-15 155 4 (3) 0(0) 0(0)
16-30 129 6 (5) 0(0) 0(0)
31-60 208 61 (29) 8 (4) 4 (2)
61+ 67 30 (45) 5 (7) o (O)_
All 956 107 (11) 14(1) 4 (0)
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6.2.3 Swab collection
From the 956 individuals examined at baseline, 956 'primary' conjunctival swabs
and sixty-seven swabs of nasal exudate were collected. In addition, forty-three
<duplicate' conjunctival swabs were taken. These were repeat conjunctival swabs from
forty-three (91%) of the forty-seven individuals who had been randomly pre-selected
for their collection (see Section 5.4.6, p.114): the other four selected individuals did not
present to be seen. A total of 1066 swabs were therefore collected for peR at baseline.
6.2.4 Reproducibility of laboratory results
(a) Reproducibility of the qualitative result
Of the forty-three individuals who had two conjunctival swabs taken for peR at
baseline, the primary and duplicate swabs gave the same result by Amplicor in forty-
two (98%). The one discrepant result involved an Amplicor negative primary swab and
an Amplicor positive duplicate. Two separate 4JLL aliquots of the duplicate sample
subsequently failed to produce a specific amplified product in the Lightflycler,
suggesting that infection was present at only a very low level.
(b) Sensitivity of the quantitative assay
Performing quantitative peR on Amplicor positive baseline samples from all three
sites of the 'Strategies for the control of blinding trachoma' study required a total of
seventy-one separate Lightf'ycler runs. Each run included one capillary assaying a 4JLL
aliquot of the most dilute standard (S 1), which was prepared at a concentration of one
copy of ompl per 4JLL. Forty-six (65%) of the seventy-one SI capillaries amplified
successfully. Assuming homogeneous mixing of the standard solution, the number of
copies of ompJ found in repeated 4JLL aliquots of SI should have Poisson distribution,
with a mean of I copy. On this basis, 37% (=e-l) [545] of SI capillaries would be
expected to contain zero copies of ompJ, due to sampling variability. This is very close
to the observed proportion (35%) of non-amplifying capillaries. It is therefore
concluded that the Q-peR assay was able to reliably amplify one copy of the 123 base-
pair target sequence if it was present in the capillary, and that capillaries that did not
amplify did not contain any target DNA. However, the sampling variability inferred for
aliquots of the standard also applies to those taken from the samples: a capillary
prepared from an Amplicor positive swab containing a very low Cf load may have
failed to test positive by Q-PCR simply because the 4JLL aliquot sampled did not, by
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chance, contain any DNA. The derivation of a value for CI' loads in such Amplicor
positive, LightCycler negative samples is described in Section 5.7.5 (p.122).
(c) Reproducibility o(the quantitative result
Forty-three individuals had duplicate swabs taken. Five duplicates (12%) were
Amplicor positive. As mentioned above, one of these positive duplicates was part of a
discrepant pair (the primary swab was Amplicor negative, and therefore not quantified).
For the other four individuals, the estimated number of copies of ompJ determined by
Q-PCR for the duplicate sample was within one log of that determined for the primary.
At baseline, there were 115 positive samples, including ninety-one primary
conjunctival swabs (see Table 6.10, p.l40), five duplicate conjunctival swabs and
nineteen swabs of nasal exudate (see Table 6.11, p.141). In fifteen of the 115, the
volume remaining after optimisation of the assay was not sufficient to allow two
replicate 4JLLaliquots to be tested. For the remaining 100 (87%), in Figure 6.2, the
number of copies estimated per swab using the first aliquot is plotted against the
number estimated per swab using the second aliquot. Values have been 'jittered'
slightly, by the addition of a small amount of random noise, in order to separate points
that would otherwise have been superimposed. The regression line of [second aliquot]
quantified on [first aliquot] (i.e., using the results of the first aliquots to estimate the
results of the second), fitted by least squares, is also shown.
Figure 6.2: LoglOcopies ompJ determined for the second aliquot of each baseline
Amplicor positive sample against log copies omp J detennined for the first aliquot of the
same sample
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The slope (regression coefficient) of the line is 0.96 (95% cr 0.86-1.05); the
correlation coefficient (r) is 0.89 (P<O.OOOIon 98 d.f.). However, as Bland and Altman
[546] point out, the correlation coefficient measures the strength of the relationship
between two variables, not the agreement between them, and it is extremely unlikely
that two attempts to measure the same quantity would not be related. In Figure 6.3, the
difference between the estimates made on the two aliquots of the same sample is plotted
against the mean of those two estimates. The points between the two horizontal lines
represent samples for which the difference between the first-aliquot and second-aliquot
Q-PCR estimates was one log or less. Eighty-seven of the 100 samples with two
replicates (87%) fell into this category. (Data points were not jittered for Figure 6.3; in
this figure, therefore, a number of points are superimposed at (loglO(0.3),O), indicated by
the arrow, ").
Figure 6.3: Difference between the estimates of [IOglOcopies ompJ]made on the two
aliquots of each Amplicor positive sample at baseline, plotted against the mean of the
logs of the estimates from those two aliquots
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(d) Q-PCR positivity versus culture positivity
There were fifty-eight individuals with clinically active disease and an Amplicor
positive swab at baseline. Culture swabs collected in 2-SP were available for fifty-six
(97%). In this group, only those individuals who were Q-PCR positive (in addition to
being Amplicor positive) were culture positive; all five of the individuals for whom
both LightCycler replicates were negative were also culture negative (Table 6.9, p.140).
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Table 6.9: Relationship between culture result, Q-PCR result and community ocular C.
trachomatis load (COCTL) in subjects with signs of active trachoma and an Amplicor
positive swab at baseline. The derivation ofCOCTL is explained in Section 5.9.2
(p.12S); its confidence intervals were determined by bootstrapping, with 10,000
r treplica es.
Culture result Q-PCR - Q-PCR + on one or both replicates
No. subjects No. subjects COCTL (95% Cl)
(+) on 1SI passage 0 11 11770 (2723 - 31967)
(+) (+) on 2"0passage 0 17 5187 (1871 -14375)
_(+)on 3n1 to IOtn passage 0 18 217(87-621)
_(- ) (-) on 10 passages 5 5 1095 (82 - 41405)
Total 5 51
Compared to our quantitative PCR, then, the sensitivity of our culture technique
would be 22% (11151) if only one passage had been performed, 55% (28/51) if two
passages had been performed, and 90% (46/51) when ten passages were performed.
6.2.5 Prevalence of infection
Ninety-one (10%) of 956 primary conjunctival swabs, five (12%) of forty-three
duplicate conjunctival swabs and nineteen (28%) of sixty-seven swabs of nasal exudate
tested positive by Amplicor for pCT DNA. Amplicor results by age and gender for the
primary conjunctival and nasal exudate swabs are presented in Table 6.10 and Table
6.11 (p.141) respectively. None of the differences between males and females of the
same age group were statistically significant (Fisher's exact test). The prevalence of
conjunctival infection is plotted against age (males and females together) in Figure 6.1,
panel (b) (p.135).
bl 610 Am r I b d d . I bTa e . iphcor resu ts )y age an gen er, conjunctiva swa s, basehne
Age (years)
Amplicor + / number swabbed (%)
Males Females Total
0- 2/21 (10) 3/14(21) 5/35 (14)
1-2 5/30 (17) 3/36(8) 8/66 (12)
3-4 3/40 (8) 9/37 (24) 12177 (16)
5-6 7/46J15) 9/37 (24) 16/83 (19)
7-8 6/38 (16) 5/31(16) 11169 (16)
9-10 8/28 (29) 8/39 (21) 16/67 (24)
11-15 6173 (8) 4/82 (5) 10/155 (6)
16-30 2/37 (5) 1192(1) 3/129 (2)
31-60 2/82 _(2) 6/126 (5) 8/208 (4)
61+ 1127(4) 1/40 (3) 2/67 (3)
All 42/422 (10) 49/534 (9) 911956 (10)
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Tabl 611 Am li I b d d b f d b lie . ipncor resu ts )y age an gen er, swa s 0 nasa exu ate, aseme
Age (years) Amplicor + I number swabbed(%)
Males Females Total
0- 0/1101 112(50) 3/15 (20)1-2 116(17) 116_(17)
3-4 2/9 (22) 4/11 (37)
11136(31)5-6 217 (29) 3/9 (33)
7-8 2/51401 0/210)
4/11 (36)9-10 11111001 113(33)
11-15 0/21Ql 1/3 (33)
16-30 no swabs collected no swabs collected
115(20)31-60 no swabs collected no swabs collected
61+ no swabs collected no swabs collected
All 8/31 (2~ 11136 (31) 19/67 (28)
The prevalence of Amplicor positivity in swabs of nasal exudates was significantly
higher than that in conjunctival swabs. Conjunctival swabs were collected from all
consenting subjects, however, while nose swabs were collected only from individuals
who had nasal exudate visible outside the margin of the nare (Section S.4.S(c), p.112).
The relatively high prevalence of infection in nose swabs may therefore simply indicate
that individuals with nasal exudates were more likely to be infected with C.
trachomatis, with the discharge being a response to that infection. This hypothesis is
supported by the data: of sixty-seven individuals who had a nose swab taken at baseline
(regardless of whether that swab was positive), sixteen (24%) had a positive baseline
conjunctival swab, while only seventy-five (8%) of 889 individuals who did not have a
nose swab taken had positive eye swabs (z=3.93, P=O.00008).
6.2.6 Intensity of ocular infection
Figure 6.4 (p.142) is a scatter plot of the estimated number of copies of ompl per
swab by age and gender at baseline. Because the number of copies of ompl is displayed
against a log scale, only data points relating to samples positive by Amplicor (copies
omp}>O) are included. Values range from to 4.12 copies omp l (the lowest possible
value for the assay: see Section 5.7.5, p.122; seventeen individuals) to 491708 copies
ompl (an eight month-old girl). Most individuals with high copy numbers were young.
This is underscored by the differences in COCTL between age groups, shown in Figure
6.1 panel (c) (p.13S), and tabulated in Table 6.12 (p.142).
141
Figure 6.4: Copies ompl per swab by age and gender at baseline for subjects with an
Amplicor positive swab ('o'=male, '+'=female)
100000
.Q
til
I...
8....
0-
8 1000
l
0o
10
o
•
0
..o·.
0
~ ~0
+ o ~
o·.
0
0 .0
.0
0.0:.
0
10. 0
0
.0 0. .o· 0 ••
0 ~.0
·0 ••
• 0
_. .....
0
•
•
00 • o
50
Age (years)
75 10025
Table 6.12: COCTL by age group and gender at baseline. Both Amplicor positive and
Amplicor negative individuals are included. Confidence intervals determined by
. ith 10 000 libootstrapping, WI , replicates.
Age COCTL (95% Cl), n
(years) Both genders Males Females
0- 6.9 (0.3 - 35.0), 35 2.7 (0.0 - 24.4),21 18.7 (0.2 -599), 14
1-2 3.5 (0.9 - 9.2),66 4.8 (0.8 - 19.2),30 2.5 (0.1 - 12.4), 36
3-4 5.4 (1.9 - 12.6), 77 2.4(0.4 - 9.4), 40 10.1 (2.6 - 34.5), 37
5-6 5.8 (2.4 - 13.1),83 3.2 (0.8 - 9.3), 46 10.5 (2.8 - 33.7), 37
7-8 4.4 (1.5 - 10.7), 69 6.2 (1.4 - 22.0), 38 2.7(0.5 -10.2), 31
9-10 6.6 (2.7 - 15.3), 67 6.7 (2.1 - 19.6),28 6.60.6 - 21.2),39
11-15 0.8 (0.3 - 1.9), 155 1.3 (0.3 - 3.9), 73 0.4 (0.1 - 1.0), 82
16-30 0.1 (0.0 - 0.4), ]29 0.3 (0.0 -1.1),37 0.1 (0.0 - 0.4), 92
31-60 0.3 (0.1 - 0.7),208 0.1 (0.0 - 0.3), 82 0.5(0.1-1.2),126
61+ 0.1 (0.0 - 0.4), 67 0.1 (0.0 - 0.6), 27 0.1(0.0 - 0.9), 40
All 1.99 (1.44 - 2.67), 956 2.0 (1.2 - 3.0),422 2.0-(1.3 - 3.0),534
Another way of looking at the data is to consider the cumulative load of ocular C.
trachomatis with increasing age. The total estimated number of copies of omp1 found
in all baseline swabs was 1,578,724. Figure 6.5 (p.143) is a plot of the cumulative
number of copies of ompl against age in years at baseline, with cumulative load (on the
vertical axis) shown as a percentage of that total community load. Fifty percent of the
total community swab-load of C. trachomatis DNA was found in samples from children
below nine months of age, and over 90% was found in samples from children aged
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below six years and eight months. The importance of this result, and the contribution to
it by two heavily infected infants, will be considered in the discussion.
Figure 6.5: Cumulative load of omp1 found in conjunctival swabs against age at
baseline
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The wide confidence intervals for the COCTLs (and resulting lack of statistically
significant differences in this index between males and females in each age group) in
Table 6.12 (p.142) could be interpreted as stemming from the relatively narrow age
bands used. Further analysis with data combined over broader age categories was
therefore undertaken. An example is shown in Table 6.13. This shows gender-specific
COCTLs separately for those above and below the age of ten, (based on the observation
that the COCTL was markedly lower in those aged eleven and above than in the age
groups up to ten years - see Figure 6.1 panel (c), p.135). The differences in COCTL
between males and females, using these or other age categories, are not significant.
Table 6.13: COCTL for males and females, stratified into groups above and below the
age of ten years, at baseline. Confidence intervals determined by bootstrapping, with
10000 r, repncates.
Age (years)
COCTL _(95% Cl), n
Males Females
<10 3.62 (1.88 - 6.491,186 7.2613.83 -13.13_l, 174
10 or more 0.94 (0.44 - 1.69), 236 0.42 (0.19 - 0.75), 360
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6.2.7 Spatial distribution of ocular infection
Figure 6.6 (p.I44) is a map showing the distribution of infected individuals by
household at baseline. The number of people living in each house is represented by the
size of the open (black-edged) square. The number of Amplicor positive individuals in
the house is shown by the size and shade of the contained colour splash. The 'most
likely' clustering'?" of infected individuals has a radius of nearly 180 metres, and is
located within the circle drawn at the western boundary of the subvillage. This area
contained seventeen cases; the expected number, assuming homogeneous distribution of
cases amongst all swabbed cohort individuals (the null hypothesis), was 4.85 (P<0.006
based on 999 Monte Carlo replicates). None of the possible secondary clusterings
identified by SaTScan were statistically significant (Appendix 5, p.213).
6.3 TREAMENT COVERAGE
Each non-pregnant member of the cohort above the age of twelve months who
presented at baseline was offered a single oral dose of azithromycin 20mg/kg, given
immediately after swabs were collected. As described in the methods section, women
who said they were pregnant and infants less than one year old were not given
azithromycin, but instead offered two tubes of tetracycline. All but one of the 956
cohort individuals who presented accepted either azithromycin or tetracycline. One
sixty-year-old woman refused treatment because she had taken traditional medicine on
the day of our visit, and did not want its effect to be diminished. Overall, for Kahe
Mpya (the cohort), therefore, treatment coverage was 955/978, or 97.6%. Data are
shown in Table 6.14 (p.146) for males, and Table 6.15 (p.146) for females. One
individual mistakenly received treatment twice: once at home, and once at school.
In the other sub-villages of Kahe, it was not logistically possible to update the
results of the original census to the same degree of exactness as was attempted for the
cohort. Individuals who were not registered in the survey but who were resident at the
time of drug distribution were listed on treatment record cards as new individuals, and
offered antibiotics. However, no attempt was made to determine how many people
uix The term 'clustering' has been preferred to 'cluster' in this thesis, because if risk of being infected is in some way
dependent on distance to - for example - other infected indivi~uals, or a site where flies breed, then it is likely that
that risk simply fades with increasing distance, rather than having a defined boundary [547]. However. to look for
foci of elevated prevalence. it is necessary to delineate areas .betw,een which prevalence can be compared. SatScan
uses circular windows, identifying the location of each putative high prevalence area using the radius of the circle that
delimits it. and the northing and casting of its centre. The focus of elevated prevalence has therefore been drawn as a
circle in Figure 6.6. and its radius noted here. whilst recognising that a sudden transition between elevated risk of
ocular er infection and reduced (or background level) risk is unlikely in the real world.
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Table 6.14: Treatment coverage for males by age group, cohort. The denominator for
coverage in each cell is the number of male residents of that age living in the sub-village
at the time of treatment not the number examined.,
Number (% of residents in that age group)
Age Total Treated with
Given Did not Explicitly(years) residents azithromycin
tetracycline present refusedointment treatment
0- 21 9 (43) 12 (57) 0(0) 0(0)
1-2 30 30 (100) 0(0) 0(0) 0(0)
3-4 40 40 (lOO) 0(0) 0(0) 0(0)
5-6 46 46 (lOO) 0(0) 0(01 0(0)
7-8 38 38 (100) 0(0) 0(0) 0(0)
9-10 29 28 (97) 0(0) 1 (3) 0(0)
11-15 74 73 (99) 0(0) 1 (1) 0-(0)
16-30 43 37 (86) 0(0) 6(14) 0(0)
31-60 90 82 (91) 0(0) 8(9) 0(0)
61+ 27 27 (lOO) 0(0) 0(01 0(0)
All 438 410 (94) li(3) 16 (4) 0(0)
Table 6.15: Treatment coverage for females by age group, cohort. The denominator for
coverage in each cell is the number of female residents of that age living in the sub-
ill the ti f t t th b r exami dVI age at me 0 treatmen, no e num e me .
Number (% of residents in that age group)
Age Total Treated with
Given
Did not Explicitly
(years) residents azithromycin
tetracycline
present refusedointment treatment
0- 14 10 (71) 4 (29) 0(0) 0(0)
1-2 36 36 (lOO) 0(0) 0(0) 0(6)
3-4 38 37 (97) 0(0) 1 (3) 0(0)
5-6 37 37 (lOO) 0(0) 0(0) 0(0)
7-8 32 31 (97) 0(0) 1(3) 0(0)
9-10 39 39 (lOO) 0(0) 0(0) 0(0)
11-15 83 82 (99) 0(0) 1 (1) 0(0)
16-30 95 81 (85) 11 (12) 3 (3) o CO)
31-60 126 114 (90) 12 (10) 0(0) 0(0)
61+ 40 39 (98) 0(0) 0(0) 1 (2)
All 540 506 (94) 27 (5) 6 (1) 1 (O)
{continued from end p.145 J registered at the survey had died or moved out of the village
in the interval between the survey and treatment visits. Of the 4732 individuals living
in 'non-cohort' mabalozi (NCBs) in April through June 2000, 3921 (82.9%) presented
for and received treatment in July or August 2000. An additional 125 'new' individuals
were treated. Ignoring out-migration, deaths, and new-borns or new arrivals who did
not present, then, the approximate treatment coverage for NeBs was
(3921+125)1(4732+125), or 83.3%. Three NCB individuals managed to receive
treatment twice by presenting at different locations on two different days.
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Treatment of NCB residents was undertaken from the 27th July to the 10th August
2000. The final day of drug distribution in Kahe was therefore thirty days after the first
( II th July 2000: see Section 6.2.1, p.134). This cut-off date was imposed in order to
simulate, as closely as possible, synchronous mass community treatment. Between the
end of the baseline cohort round and the 10th August, eighteen new individuals were
born or moved into Kahe Mpya. Fifteen of the eighteen requested antibiotic from the
treatment teams, and were treated.
The total number of individuals treated in the village of Kahe was therefore
(955+3921+125+IS) = 5016. If we again discount the reservations about the reliability
of the denominator for the NCBs (discussed above), the overall treatment coverage for
the village was 5016/(978+4732+125+18) = 85.7%. These entire village treatment data
are shown in Appendix 6: for males in Table A6.l (p.228) and for females in Table
A6.2 (p.229).
6.4 HEIGHT AND WEIGHT DATA
Of 5016 people treated, there were thirty-five individuals (0.7%) for whom height
had not been measurable (and therefore recorded as OOOcm:see Section 5.5.2, p.1l5);
for three of the thirty-five, weight had also not been measurable (see Section 5.5.1,
p.115). Another five individuals (0.1%) had weight recorded as being below one
kilogram, despite their height being listed at sixty centimetres or more. These forty
individuals, plus the eighty-one pregnant women and 117 infants (not given
azithromycin) have been excluded from the analysis that follows, which is therefore
based on the records of 4778 azithromycin-treated people (95.3% of those treated;
83.8% of the best-estimate village population). Azithromycin dose was determined by
weight. The minimum weight required for tablets to be offered was 10.0kg; people
below this weight were offered azithromycin suspension. A total of 4350 people were
given one or more azithromycin tablets. Summary statistics for the heights of people in
each weight-based tablet dosing category comprise Table 6.16 (p.148). These
distributions are shown graphically in Figure 6.7 (p.148).
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Table 6.16: Recorded heights of subiects in five weight-based tablet dosinz categories
No. of Height (cm'
tablets No. of 25th 75th(by people Minimum percentile Median percentile Maximum
weight)
0 428 48 70 76 82 157
1 770 65 90 97 103 120
2 920 88 115 121 128 143
3 691 125 136 142 147 179
4 1969 48 154 159 164 184
Overall 4778 48 109 140 157 184
Figure 6.7: Cumulative height distributions of azithromycin-treated Kahe residents, by
weight-based dosing category. Symbols used to construct each curve represent the
number of tablets received per person when dosed by weight.
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The data used in the construction of the curves in Figure 6.7 can be used to choose
thresholds between one and two tablets (1v2), two and three tablets (2v3), and three and
four tablets (3v4), for dose assignment by height. The process is more easily described
and visualised by a graphical than by a tabular explanation. First, an appropriate trade-
otT between underdosing and overdosing (denoted here by 1/1, where I/I=number
overdosed / number underdosed) must be defined. Then, on the graph, a perpendicular
to the horizontal axis (representing the height threshold between doses) is drawn such
that the number of individuals to the right of the perpendicular on the curve in the lower
weight-based dosing category (overdosed individuals) is 1/1 times the number of people
to the left of the perpendicular on the curve in the higher weight-based dosing category
(underdosed individuals). A 1/1 of 10 was (arbitrarily) set for each of the 1v2, 2v3 and
148
3v4 thresholds. In practice, because height data were grouped at lcm intervals, it was
not possible to achieve a 1/1 of exactly 10 (see Table 6.18, p.150).
For the threshold between zero and one tablet (Ovl), the curves may be misleading
if used in this way, since the zero tablet curve includes a number of individuals who
were given suspension simply because they were physically unable to swallow
azithromycin tablets, rather than because their body mass was too low to be given
250mg of drug. Further, arbitrary imposition of a trade-off between overdosing and
underdosing at this boundary is probably inappropriate. Because children below the
one-tablet height limit can be conveniently and reliably weighed using a spring scale,
then allocated a dose of suspension (POS), the most important factor in determining the
Ov1 threshold is ensuring that long thin children are not given excessive drug. A higher
threshold will tend to be safer. To explore the minimum height requirement for one
tablet. data from the 430 non-pregnant treated people over the age of twelve months
were re-queried. and those who were eligible (by weight) to receive two or more tablets
(n=17) excluded. The dose-per-kilogram, should one 250mg azithromycin tablet be
administered. was then determined for each of the remaining individuals. If the lower
height bound for one tablet is set at 76cm, 199 people would be given one tablet, with
the dose given ranging from 15.2--40.3mg/kg. Only five one tablet recipients would
receive more than 3Omg/kgazithromycin (30.1, 30.1, 30.1, 31.6 and 40.3mg/kg).
The height-based dosing schedule based on these calculations appears in Table
6.17. Table 6.18 (p.150) compares the number of tablets assigned using the current
weight-based schedule with the number of tablets assigned using the schedule in Table
6.17. Table 6.19 (p.150) presents an equivalent comparison, but with dose shown in
mg/kg body weight rather than in number of tablets.
Table 6.17: Height-based dosing schedule for azi omycin
Height (cm) Number of tablets
<76 o (weigh with spring scale and give POS)
76 -102 1
103 - 129 2
130 - 143 3
144+ 4
ithr
149
Table 6.18: Comparison of weight-based and height-based dosing (1). People in each
weight-based dosing category (rows) are divided by column to indicate the number of
tablets that they would have received using the height-based schedule proposed. Cells
shaded green are those containing people for whom the number of tablets assigned by
height and weight would be the same. People above this green diagonal would be
overdosed by the height-based schedule; those below would be underdosed. People
ass ed to '0 tabs' either method would be' to receive POS.
o.oftablets
determined by
weight
No. of individuals planned to receive each dose
(classed by no. of tablets), ifno. of tablets determined
hei Total
Table 6.19: Comparison of weight-based and height-based dosing (2). As for Table
6.18, but categories here determined by dose of azithromycin tablets in mg/kg body
weight. Cells shaded orange contain people who would receive a 'safe and effective'
dose using the height-based schedule (or the same dose as that given by weight); those
shaded low contain 'underdoses" those shaded red contain 'overdoses'.
Dose in mglkg of
tablets when no. of
tablets determined
by weight
No. of individuals planned to receive each dose
(classed by mg of tablets /kg body weight), ifno. of
tablets determined Total
0.01 - 15.00-
14. 29.
The choice of IS-30mglkg as the 'safe and effective' dose range is somewhat
arbitrary [507], but parallels the range of actual doses received by most individuals
dispensed azithromycin tablets by body weight. In Kahe, for example, there were
eighty-one individuals (1.7% of 4778) for whom the standard weight-based schedule
would deliver less than 15mg azithromycin per kilogram recorded body weight (Table
6.19, cell [aJ). All eighty-one were adults due to receive the maximum dose of 19 (four
tablets). During the 2000 distribution, in fact, all eighty-one did take four tablets. The
height-based schedule is similarly restricted to a four tablet maximum, and correctly
assigns four tablets to each of these individuals. Cell [a] has therefore been shaded
orange, to indicate a presumed 'safe and effective' dose by height, even though the
actual dose received by this group would range from 14.99mglkg down to 10.91mglkg.
150
The height-based schedule refers for a weight-determined POS dose forty individuals
(Table 6.19, cell [b]) who would have received a 'safe and effective' 15-3Omglkg of
tablets with the weight-based schedule. One of these forty was a twenty year-old
woman whose height was (almost certainly erroneously) recorded as 48cm and whose
weight was recorded as 39.9kg. Of the other thirty-nine, twenty-nine were unable to
swallow an offered tablet, and required suspension in any case. None of the forty would
be misdosed as a result of the height-based scheme.
In all, only eighteen people (Table 6.19, cell [cl; 0.4% of 4778) would be
underdosed using the height-based schedule, if underdosing is defined as a dose below
l Smg/kg body weight and less than that offered by the weight-based schedule. All
eighteen would be given more than 13mglkg. Some 4379 people (91.6% of 4778)
would receive a presumed safe and effective dose. A total of381 (8.0% of 4778) would
receive more than 3Omglkg. A breakdown of doses determined for this group is
presented in Table 6.20. The characteristics of the five individuals scheduled to be
given more than 40rnglkg are shown in Table 6.21.
Table 6.20: Dose ranges of those receiving more than 30mg azithromycin per kilogram
body weight using the height-based dosing schedule
Number of individuals in Kahe who would have received this dose, if
Dose in mg/kg no. of tablets determined by height (% of 4778 azithromycin-treated
_Qe~ltU
30.00 - 32.49 245 (5.1)
32.50 - 34.99 93 (1.9)
35.00 - 37.49 30(0.6)
37.50 - 39.99 810.1)
40.00+ 5 (0.1)
Table 6.21: Further details of the five individuals who would receive more than 40mg
azithromycin per kilogram if doses were determined by recorded height. BMI=body
mass index
Weight Height BMI Dose by
Dose by Actual dose Actual dose
height (no. schedule dispensed (no. dispensed(kg) (cm) (kg/nr') of tablets) (mg/kg) of tablets) (m~
6.2 84 8.8 1 40.3 0(3mLPOSl 19.3
12.0 103 11.3 2 41.7 1 20.8
11.3 113 8.8 2 44.2 1 22.1
15.2 163 5.7 4 65.8 4 65.8
13.6 148 6.2 4 73.5 3 55.1
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As shown in Table 6.21, all five individuals slated to receive over 40mglkg by the
height-based dosing schedule were exceptionally tall for their weight. It is not known
whether measurement or recording of height or weight were in error.
6.5 LONGITUDINAL STUDY: FOLLOW-UP
6.5.1 Follow-up success
The number of people resident in Kahe Mpya and the number of people examined
at each time point are shown in Table 6.22. In this table, and subsequently, the two
month follow-up point has been designated '2/12', the six month follow-up '6/12', and
so on, Examination coverage at baseline and the four follow-up time points has been
calculated as the number of people seen divided by the number of people resident in the
sub-village at that time, as determined at the census review conducted immediately prior
to examination and swabbing. On this basis, the mean examination coverage for the
five rounds was 93%.
The trial profile for the cohort is shown in Figure 6.8 (p.153). Each row in this
Figure represents a examination point in either the surveyor longitudinal study. At
each of those time points, the numbers in boxes show the status (indicated by the
column heads) of all individuals registered at any time prior to that point as living in
Kahe Mpya. Arrows with solid tails indicate movement of cohort members from one
category (e.g., living in Kahe Mpya) to another (e.g., lost to follow-up). Arrows with
dashed tails represent individuals remaining in one category between successive
examination points. New individuals are introduced from the far left of the Figure. In
the interval between the original census and the completion of the final follow-up round
eighteen months after treatment, a total of 206 new individuals were born into (n=65) or
moved into (n=141) Kahe Mpya.
Table 6.22: Number of people resident in Kahe Mpya and number of people seen at
h . . fth 1 itudi al deac time point 0 e ongit m stul}'_
Time point Number resident Number seen (% of resident~
Baseline 978 956 (98%)_
2/12 959 905J94%)
6/12 973 879 (90%)_
12/12 984 907_(92o/l!l
18/12 978 889 (91%)
Total 4872 (mean=974) 4536_(93o/~
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Figur 6. : Longitudinal study profile
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6.5.2 Prevalence of active trachoma over time
Figur 6.9 (p.154) sho s th prevalence of active trachoma in one or both eyes, by
ag group, at baseline and the four follow-up points of the longitudinal study. At each
tim point the peak in disease prevalence was in young children. The all-ages
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pre alene of acti e disease was significantly lower at each follow-up point than it was
at ba line tx o-sided P<0.001 for each comparison). The prevalence at twelve months
94/907, 10.4%) \: as significantly higher than it was at either six months (54/879, 6.1%)
(z=3.15 P=0.0016) or eighteen months (54/889, 6.1%) (z=-3.22, P=0.0013). The
reason for this finding is unclear. Seasonal fluctuation in transmission of C.
tra homatis or other ocular pathogens might be responsible: as was suggested in
S ction 2.6.12(ii) (p.63), it has been hypothesised that a variety of micro-organisms
might b abl to induce conjunctival changes reminiscent of active trachoma in
indi iduals ho ha e previously been exposed to ocular Chlamydia. The prevalence of
TF in on to nine ear-old children was 117/325 (36.0%) at baseline, 411311 (13.2%) at
two month 36/295 (12.2%) at six months, 66/319 (20.7%) at twelve months, and
39/315 12.4%) at eighteen months: a profile of prevalence over time similar to that
displa ed for all-ages acti e disease in Figure 6.9.
Figur 6.9: Pre al ne of active disease by age group over time
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6.5.3 Prevalence of infection over time
The observed prevalence of C. trachomatis positive swabs at each time point is
shown in Table 6.23. The prevalence of conjunctival infection progressively decreased
over the course of follow-up. The decrease from baseline to two months was
statistically significant (z=-6.69, P<O.OOOI). At six months, twelve months and
eighteen months, the prevalence of ocular positivity remained significantly lower than it
was before treatment (P<O.OOOIfor each comparison), but was not significantly below
that recorded for the previous round.
The proportion of nasal exudate swabs that were C. trachomatis positive
progressively decreased from baseline up to twelve months, then increased from 1% to
3%. At each follow-up point (two, six, twelve and eighteen months), the proportion
positive was significantly lower than that at baseline. The increase in the prevalence of
positivity from twelve to eighteen months was not significant (z = 0.67, P = 0.50).
Table 6.23: Arnplicor results for primary eye swabs, duplicate eye swabs and swabs of
l exudate azai .nasa ate g nst time
Time No. Number Arnplicor positive/number taken (%)
point seen Primary eye swabs Duplicate eye swabs Nasal exudate swabs
Baseline 956 911956 (10%) 5/43 (12%) 19/67(28%)
2/12 905 19/905 (2%) not done 6153 (11%)
6/12 879 13/879 (1%) not done 2/30 (7%)
12/12 907 8/907 (1%) not done 1179(1%)
18/12 889 5/889 (1%) DOt done 1132(3%)
Total 4536 136/4536 (3%) 5/43 (12%) 29/261 (11 %)
6.5.4 Intensity of ocular infection over time
Figures 6.l0 through 6.l3 (p.lS6-157) are scatter plots of the estimated number of
copies of ompl per swab by age and gender at two, six, twelve and eighteen months
respectively. As for the baseline data plotted in Figure 6.4 (p.142), only data points
relating to samples positive by Amplicor (copies omp}>o) are included. At two months,
the highest ompl swab load was 4264 copies omp l (compared to 491708 at baseline); at
six months, it was 2164; at twelve months, it was 236; and at eighteen months, it was
14178. In general, as at baseline, higher loads were found in younger individuals,
though a sixty-two year-old woman and an eighty-eight year-old woman both had low-
level positive swabs at eighteen months (Figure 6.13, p.lS7). There were no other CT-
positive individuals at eighteen months in the household (or even balozi) in which either
woman was living.
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Figure 6.10: Copies omp J per swab by age and gender at two months for subjects with
an Amplicor positive swab ('o'=male, '+'=female)
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Figure 6.11: Copies ompJ per swab by age and gender at six months for subjects with
an Amplicor positive swab ('o'=male, '+'=female)
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Figure 6.12: Copies omp l per swab by age and gender at twelve months for subjects
with an Amplicor positive swab ('o'=male, '+'=female)
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Figure 6.13: Copies omp l per swab by age and gender at eighteen months for subjects
with an Amplicor positive swab ('o'=male, '+'==female)
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Frequency distributions of the number of copies of omp l per swab found amongst
those with Amplicor positive swabs at each time point comprise Figure 6.14 through
Figure 6.18 (p.l 58-1 59). Table 6.24 (p.159) shows the COCTL for the cohort at each
time point; these data, including the 95% confidence intervals, are shown in Figure 6.19
(p.160). The COCTL is shown by age group in Figure 6.20 (p.160), and by age group
and gender in Figure 6.21 (p.160).
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Figure 6.14: Frequency distribution of copies amp] per swab in Amplicor positive
subjects at baseline
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Figure 6.15: Frequency distribution of copies amp] per swab in Amplicor positive
subjects at two months
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Figure 6.16: Frequency distribution of copies amp] per swab in Amplicor positive
subjects at six months
20
I;1 I r I
v
10 100 1,000 10,000 100,000 1,000,000
Copies amp 1 per swab
158
Q) 15
0.
0
Q)
0...... 100
.....
Q)
.D
E
:::l 5z
0
Q) 15
Q._
0
Q)
0.
'0 10
Iii
.D
E
:::l 5z
0
Figure 6.17: Frequency distribution of copies omp l per swab in Amplicor positive
subjects at twelve months
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Figure 6.18: Frequency distribution of copies omp l per swab in Amplicor positive
subjects at eighteen months
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Table 6.24: COCTL, all ages and both genders, at each time point. Confidence intervals
. h 0000 I' tdetermined by bootstrapping, WIt I , rep lea es.
Time point No. seen COCTL (95% Cl), f% of baseline]
Baseline 956 1.99 (1.44 - 2.67), [100]
2112 905 0.26 (0.14 - 0.43), [13]
6112 879 0.16 (0.07 - 0.29), (8]
12 12 907 0.08 (0.03 - 0.16), [41
18/12 888 0.07 (0.01 - 0.19), f41
159
Fi ur 6.19: COCTL, all ages and both genders, against time (vertical bars show
95% I at each time point)
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Figur 6.20: COCTL by age group against time
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Figur 6.21: OCTL by age group and gender against time
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The observed reductions in COCTL following treatment were striking. For the
community as a whole (Figure 6.19), the index dropped to 13% of its pre-treatment
level two months after mass distribution of single-dose azithromycin. Thereafter, it
continued to fall, being 8% of its baseline level at six months, 4% at twelve months, and
4% at eighteen months. Falls in COCTL were observed in all age and gender groups
(Figure 6.20 and Figure 6.21). Other than the supply of two tubes of tetracycline eye
ointment to individuals with clinical evidence of active disease at the six month (fifty-
four people) and twelve month (ninety-four people) follow-up points, there were no
other formal trachoma control efforts undertaken in the village during this period. The
possible contribution of topical treatment to the observed reduction in infection intensity
will be discussed in Section 7.3.4 (p.187).
InTable 6.25, the ages for the so" and 90th centiles of the cumulative load of ocular
C. trachomatis are shown for each time point. These are the ages below which 50% and
90% respectively of the total ocular chlamydial burden was found. The so" centile was
consistently located below six years of age; the 90th centile was consistently below
fifteen years of age. These data underline the importance of children as a reservoir of
ocular CT.
Table 6.25: Cumulative ocular C. trachomatis load with increasing age at each time
. tpom
Time point Ag_eat so" centile Age at 90m centile
Baseline o_years9 months 6 years 8 months
2/12 5 years 11months 6 years 0 months
6/12 3 years 1month 6 years 2 months
12/12 4 years 7 months 14 years 7 months
18/12 5 years 0 months 5 years 0 months
6.5.5 Risk factors for ocular infection at two months
A description of and rationale for the methods used to investigate risk factors for
post-treatment infection were both presented in Section 5.9.3 (p.125). Everyone
swabbed at two months who had received tetracycline eye ointment at baseline or one
month lived in a house with access to a latrine. This meant that baseline tetracycline
use and latrine access were collinear in the regression model. When latrine access was
dropped from the first phase of analysis, tetracycline use was not significantly
associated with the risk of having a positive ocular swab, but when tetracycline use was
dropped, latrine access was associated with decreased risk of being Amplicor positive.
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Individuals with ocular or nasal discharge were significantly more likely than others to
be positive. These results are shown in Table 6.26.
Table 6.26: Logistic regression results for risk of being Amplicor positive at two
months. Information about latrine access was not available for 29 individuals. Only
f hi h th ad' ed dd t ti . 11 .fi hexposures or w c e ljust 0 s ratios were s a stica tv sigm cant are sown.
Prevalence of
'Exposure'
'exposure' Crude (unadjusted) Adjusted odds ratio
exposed/seen odds ratio (95%CI)
(%)
Access to a latrine 870/876 (99.3) 0.037 0.029 (0.0048-0.17)
Nose discharge 53/905 (5.9) 4.6 4.7 (1.4-15)
Eye discharge 2/905 (O.2) 49 32 (3.8-263)
6.5.6 Risk factors for ocular infection at six months
None of the individuals examined at this time point had any ocular discharge
visible on examination, so the 'exposure' 'eye discharge' was dropped from the
analysis. Only two factors were significantly associated with the risk of being Amplicor
positive at six months: increasing age, which was associated with reduced risk of being
positive, and the presence of a visible nasal discharge, which was associated with an
increased risk (Table 6.27). The odds ratios shown for age are for each additional year
of age, suggesting a progressively reduced risk of being ocular CT positive in older
people.
Table 6.27: Logistic regression results for risk of being Amplicor positive at six months.
Only exposures for which the adjusted odds ratios were statistically significant are
shown
Prevalence of
'Exposure'
'exposure' Crude (unadjusted) Adjusted odds ratio
exposed/seen odds ratio (95% Cl)
(%)
Age (for each year) not applicable 0.89 0.91 (0.86-0.97)
Nose discharge 30/879 (3.4) 14 6.7 (2.0--22.4)
6.5.7 Risk facton for ocular infection at twelve months
At twelve months, none of the seventy-nine individuals with nasal discharge, the
nineteen individuals with examiner-observed fly-eye contact, or the eight individuals
with ocular discharge had swabs that tested positive by Amplicor in the laboratory.
These three 'exposures' were therefore eliminated from the analysis. All eight twelve
month Amplicor positive individuals had access to a latrine. This 'exposure' was
therefore also not considered. Only two terms returned significant odds ratios in the
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regression model (Table 6.28). As was noted at six months, at twelve months,
increasing age was associated with decreasing risk of having an Amplicor positive
conjunctival swab. Receipt of tetracycline eye ointment at the six month examination
was associated with a significantly increased risk of being Amplicor positive at twelve
months.
Table 6.28: Logistic regression results for risk of being Amplicor positive at twelve
months. Only exposures for which the adjusted odds ratios were statistically significant
are shown.
Prevalence of
'Exposure' 'exposure'
Crude (unadjusted) Adjusted odds ratio
exposed/seen odds ratio (95% Cl)
(%)
Age (for each year) not applicable 0.91 0.94 _(0.89-O.9~
Tetracycline at 6/12 52/907 (5.7} 18 11 (2.8-45}
6.5.8 Risk factors for ocular infection at eighteen months
All five Amplicor positive individuals at eighteen months had been treated with
azithromycin at baseline or one month; none, therefore, had been given tetracycline at
either time. None of the five Amplicor positive subjects had either ocular or nasal
discharge on examination. The exposure variables representing treatment at baseline or
one month, and eye and nose discharge at twelve months were therefore dropped.
According to the model, when the effect of other variables is controlled, increasing age
was associated with an increased risk of infection at eighteen months (Table 6.29), in
contrast to the reduction in risk with increasing age seen in the analyses for the previous
two time points (see Sections 6.5.6 and 6.5.7 above). As at twelve months, at eighteen
months, people who had received tetracycline eye ointment at the previous examination
were significantly more likely than others to have an Amplicor positive eye swab.
Access to a latrine was associated with decreased risk of having a positive swab.
Table 6.29: Logistic regression results for risk of being Amplicor positive at eighteen
months. Only exposures for which the adjusted odds ratios were statistically significant
are shown .
Prevalence of
'Exposure' 'exposure'
Crude (unadjusted) Adjusted odds ratio
exposed/seen odds ratio (95% Cl)
(%)
Age (for each year) not applicable 1.02 1.04 (1.004-1.1_l
Tetracycline at 12112 88/889 (101 14 1813.2-1001
Access to a latrine 873/889 (98) 0.22 0.014 (0.0020-0.094}
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6.5.9 Spatial distribution of ocular infection over time
Figure 6.22 through Figure 6.25 (p.166-169) are maps of the distribution of ocular
infection by household at two months, six months, twelve months and eighteen months.
On the two month and twelve month maps, the locations of the 'most likely' clusterings
identified in the SaTScan analysis are shown as circles. At six months and eighteen
months, none of the clusterings identified in the analysis were statistically significant.
The significant clusterings demonstrated at baseline, two months and twelve months do
not overlap. The hypothesis underlying these analyses was that there might be fixed
exposures in or near Kahe Mpya predisposing local residents to an elevated risk of
ocular CT infection. Based on these data, no support is found for such a hypothesis.
6.5.10 Relationship between signs of active disease and prevalence and intensity of
ocular infection
The prevalence of infection in different active disease clinical categories is shown
in Table 6.30 (p.170). At baseline, the highest prevalence of Amplicor positivity (55%)
was noted in individuals who had both TF and TI, while only 4% of individuals without
signs of active disease were Amplicor positive. Similarly, at the two, six and eighteen
month follow-up points, individuals with both TF and TI had the highest prevalence of
infection, and those without either sign were rarely infected. At twelve months,
however, 0/12 individuals with both TF and TI were infected.
There is a similar lack of consistency in relative values of COCTL by sign of active
disease, which are tabulated in Table 6.31 (p.170). There was a trend for people with
both TF and TI to have the highest ocular CT loads, but this was not the case at the
twelve month follow-up point, when none of the individuals in this clinical category
were infected.
Table 6.32 (p.17l) shows the proportion of the total ocular CT load in the
community found in individuals in each active disease clinical category. No clinical
category consistently represented more than half of the total ocular CT load. Though
individuals without signs of active disease had a very low prevalence of infection (Table
6.30) and a very low COCTL (Table 6.31) at each time point, at both two months and
twelve months they harboured more than a quarter of the total community ocular CT,
and at six months they had 60%. Considered together, these data make it difficult to
support the use of clinical signs for directing community-based antibiotic treatment
aimed at the elimination of trachoma. Determining target groups by age, rather than
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clinical status, would be more logical in this setting, for two reasons. First, the bulk of
the community ocular CT load was consistently found in children, both before
azithromycin treatment and at each post-treatment time point (Table 6.25, p.161).
Second, the use of age thresholds is simpler and requires less specialised personnel.
This will be discussed further in Section 7.4.2 (p.188).
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7. DISCUSSION
7.1 GENERAL
The results of this study have major significance for trachoma control programmes.
They show - in the setting studied, at least - that (1) the quantitative bulk of ocular C.
trachomatis is found in young children; (2) a dramatic and sustained reduction in the
community ocular CT burden is achievable with mass antibiotic treatment; (3) age is a
better measure than clinical signs for determining target groups for antibiotic treatment;
and (4) height could safely be used in place of weight to determine the number of
azithromycin tablets required for each individual. Before these arguments can be
sustained, though, there is a need to establish both the reliability of the data and the
logic of the assumptions made as part of their interpretation. In particular, is it
reasonable to propose that the quantitative-PCR-estimated concentration of ompl in a
sample of conjunctival swab extract is related to the load of ocular C. trachomatis in the
swabbed individual? Is Q-PCR the best assay for determining this load? And what
evidence exists to suggest that C. trachomatis load has clinical or epidemiological
relevance? These three questions are addressed in Sections 7.1.1, 7.1.2 and 7.1.3
respectively.
7.1.1 How accurately do the laboratory results quantify infection?
Accuracy - the closeness of a measured value to the true value - is affected by both
the bias and the reliability (or reproducibility) of the measurement technique. Since the
quantitative methods described in this thesis are new, and since there is currently no
gold standard for quantification of C. trachomatis (discussed in more detail in section
7.1.2), any bias inherent in the Q-PCR assay is impossible to assess. Only the
reproducibility of the protocol can be formally considered here.
Forty-three people had two conjunctival PCR swabs taken at baseline. Forty-two
(98%) of the duplicate swabs returned the same result (by Amplicor) as the primary
swab. Four individuals were Amplicor positive for both primary and duplicate swabs;
for all four the geometric mean of the numbers of copies of ompl estimated on the two
aliquots of the duplicate was within one log of the geometric mean of the estimates on
the two aliquots of the primary. For eighty-seven of one hundred positive baseline
samples, the estimate of the number of copies of ompl made for the second aliquot was
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within one log of the estimate for the first aliquot. These comparisons suggest a
reasonable degree of reproducibility for both the qualitative and quantitative stages of
quantification, but do reveal the existence of some variation. Potential sources of this
variation, and the measures taken to try and prevent them from affecting the study, are
discussed below.
(a) Sample collection
A detailed protocol for collection of conjunctival swabs was developed and
consistently followed for each subject at each time point. Swabs were held and applied
in a highly standardised fashion, with the same examiner collecting all swabs taken
during the course of the study. Despite this, it is not suggested that an equal number of
conjunctival cells or the same volume of tear fluid was collected from each subject, or
indeed that it would be possible to achieve perfectly standardised conjunctival sampling
using any swabbing technique. Variation between individuals in the amount of tissue
collected is unavoidable, because of individual differences in the friability of
conjunctivae, and the unpredictable nature of each subject's physical response to
swabbing.
To normalise the quantitative results to the volume of tissue sampled, it would be
possible to report the load of C. trachomatis as the number of copies of ompl divided
by the number of copies of a single copy human gene present in the same sample. This
approach was used by Bieche et al. [295], who applied quantitative PCR to the analysis
of oncogene amplifications in human breast cancer. Intuitively, however, it seems
likely that the ratio of chlamydial to human DNA would be misleading in the present
case, since such an index ignores the contribution of both extracellular C. trachomatis
elementary bodies and accelerated shedding of inflamed tissues [548] to the number of
copies of ompJ present on the swab. Both of these are likely to be important in
determining the potential of one eye to become a source of infection for another.
Cross contamination of swabs taken from successive subjects is a potential
problem. Much effort was expended in the attempt to prevent it in this study. The
balzoi leader who helped steady children for examination and swabbing did not touch
subjects' faces. The examiner wore a new pair of latex gloves to examine and swab
each subject, and touched neither the outside surface of any pair of gloves nor the glove
discard bin, which was opened and closed by a field assistant. Only the examiner
touched any part of the swab stick. A second assistant, taking care not to touch the
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swab itself, opened the peel-back swab pack to expose the shaft at the end opposite the
swab head; the examiner held that end of the swab throughout the procedure. The
sterile polypropylene tubes used to transport the swabs were opened by this same
assistant, who had been trained not to touch the inside of the tube or cap, and who
ensured that her hands remained clean. The swab head and proximal half of the swab
shaft was snapped off into the transport tube by bending, rather than by cutting with
shears or scissors, the use of which could have provided a route for carry-over
contamination. A new cotton bud was used as an aid to lid eversion for each subject.
These were handed to the examiner by a third assistant, who did not touch the general
waste or glove discard bins, nor handle any material in the post-swabbing sample
collection sequence.
(b) Swab storage and transport
All swabs for peR were placed on ice in the field, frozen at -20°C within eight
hours, and shipped to London on ice or dry ice in the hold of commercial aircraft. At
LSHTM, they were stored at -20°C prior to processing. Upon arrival, all swabs
inspected had remained frozen during transport. Storage and handling procedures were
the same for samples collected at each of the five time points.
(c) Amplicor
The inclusion of AmpErase in the Amplicor PCR format should eliminate the risk
of carry-over amplicon contamination between successive plates. However, cross-
contamination of negative samples by positive controls or positive clinical specimens in
the same run can be avoided only by good laboratory practice [276]. Standard operating
procedures in place in our laboratory (as described in Section 5.7, p.119) were designed
with this in mind.
The use of the Amplicor's internal control should have minimised the number of
positive samples overlooked because of inhibition of DNA polymerase.
Recently, concern has been expressed over quality control in manufacturing of the
NAA Ts, stemming from occasional imperfect reproducibility noted with Amplicor and
other commercial NAAT kits [280]. For example, evaluating cervical specimens by "an
antigen detection method", tissue culture and Amplicor, Peterson et al. found that
sixteen of 591 patients (2.7%) returned results that were discrepant between those three
methods, and that all but one eventual "interpretation change" was due to a change in
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Amplicor status on repeat testing [277]. Some of these were samples that were
Amplicor positive on the first test and negative on retesting, while others were initially
Amplicor negatives that were ultimately shown to be positives: the actual number in
each category is difficult to determine from the data given in the paper. What would
have been the effect of a similar number of samples being misclassified in the present
study? If 2.7% of the Amplicor negatives at each time point were actually low copy-
numbeFi positives (in other words, if the sensitivity of the Amplicor kit is 97.3%,
rather than the 100% assumed until now in this thesis), twenty-four of 865 (2.7%)
baseline negatives in the cohort dataset should have been assigned an ompl copy
number corresponding to the lowest possible value (4.12) on Q-PCR. This would
increase the overall baseline prevalence of ocular CT positivity from 9.5% to 12.0%.
The overall COCTL would change from 1.99 (95% Cl 1.44 - 2.67) to 2.10 (95% Cl
1.54-2.79). Changing a similar proportion of eighteen month negatives (twenty four of
883, 2.7%) to positive would result in the estimated prevalence rising from 0.6% to
3.3%, while the COCTL would increase by a smaller margin - from 0.07 (95% Cl 0.01-
0.19) to 0.15 (95% Cl 0.08-0.27). The magnitude and statistical significance of the fall
in the intensity of community infection after antibiotic treatment would be preserved.
This scenario probably represents an extreme analysis: the actual proportion of false
negatives is likely to have been smaller than 2.7%.
(d) Quantitative peR
Each LightCycler assay used a 4#LLaliquot from a total volume of 50#LLQIA-amp-
eluted DNA. The LightCycler's ability to work with small volumes in glass capillaries
is one of its attractions, since this reduces the cost of reagents, speeds thermal cycling,
and allows real-time detection of amplified product without tube opening in a true
kinetic quantitative PCR format. However, small volumes also increase the effect of
sampling variation between aliquots, and - as an extension of that phenomenon in this
study - helped increase the chance that samples with small amounts of chlamydial DNA
would test positive by Amplicor but negative in the LightCycler. Reliable amplification
of one copy of ompl is suggested by detection of specific product in 65% of seventy-
one amplifications of the most dilute standard - an excellent approximation for the
aui Sdlachter and Moncada report that a very small proportion of high-level positive (high signal to cutoff ratio)
specimens arc not reproducibly positive (by Lex) in their laboratory. However, most of the samples that return
variable results in their hands are those with low level positive reactions, which are presumably those with low
chlamydial loads [280).
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proportion of capillaries prepared with that standard that would be expected to contain
at least one copy of the target (63%), based on a Poisson distribution [238, 545]. To
compensate for sampling variation between aliquots, two replicate assays were
performed in the LightCycler for each Amplicor positive swab, and the geometric mean
of the two estimates taken as the swab result. To compensate for the sensitivity
advantage of Amplicor over the quantitative assay, the copy number per Amplicor
positive, LightCycler negative swab was estimated by maximum likelihood.
(e) Analysis
In determining the maximum likelihood estimate for the number of copies of omp1
per Amplicor positive, LightCycler negative swab (Section 5.7.5, p.122), it was
assumed that each EB contained four plasmids. This is based on the mean number of
plasmids per EB determined by Pickett et al. [127] for a laboratory strain ofserovar Ll
C. trachomatis. The actual number of plasmids in any real population of chlamydiae is
likely to differ from EB to EB, and to change within an individual organism as it
progresses through its life cycle. To date, no formal estimate of the mean number of
plasmids per organism has been published for any of the ocular serovars of C.
trachoma tis, or for a wild-type strain of any serovar.
7.1.2 Is quantitative peR the best way to quantify ocular chlamydial infection?
This study is the first to use real-time quantitative PCR to explore the epidemiology
of ocular chlamydial infections, but not the first to attempt to quantify such infections.
The laboratory techniques used in this study build on the work of Bobo [168, 234],
Bailey [206], Mahony [225], Huang [238], and their collaborators, amongst many
others. Bobo published the first account of the use of PCR to quantify C. trachomatis.
She coupled thirty cycles of an ompl-based peR to in-solution hybridization with
biotin-labelled RNA probes. These were then captured on solid phase and detected by
EIA [234]. The test returned more positives than DFA or culture in the evaluation of
endocervical specimens [234], and more positives than DFA when testing conjunctival
specimens [168]. For the conjunctival swabs, the EIA fluorescent signal strength
showed some correlation with the presence or absence of TF and TI [168]. Using the
same assay, Muiioz et al. found evidence of more intense infection in Tanzanian women
with trichiasis than in control women living in the same villages [187]. Unfortunately,
the absence of an internal standard (to permit quantification using the competitive route)
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and measurement of signal strength only at end point (ruling out kinetic quantification)
made this assay only semi-quantitative, as Bobo et al. acknowledged [168, 234].
Frost et al. [549] developed a semi-quantitative PCR assay for C. trachomatis using
a competitive format, with primers based on an omp1 sequence of serovar C. The assay
was only semi-quantitative, because quantification of DNA product was achieved by
running an aliquot of the amplified product on an agarose gel, staining it with ethidium
bromide, and comparing (by inspection) the intensity of the band produced with that
generated by PCRs containing known concentrations of a DNA standard. They used
this protocol to quantify CT serovars D, E, F, la, J and K in twelve cervical and urethral
specimens, and compared its sensitivity and reproducibility against that of quantitative
culture and direct immunofluorescence. When results were adjusted for the equivalent
volume of original sample used in the three techniques, the mean ratio of DNA copies
detected to inclusion forming units seen in culture was 595:1, and the mean ratio of
DNA copies to immunofluorescent particles visualised at microscopy was 14:1,
suggesting that PCR was the most sensitive method. The relationship between Q-PCR
and culture was non-linear, though: the number of inclusions seen after three days
growth was approximately proportional to the log of the DNA copy number. The
reproducibilities of the three methods (as determined by their coefficients of
variationxxxii on ten replicate determinations on the same sample) were approximately
equal.
Eastick et al. [550] presented the development of LightCycler-based real-time
quantitative peRs for C. trachomatis amp} and plasmid sequences. Testing 501 urine
specimens from women attending a genitourinary clinic, they found their Q-PCR to be
about as sensitive as the Roche Cobas Amplicor PCR kit. Seven CobaslLightCycler
discrepant specimens were thought to contain chlamydial loads around the detection
limit of both assays. In their abstract, the authors mention that the LightCycler assay
was able to quantify DNA over a 10,000-fold range, but no data on actual chlamydial
loads are included.
Huang et al. [238] adapted hot-start PCR to the LightCycler for the detection of
chlamydiae. Their SYBR Green assay, upon which the assay used in this thesis was
based, was able to demonstrate as few as one copy of the target amp} sequence. Using
xxxii The coefficient of variation is the standard deviation of multiple estimates made on aJiquots of the same sample.
expressed as a percentage of the mean of the estimates. The description given by Frost et al. seems to suggest that to
determine this coefficient for Q-PCR and the antigen detection method. ten separate aliquots of the same clinical
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serial dilutions of C. psittaci B577 stock, they were able to demonstrate an
approximately linear relationship between the number of copies of chlamydial DNA
target and the number of inclusion-forming units in culture.
More recently, other groups have developed quantitative PCR assays and applied
them to the study of non-ocular chlamydial infections [551-553] and chlamydial
infections in mammals other than man [554, 555]. There appears to be a general
consensus that the sensitivity, specificity, dynamic range, rapidity and automation of
these tests give them a significant advantage over earlier techniques for quantification of
chlamydialloads.
7.1.3 What is the clinical and epidemiological significance of high ocular C'I'
loads?
The fall in the prevalence and intensity of infection in Kahe Mpya following mass
treatment with azithromycin was expected. It was not expected that the fall would be
sustained for the entire eighteen months of follow-up. One of the consequences of this
was to compromise analyses on re-infection. It had been hoped that such analyses could
be used to identify load thresholds associated with transmission of infection to family
members and other close contacts of infected individuals. In the event, this was not
possible, because the prevalence of infection at each post-treatment time point was
lower than that at the previous round. The only results from this study, therefore, that
contribute to answering the question about the significance of high loads in transmission
of C. trachomatis are the comparisons of LightCycler and culture data on subjects seen
at baseline. For individuals with clinical evidence of active disease, the detection of
chlamydial chromosomal DNA in a swab taken from the conjunctiva strongly correlated
with the individual being CT culture positive. Culture positivity indicates that viable
chlamydiae are being shed, which suggests that the individual is able to infect others.
Therefore, if an individual has active disease, and has an ocular infection intense
enough for one or more copies of omp l to be present per 4#LLaliquot after the
laboratory extraction protocol described, they should be considered a possible source of
infection. Parallel longitudinal studies using Q-PCR conducted at the other sites of the
'Strategies for the control of blinding trachoma' programme may demonstrate higher
rates of post-treatment infection and re-infection, and may be able to use quantitative
sample were tested. For tissue culture, however. on ten separate occasions the number of inclusions seen in one
culture were counted by the same observer [549]. which is not really an equivalent test of reproducibility.
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data to determine which ocular loads of CT DNA are of epidemiological significance.
The clinical significance of these measurements should be determined by data showing
an association between load over time and progression to conjunctival scarring and
trichiasis. Such a study would require long periods of follow-up, possibly without
treatment, and might not be ethically acceptable.
7.2 RESULTS AGAINST OBJECTIVES
7.2.1 Objective (1): to determine, using quantitative PCR, the ocular load of C.
trachomatis in different age and gender groups in a community of approximately
1000 individuals before antibiotic treatment
These data support the hypothesis that children carry the major reservoir of ocular
C. trachomatis. At baseline, over 90% of the total quantity of ocular chlamydiae
detected was found in swabs taken from children less than nine years old. Over 50% of
the total burden was in infants under nine months of age. Children are therefore likely
to constitute the major source of organism for transmission to others.
The age brackets for fractions-of-total-load at baseline are heavily influenced by
two female infants aged eight months and five months, whose swabs together contained
nearly 60% of the total community burden of ocular CT. If these two subjects are
excluded from the analysis, 50% of the total load is found in residents below four years
and two months, and 90% in those aged below nine years and six months; nearly 12%
of all ocular C. trachomatis is still found in those under one year old. The contribution
of under-ones to the ocular CT reservoir is particularly important, as current Tanzanian
guidelines exclude children below twelve months of age from receiving the drug as part
of mass antibiotic distribution campaigns.
A high prevalence of infection has been reported in infants in other settings. In a
trachoma hyperendemic area of Egypt, Schachter and Dawson [330] followed a group
of eighty-eight infants from birth to one year of age, taking monthly conjunctival
scrapings for evaluation by Giemsa. None of the babies studied had conjunctivitis in
the first two weeks of life (suggesting that ocular infection from the mother's genital
tract was unlikely), but inclusions were seen from some (number not given) of the one-
month old individuals, and forty-eight (55%) of the eighty-eight children had inclusions
in one or more of the swabs taken in the first six months oflife [330]. Therefore, in the
current study, the high prevalence of ocular chlamydial infection seen in infants was not
a new finding. The degree of pooling of the ocular load in children under ten years of
179
age, though, and the finding of the highest-of-all loads in children under one were not
expected.
As suggested by Figure 6.1 (p.135), ten years of age was something of a transition
point for ocular CT infection, with both the prevalence of infection and the load of C.
trachomatis being markedly lower in those above than those below that mark. For both
males and females, the difference in the eOeTL for individuals aged ten years or more
versus below ten years was statistically significant (Table 6.13, p.143). In Kahe Mpya
in July 2000, if only those aged below ten years (38% of the kitongoji population) had
been given antibiotics, more than 97% of the total community ocular CT load would
have been covered with either azithromycin or topical tetracycline.
At baseline, there was no consistent trend amongst age groups for males or females
to have a higher prevalence or load of infection. In the ten age groups in Table 6.12
(p.142), females had higher average loads than males in four, males had higher average
loads than females in five, and in the oldest age group, the average load was essentially
equal. There was up to a seven-fold difference in the COCTL between genders within
age groups, but these differences were not statistically significant. This reflects the
extraordinary range in individual CI' loads and the relatively small numbers of
individuals in each division, which tends to make the confidence limits for these
estimates wide. However, the lack of statistically significant differences in the eOCTL
between the genders persisted regardless of how age groups were bracketed. Overall,
the data do not support the hypothesis that either males or females carry higher
infectious loads of ocular chlamydiae in this setting.
The lack of a gender difference in loads is somewhat at odds with expectation.
Females typically have a higher burden of clinical signs of disease than males. In
central Tanzania, female pre-school children have been noted to have a significantly
elevated prevalence of constant, severe, conjunctival inflammation, compared to their
male counterparts, and this clinical picture would be expected to correlate with intense
infection [357]. Moreover, the difference in the prevalence of clinical signs between the
genders generally widens with increasing age. Why did we see no gender difference in
quantitative load? Were patterns of clinical disease similar to that seen elsewhere?
The prevalence of active disease (in either or both eyes) in one to nine year-old
males in the cohort at baseline was 16/165 (37%) and in one to nine year-old females
79/160 (49%); this difference was statistically significant (z with continuity
correction=2.1, two-sided P=O.03). In subjects ten years of age and above, the baseline
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prevalences were 13/236 (5%) and 29/360 (8%) for males and females respectively
(z=1.02, P=O.3). At the time of the survey, in Kahe as a whole, twenty-eight of 2434
males examined (1.2%) and forty-eight of 3066 females examined (1.6%) had trichiasis
(z=1.19, P=O.2). These data are in contrast with those obtained in Kongwa, for
instance, where women have been noted to have a fourfold increased risk of trichiasis
compared to men [331] - a risk ratio that is consistent with that observed in a variety of
studies in other endemic areas. It might be speculated that particular social or
immunological factors particular to Rombo cause the epidemiology of disease there to
differ from the paradigm.
7.2.2 Objective (2): to measure, using quantitative methods, the effect of
community-wide mass treatment with oral azitbromycin 20mg/kg on the ocular
load or C. trachomatis in different age and gender groups
The overall community load of ocular C. trachomatis, as determined by the
COCTL, was 13% of its pre-treatment level two months after mass treatment, 8% at six
months, 4% at twelve months, and less than 4% of pre-treatment at eighteen months.
The confidence intervals around all four of the follow-up COCTLs suggest that the
reduction compared to baseline was statistically significant at each time point, though
the decreases seen from two to six months, from six to twelve months, and from twelve
to eighteen months were not themselves significant. There were no statistically
significant differences in the post-treatment COCTLs between age groups, or between
males and females. In other words, decreases in ocular chlamydial load occurred
throughout the community. It is possible that the sample size was simply too small to
detect a differential effect of treatment by age or gender. However, if there truly is a
difference in the efficacy of azithromycin against ocular C. trachomatis in different age
groups, or in males and females, and a study of nearly 1000 people is not sufficiently
large to detect it, it is doubtful that the effect is of sufficient clinical significance to be
useful in the planning of trachoma control programmes.
This study was not designed to evaluate the efficacy of azithromycin against
clinical trachoma or ocular chlamydial infection, so there was no control group. It is
therefore impossible to conclude that the observed reduction in COCTL in Kahe Mpya
during the eighteen months after treatment was caused by the intervention alone: a
regional secular trend in trachoma [556], enhanced personal hygiene in study
participants, or local improvements in environmental factors can not be excluded. No
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attempt was made to gather evidence about the first of these potential confounders. If
the latter two occurred they were too subtle to have been apparent to the author. One
additional contributor to the magnitude of the decrease should be considered: the
treatment with topical tetracycline of individuals with active disease at twelve and
eighteen months. This will be discussed below, in Section 7.3.4 (p.187).
7.2.3 Objective (3): to measure, using quantitative methods, the rate at which
infection is re-introduced following community-wide mass treatment with
azithromycin
Infection was not re-introduced to the community for at least eighteen months after
mass treatment. Rather, an initial rapid fall in the COCTL after treatment was sustained
for at least eighteen months. This sustained reduction in community CT load occurred
despite the arrival of 202 new residents. Analysis of the swabs collected from these
individuals (taken at the first census review or follow-up point at which they consented
to a swab being taken) showed that none of the newborns and only two of the in-
migrants were Amplicor positive at the time of enrolment. The latter comprised a
sixteen year-old girl, who arrived just before the two-month census review and had 15
copies ompJ in her swab at that time, and a thirteen year-old girl, who arrived just after
the five-month census review, and had 19 copies ompJ in her swab at six months and
162 copies omp 1 in her swab at twelve months. There is no evidence that the contacts
of these girls became infected as a result of exposure to them. Ongoing follow-up of the
Kahe Mpya cohort, during which ocular CT may return, may provide more data to
answer the question of how quickly infection returns to the community.
7.2.4 Objective (4): to determine the relative importance of different risk facton
In predicting re-emergent Infection following community-wide mass treatment
with azithromycin
Because they are based on only a very small number of post-treatment infections,
the analyses for risk factors for infection at each post-treatment time point should be
interpreted with great caution. Colleagues with more extensive regression modelling
experience than the author advise that to avoid statistical instability, at least ten
'failures' (in this case, Amplicor positives) are needed for every potential explanatory
variable included in the model. This rule of thumb has been ignored here, because
adhering to it would have meant examining only age, the exclusion of which - given the
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distribution of infection at each time point - would have been difficult to justify, and at
most one other variable for two months and six months. Analyses for twelve and
eighteen months would had have to have been abandoned, since there were less than ten
positives at both of these time points.
Liberally salted with the caveat that it may in fact mislead rather than inform, some
cautious commentary on risk factors for post-treatment infection in Kahe Mpya will
now be offered. It will be noted that interpretations of the data have been heavily
weighted by a priori hypotheses about biologically plausible risks.
The association of increasing age with decreasing risk of infection at six months
and twelve months is consistent with both the epidemiology of clinical disease and
current concepts of the importance of acquired immunity in chlamydial infection [154,
155]. In contrast, at eighteen months, increasing age conferred a very modestly
increased risk of being infected. This could be a spurious finding; reflect the beginnings
of re-introduction of C. trachomatis into the community by two older individuals (who
presumably would be more likely than the very young to have had contact with others
from outside the village); or (given the low numbers involved) even represent ocular
infection with genital strains of C. trachomatis. Genotyping of strains collected during
the course of this study is underway.
At two months and six months, subjects with visible ocular or nasal discharges
were much more likely to be Amplicor positive than those who had no discharge visible
on examination. The most probable explanation for these findings is reverse causality -
in other words, people who have chlamydial infections of their ocular and nasal
epithelia are more likely than uninfected people to produce inflammatory exudates at
those sites. However, discharges attract muscid flies, and could provide a means of
entry for organism into new hosts: the association may be bi-directional.
In the models generated for two months and eighteen months, access to a latrine
was associated with markedly lower risk of infection. At twelve months, paradoxically,
all the Amplicor positive individuals had access to a latrine. The interpretation of these
data is problematic. Latrine ownership is compulsory in Rombo, and health inspectors
impose fines on householders who do not have them, or whose latrines are in a poor
state of repair. As a result, many latrines are only for display purposes, while in
practice people defaecate in the shamba, ensuring that the pit stays relatively empty and
that the enclosure is always clean enough to pass inspection. Because of the low
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numbers of positive infections post-baseline, data on variables reflecting whether or not
the latrine was actually in use were not analysed.
The output of the twelve month model suggested that people who had received
tetracycline at six months were about eleven times as likely to have a CT -positive swab
as those who had not. Similarly, at eighteen months, having been treated at twelve
months seemed to confer increased risk. These findings probably represent an
association between being Cf positive at one examination and having had clinically
active disease at the previous examination (since it was those with active disease who
were given tetracycline), or are simply chance findings. It is possible, but perhaps less
likely, that sharing of tubes of tetracycline eye ointment between those to whom it was
prescribed and other, infected, symptomatic people, resulted in enhanced transmission
of organism within the community.
7.2.S Objective (S): to trace sources and routes of reinfection with C. trachomatis
following community-wide mass treatment with azithromycin
Owing to the small and declining number of positive swabs at each post-treatment
time point, tracing sources and routes of 'reinfection' was not possible using data
collected in the cohort between baseline and eighteen months after treatment. Ongoing
follow-up of this population may provide clues as to the ways in which infection returns
to a community after treatment.
7.2.6 Objective (6): to determine the feasibility of using height to guide the dose
of azithromycin in a trachoma endemic community in Tanzania
Using the height-based dosage schedule in Table 6.17 (p.149), and spring scales for
individuals assigned by that schedule to '0 tablets', 4379 of 4778 (91.6%) azithromycin-
treated people in Kahe would receive either a dose between fifteen and thirty milligrams
per kilogram, or the same one gram dose determined by weight (Table 6.19, p.150).
Eighteen people would receive a dose in the range 13-15mglkg, 338 a dose in the range
30-35mglkg, thirty-eight a dose in the range 35-4Omglkg, and five would receive more
than 4Omglkg. The selection of 15-30mglkg as the safe and effective dose range is
arbitrary, and may even be conservative, particularly at the top end. The lower bound,
which should be determined by the lowest per-kilogram dose likely to ensure successful
treatment whilst avoiding selection of macrolide-resistant pathogens [513]. is presently
unknown. The upper bound should be calculated to minimise toxic effects. Though
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unlicensed for this indication, the recommended dose of azithromycin for typhoid in
adults is 500mg daily for seven days. Given azithromycin's prolonged half-life (Section
2.9.3, p.86), it is likely that towards the end of such a course of treatment, the drug is
present in vivo at concentrations far in excess of that produced by one 20mglkg dose.
The use of the proposed height schedule (Table 6.17, p.149) for single dose
treatment for trachoma would probably be almost as safe and effective as the current
weight-based system. In addition, it would lighten the load carried by drug distribution
teams, be less prone to equipment malfunction, and be more easily taught to new
distributors as trachoma control programmes are progressively expanded to cover more
of the total population at risk of trachoma blindness. Height-based treatment should be
recommended.
7.3 LIMITATIONS OF THIS STUDY
7.3.1 One study site
This dissertation presents the results of research conducted in a single village in
Rombo District, northern Tanzania. Conclusions drawn on the basis of this work should
not be assumed to be generally applicable. Unique environmental, social and possibly
genetic characteristics of each trachoma endemic area are likely to influence the local
distribution of ocular chlamydial infection, effect of mass treatment, and relationship
between height and weight in the population. Data presented here, however, have
already been compared to data from other trachoma endemic areas in two manuscripts.
Both papers suggest that the patterns observed in Rombo may be broadly representative
of those that will be found in other communities.
"Strategies for the control of trachoma: an observational study using quantitative
PCR" (in press in The Lancet [557] at the time of submission of this thesis) examines
and compares the pre-treatment distribution of ocular CT load at the three sites of the
'Strategies for the control of blinding trachoma' research programme: Kahe Mpya,
Maindi sub-village of Kongwa District, central Tanzania, and the Jareng cluster of
fourteen villages in the Upper Saloum District, Central River Division, The Gambia.
Similar field methods were employed at each site, and laboratory protocols for all
samples were as described in this thesis. At all three sites, children had the highest
ocular loads of C. trachomatis, though the degree of pooling in younger age groups was
less marked at the site (Jareng) with the lowest prevalence of active trachoma. There
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was no statistically significant difference between the genders in the number of copies
of ompI found in ocular swabs at any site.
"Antibiotic dosing in trachoma control programs: height as a surrogate for weight
in children" was published in the April2003 issue of Investigative Ophthalmology and
Visual Sciences [558]. It considers azithromycin dosing by height. Data on height and
weight were obtained for a total of 5,558 children aged between six months and fifteen
years living in Kahe, Kongwa, Jareng, Malakal (Sudan) and Daboya (Ghana). Using
the Kahe dataset as the reference group, this study showed a single height dosing model
(more conservative than the one suggested here, but including the use of half tablets) to
be adequate for all five populations: more than 97% of children who contributed data to
the study would have received between 15mglkg and 30mglkg azithromycin using the
schedule proposed. Height-based dosing is also supported by a separate study by
Basilion et al. that used datasets from Vietnam, Tanzania, Ghana and Mali [559].
7.3.2 Higb coverage levels
In the longitudinal study, 94% of the resident population of Kahe Mpya (the cohort
sub-village) received directly-observed azithromycin immediately after the collection of
baseline swabs. A further 4% of the population received topical tetracycline for use at
home. For a variety of reasons, similarly high coverage levels are not usually achieved
in trachoma control programmes. In 2002, for example, antibiotic coverage achieved by
the ITI-supported programme in ten treated communities in Rombo ranged between
41% and 59% [560]. Coverage levels reported from other settings are sometimes higher
than this (in Ghana: 81% and 85% for 2001 and 2002 respectively [561]), but are
generally less than 90%. The impact on the community ocular chlamydial load of
achieving only moderate antibiotic uptake can not be estimated purely on the basis of
the results from the current study. In fact, there are presently few data that could be
used to define a division between coverage levels likely to be effective in reducing the
prevalence (or load) of infection, and those likely to be ineffective.
7.3.3 Monthly population surveillance
For logistical reasons, census reviews could not be undertaken more frequently than
monthly. As a result, the definition of residency was somewhat exclusive (Section
5.3.2, p.l06). Visitors, and even people who considered themselves to be permanent
residents but who spent the majority of their time living outside the village were not
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included. Many individuals would have spent a few days to weeks in the village during
the period of follow-up without being seen by study personnel. A proportion of these
people probably had ocular chlamydial infection. Fortunately, the lack of demographic
and microbiological information about them can for the most part be overlooked,
because imported cases failed to produce an increase in either the prevalence or
intensity of infection in the cohort as a whole. In other words, explanations for post-
treatment re-infection need not be sought.
7.3.4 Treatment of subjects with clinically active disease at six and twelve months
Under the terms of the study's ethical approval, it was necessary to provide topical
tetracycline to any individual noted to have signs of active disease six or twelve months
after mass treatment. At six months, fifty-four people were given tetracycline,
including seven of the thirteen (54%) who were subsequently shown to be CT-positive.
At twelve months, ninety-four people were given ointment, including five of eight
(63%) who were infected. The extent of compliance with the recommended six weeks
topical treatment is unknown, but a proportion of the observed longevity of the
reduction in COCTL could be ascribed to topical treatment of active cases. An
infection-suppressing role for tetracycline is not supported by the increased risk of
positivity at twelve and eighteen months in those given ointment at six and twelve
months, though doubts about the relevance of this association exist, as has already been
discussed. In any event, routine twice-yearly screening of entire communities for active
disease as a follow-up to mass treatment is beyond the capacity of most trachoma
control programmes, and could not be recommended as an intervention.
7.4 IMPLICATIONS FOR TRACHOMA CONTROL PROGRAMMES
7.4.1 ChUdren are the key demographic group at which to target antibiotics
Children harbour most of the ocular load of C. trachomatis in the community, and
should therefore be the principal targets in any population-based antibiotic distribution
programme. Because transmission of infection is a dynamic process, and because re-
infection after treatment was too infrequent in this study to permit definitive
conclusions to be drawn about the risk factors for its occurrence, it is difficult to predict
the effect of limiting treatment to children, as compared with the effect of offering
treatment to everybody. However, children less than ten years old carried more than
97% of the total ocular Cl' burden at baseline; if the two infants with the most intense
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infections are excluded, children under ten still contribute nearly 93% of the remaining
community load. At two, six, twelve and eighteen months after mass treatment,
children below ten had 94%, 99%, 66%, and nearly 100% respectively of the total
burden of ocular chlamydiae in Kahe Mpya, while making up only 38% or 39% of the
total population of the sub-village at any time point. Studies that will empirically
determine the differential effect between mass treatment and treatment only of children
may be worth conducting, though implementation of an under-tens-only policy might
well be unpopular in treated communities. Adults who have previously taken
azithromycin are generally enthusiastic about the prospect of receiving it again. For
communities that have no prior experience with the drug, without concerted efforts to
involve opinion leaders in decision making, treatment only of children might be
mistrusted.
The two highest individual CT loads were found in girls aged eight months and five
months respectively. There is no reason to suspect that these two were 'outliers', in the
sense of their swab results being erroneous. Current guidelines that bar distribution of
azithromycin to infants should be re-evaluated in the light of these findings, particularly
as there are currently no data suggesting that the drug is unsafe in this age group, and
good data to suggest that it is safe in pregnancy (Section 2.9.9(a), p.91).
There were no significant differences in the prevalence or load of infection between
the genders. On the basis of the data presented here, there is no rational basis for
restricting treatment to either males or females in any age category. In particular, the
Tanzanian recommendation that, in villages in which the prevalence of active disease is
10-20%, all children and adult women, but not adult men, be treated receives no
support.
7.4.2 Active disease predicts C'f' load, but not so well as to justify examination of
whole endemic communities
Particularly as the prevalence of trachoma declines, some control programmes
begin to favour targeted treatment of individuals with active disease over mass
treatment of all members of affected communities. At baseline, use of this approach
would have resulted in treatment of 98% of the total community load of C. trachomatis.
Why, then, has the primary focus in this dissertation been on loads in demographic,
rather than clinical groups? There are three reasons. First, examination usually requires
skilled ophthalmic personnel. These people are in short supply in most trachoma
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endemic areas, and the demand for their services is high. If less highly trained graders
are used, poor diagnostic accuracy and reliability could mismatch treatment with need,
destroying any potential advantage of the targeted strategy. Selecting (say) all children
under ten as the treatment target group is easier than selecting all people with TF and/or
TI according to the strict WHO-defined criteria. Second, screening whole communities
is very time consuming. Treating all children under ten in the cohort would have
required zero examinations and the dispensing of 360 doses of azithromycin. Treating
all those with TF and/or TI would have required 956 examinations and 174 doses of
azithromycin, with (presumably) an equivalent impact on community levels of
infection, given the relative proportion of the total community CT load found in each of
these population subsets. Third, after a single round of treatment, children under ten
years of age had a higher fraction of the total community ocular CT load at each time
point than did the group of individuals with signs of active disease (compare Section
7.4.1, p.l87, with Table 6.32, p.l71). In this setting, therefore, directing treatment at
children rather than people with active disease would have been more time-efficient at
baseline, and (had re-treatment of the entire community been scheduled at any post-
baseline time), it would still have been more efficient to use an age-directed than
disease-directed strategy.
7.4.3 High coverage may produce a sustained impact on community load
In this study, high coverage mass azithromycin treatment of a trachoma endemic
community was associated with a substantial decrease in both the prevalence and
intensity of ocular C. trachomatis infection. The decrease was sustained for at least
eighteen months after treatment, perhaps assisted by distribution of tetracycline eye
ointment to individuals with clinically active trachoma at six and twelve months.
Because of the lack of a control group, the evidence is only circumstantial, but
nevertheless suggests that the potential efficacy of mass azithromycin treatment may be
far more dramatic than had previously been supposed. As already indicated, similarly
high coverage levels and six-monthly individual re-examinations are unlikely outside
the research setting. Further investigations of the effect of mass treatment on infection
in other communities where uptake of antibiotics is lower would help to determine
necessary coverage levels for best impact, and whether in fact there is a threshold
coverage that will lead, as may have occurred in Kahe Mpya, to a permanent
suppression of ocular chlamydial infection in the population. In the absence of real data
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comparing coverage with effect, it is probably not drawing too long a bow to suggest
that the higher the coverage, the greater the reduction in Cf load.
7.4.4 Height-based treatment is likely to be safe and effective
Azithromycin is virtually the ideal antibiotic for the treatment of trachoma. It is
effective in single dose, extremely well tolerated, generally popular amongst recipients,
and - thanks to the generosity of its manufacturer - is provided free to a number of
control programmes. The drug works and is available, but in the field, some method for
determining how much of the drug is to be given to each individual lining up to receive
it is required. Standard weighing scales become unreliable when transported over rough
roads and used outside in dusty or wet conditions. The relatively robust electronic
scales used for this research project were expensive, and hundreds would be needed to
outfit a national azithromycin distribution programme. A better option would be to use
height sticks or tapes to determine the number of tablets required, and spring scales
(which are durable, portable, and available for approximately £15 each from TALC) to
weigh children who need azithromycin suspension, provided of course that height-based
determination of tablet dose is safe and effective. It is, according to the data generated
here. The argument behind this assertion was presented in Section 7.2.6 (p.184).
7.5 SUGGESTIONS FOR FURTHER RESEARCH
(1) Members of the cohort enrolled in the longitudinal study in Kahe Mpya have
been enthusiastic partners in this research, and represent a willing, useful resource for
ongoing studies of the epidemiology of ocular chlamydial infection. Under the terms of
the ethical approval obtained for the project, re-treatment of Kahe village with
azithromycin was required at two years. However, all consenting residents were
examined and swabbed prior to that treatment round, and follow-up will continue at six-
monthly intervals for at least another eighteen months.
(2) Given the high loads noted in infants in this project, studies to establish the
safety of azithromycin in children below the age of six months are required. There are
currently no data that suggest that the use of the drug in this age group should continue
to be contraindicated.
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(3) Mass treatment with azithromycin has been associated with increased genotypic
variation of ocular C. trachomatis isolates. In the Tanzanian arm of the ACT trial, one
year after mass treatment, the proportion of infected individuals whose CT isolates had
amino-acid-sequence-altering nucleotide substitutions in ompJ (compared to baseline
genotypes) was higher in azithromycin than tetracycline treated subjects [562].
Whether this reflects the introduction of new isolates from untreated immigrants or de
novo selection of mutants is not known. Alteration in the primary structure of MOMP
could potentially lead to immunoevasion. Further studies are warranted. We are
currently undertaking full length sequencing of ompJ from all positive samples
collected during the course of the longitudinal study.
(4) Similarly, research into the potential for selection of macrolide resistance in C.
trachomatis, S. pneumoniae, and other human pathogens by the use of azithromycin for
trachoma control should be a priority. The establishment of regional sentinel sites with
access to -70°C freezers or liquid nitrogen facilities (to preserve samples for chlamydial
culture and sensitivity determination) may be the best way to undertake this kind of
monitoring.
(5) Ongoing work at the other two sites of the 'Strategies for the control of
blinding trachoma' programme may help to discover contact chlamydialloads and kinds
of exposure that constitute a risk for transmission of infection.
(6) Inexpensive, locally acceptable, sustainable strategies for achieving high
coverage in azithromycin distribution campaigns should be sought. Community
directed distribution, as deployed in the African Programme for Onchocerciasis Control,
may be worth evaluating.
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Survey form (a) Date: __ --"-I __ ....!./ _ FA:
Name of head ofbalozi: _
Name of head ofkaya: _
Balozi I kaya: DODD BIK. number painted? (YIN): 0
Draw a map of the kaya here.
Room
number
Roof type
(T=tin, S=straw,
N=none)
Structure E # satsN Time
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Survey fonn (d) (English) Date: __ L__ l: _ FA:. _
Name ofbalozi leader: _
Name of head ofhousehold: _ DODD
How many cattle stay in the shamba around this house overnight? (1)
How many cattle does the family own in total (both here and elsewhere)? (2)
How many sheep do the family own in total? (3)
How many goats do the family own in total? (4)
How many ducks do the family own in total? (5)
How many chickens do the family own in total? (6)
How many dogs live with this family? (7)
How many pigs do the family own in total? (8)
How many rabbits do the family own in total? (9)
How many pigeons do the family own in total? (10)
How many minutes does it take to walk from the house to the place where water is collected in the (11)
wet season?
How many times a week are you able to collect water in the wet season? (12)
How many minutes does it take to walk from the house to the place where water is collected in the (13)
dry season?
How many times a week are you able to collect water in the dry season? (14)
Do the family have access to a latrine? (No=O,Family use only=i, Sh.red=2, Refused to .nswer=5) (15)
If the family bas access to a latrine, ask if you can go and see it. Is there a beaten path to the door? (16)
(No-O, V... t, Not IPpllcabIt [no latrlne)=3, Refused to allow Inspection=5)
Is there adequate screening of the latrine for privacy? (No=O,Vu=i, Not applicable [no latrine)=3, (17)
RIfuMd to allow Jnapec:tIon-5)
Are there flies around the latrine? (No-o, V.. =t, Not applicable [no Jatrlne)=3, Refused to allow (18)
JnapectIon-5)
What kind of floor does the latrine have? (NonPO, Stlcks-S, Wood·W, Cement=C, Another type=A, (19)
Not IPpJlcabJe [no 1atrineJ-3, RtfuMd to IIlow Inspection-5)
When you look into the latrine with a torch. can you see faeces? (No-O, VtI(top more than 6Oc:m (20)
below ground JevIl)-1, V.. [top ItIIthan 60cm below ground levelJ=2, Not applicable [no latrlneJ=3,
RafuMd to allow Jnapec:tIon-5)
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Survey fonn (d) (Kiswahili) Tarehe: / /--....:...._----'---- FA: __
Jina la balozi: _
Jina la mkuu wa kaya: _ DODD
Ng'ombe wangapi wanaishi hapa? (1)
Ng'ombe wenujumla ni wangapi pamoja na walio kwa watu? (2)
Kondoo wenu jumIa ni wanngapi? (3)
Mbuzi wenu jumIa ni wangapi? (4)
Bata wenu jumJa ni wangapi? (5)
KuJru wenu jumla oj wangapi? (6)
Mbwa wangapi wanaishi pamoja na nyinyi? (7)
Nguruwe wenu jumla ni wangapi? (8)
Sungura wenu jumJa ni wangapi? (9)
Njiwe wenu jumla ni wangapi? (10)
Mnachukua dakika ngapi toka hapa mpaka mahali pakuteka maji wakati wa masika? (11)
Mnapata maji kwenye bomba mara ngapi kwa wiki wakati wa masika? (12)
Mnachukua dakika ngapi toka hapa mpaka mahali pakuteka maji wakati wa kiangazi? I (13)
Mnapata maji kwenye bomba mara ngapi kwa wiki wakati wa kiangazi? (14)
Je, mna choo? (Hamna-O, KWImatumlzla nyumba hli tu=1, Tunachangla=2, Wamekataa kujibu=5) (15)
Kama Iruna cboo, waombe kama unaweza kukiangalia. Je, kuna kiehochoro cha njia kwenda (16)
ebooni? (HlmnPO, Ndlyo-1, Haipo [hakuna choo)=3, Wamekataa kukuruhusu kukagua=5)
Ina uzuio wa kutosha mtu asionekane? (Hamna=O, Ndiyo=1, Haipo [hakuna choo)=3, Wamekataa (17)
kukuruhulu kukagu .. 5)
Kuna inzi karibu na choo? (Hamna=O, Ndlyo=1, Halpo [hakuna chooJ=3, Wamekataa kukuruhusu (18)
kukagua-5)
Cboo kina sakafu ya aina gani (Hamna=O,Mitl [§tIcks)aS, Mbio JWood)=W, Sementl ~ement)=C, (19)
Nylnglne [AnothIrJ-A (tafIdhall taja lIWII8WaJ, Halpo [hakuna chooJ=3, Wamekataa kukuruhusu
kukagua-5)
Ukimwulika kwa toTehi ndani ya ehoo, unaweza ukayaona mavi? (Hapana=O, Ndlyo [kama kimejaa (20)
na kubaklza Didl ya Mntimeta IItInl toka ullwa WI arthIJ=1, Ndlyo[kama kimejaa na kubakiza chlnl ya
Mntimeta sltinl toka uaawaa Wlllthq=2, Halpo [hakuna chooJ=3, Wamekataa kukuruhulu kukagua=5)
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APPENDIX 3: CODES
Field
Table A3.1: Codes for recording demographic details
How recorded on the formAbbreviationon form
Mwenyeji number # There are two boxes on the form on the form for
each mwenyeji. On the first survey form (c) for
any household, fill in these boxes from the top of
the form to the bottom with the numbers 1 to 10,
likethis:~ to 11 I 0 I
If there is more than one page, the first mwenyeji
on the second page should be given the number
11, the next one 12, and so on.
First and last name Name Written in capital letters using standard alphabet
Room (chumba)
number
C
Alias (nicknames) Alias
Date of birthDate of birth
(DOB)
The room number (as shown on the map of the
compound) in which that person sleeps at night.
Written in ca_pitalletters using standard alphabet
The person's date of birth written in the formatI day Imonth I year I
• Write the year in full (for 6th February 1975,
write 06/0211975, rather than 06/02/75)
• The best estimate of the individual or their
family will be acceptable, though if some kind
of official record (eg vaccination card, birth
certificate) is available, it should be used.
• If the person gives you their age rather than
their date of birth, look at the ages to dates of
birth conversion table to determine the year of
birth.
• If an adult is unsure of their age and date of
birth, use the local events calendar to
determine the approximate year of birth.
• If you can only determine the year of birth but
not the month or day, record DOB as the first
of January in that year (OllOl/yyyy). If you
can determine the year and month but not the
day, record DOB as the first of that month
(Ol/mm/_yyyy).
Sex Sex 1= Male/mwanaume
2 = Female/mwanamke
8 = Not known
EthEthnic group 61- Chagga
62 =Kamba
63 =Masai
64 =Kikuyu
65 =Mpare
66=Msambaa
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67=Msukuma
68=Wameru
69 = Wairak
70 = Mang'ati
87 = Other (tafadhali taja sawasawa - andika
'comments')
88 = Not known
Highest level of Edu 00 = no formal education/did not finish standard 1
formal education 01 = standard 1
completed 02 = standard 2
03 = standard 3
04 = standard 4
05 = standard 5
06 = standard 6
07 = standard 7
08 = standard 8 (Kenya only)
09 = standard 9
10 = standard 10
11 = standard 11
12 = standard 12/fonn four
13 = standard 13/fonn five
14 = form six
15 = college or university
88 = not known
School currently Shnow 00 = not at school
attended 31 = Kiura Primary
32 = Kahe Primary
33 = Mtikome Primary
34 = Mamonjo Primary
35 = Kwalamahondo Primary
36 = Usseri Primary
37 =Mreyai Primary
38 = Reha Primary
39 = Kingachi Primary
40 = Nesae Primary
41 = Matolo Secondary
42 = Kirongo Secondary
43 = Tarakea Secondary
44 = Mamtukuna Folk Development College
88 = not known
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Table A3 2· Codes for facial cleanliness variables..
Variable Abbreviation Codes for recording I data entry
Pus or dried secretions around E No=O
one or both eyes dlc Yes=1
Refused to allow inspection=5
Already examined elsewhere=7
Visible discharge from the nose N No=O
dlc Yes=1
Refused to allow inspection=5
Already examined elsewhere=7
Flies seen in contact with the eye Fly No=O
Eye Yes=1
Refused to allow inspection=5
Already examined elsewhere=7
Table A3.3: Codes or recor mg treatment
Code Treatment given
01 Given tablets: swallowed all
02 Given tablets: swallowed some but not all
03 Given suspension: swallowed all
04 Given suspension: swallowed some but not all
05 Offered tablets: refused; given suspension, swallowed all
06 Offered tablets: refused; given suspension, swallowed some but not all
07 Offered tablets: refused; offered suspension; refused; given tetracycl, ointment
08 Pregnant -+ given tetracycline ointment
09 Pregnant -+ offered tetracycline ointment: refused
10 Less than twelve months old -+ given tetracycline ointment
11 Less than twelve months old -+ given tetracycline ointment: refused
12 Seriously ill -+ unable to take medicine
55
Not pregnant, not less than twelve months old, not ill, but did not present or
presented and refused all treatment
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APPENDIX 4: AZITHROMYCIN DOSAGE TABLES
Table A4.1 : Dose of azithromycin tablets, b) weight
Weight in kilograms Number of 25Om_g_tablets
10.0 - 16.6 1
16.7 - 26.4 2
26.5 - 39.4 3
39.5 and above 4
Table A4.2: Dose ofazithromycin suspension (for children who weigh less than IOkg,
and heavier children who can not take tablets), by weight
Weight in kilograms Millilitres of suspension i40m_gt'_mL_l
2.0 - 2.4 1.0
2.5 - 3.4 1.5
3.5 -4.4 2.0
4.5 - 5.4 2.5
5.5 -6.4 3.0
6.5 -7.4 3.5
7.5 - 8.4 4.0
8.5 -9.4 4.5
9.5 -10.4 5.0
10.5 - 11.4 5.5
11.5 - 12.4 6.0
12.5 - 14.9 7.5
15.0- 24.9 10.0
25.0-34.9 15.0
35.0-44.9 20.0
45.0 and above 25.0
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APPENDIX 5: SATSCAN OUTPUT
SaTScan V.3.0.4
Program run on: Sun Mar 23 08:51:08 2003
Purely Spatial analysis
scanning for clusters with
high rates using the Poisson model.
SUMMARY OF DATA (Baseline)
Study period : 2000/7/11 - 2000/7/22
Number of census areas: 205
Total population : 956
Total cases : 91
MOST LIKELY CLUSTER
1.Census areas included.: 5808, 5809, 5810, 5811, 5801,
5812,
5805, 5804, 5608, 5806
Coordinates / radius ..: (9.66308e+06,344813) / 179.76
population : 51
Number of cases : 17 (4.85 expected)
OVerall relative risk.: 3.502
Log likelihood ratio ..: 10.059977
Monte Carlo rank : 6/1000
P-value : 0.006
SECONDARY CLUSTERS
2.Census areas included.: 4809, 4808, 4810, 4812, 4807,
4709,
4811, 4806, 4710
Coordinates / radius ..: (9.66362e+06,346540) / 185.17
Population : 37
Number of cases : 12 (3.52 expected)
OVerall relative risk.: 3.407
Log likelihood ratio ..: 6.657397
Monte Carlo rank : 102/1000
P-value : 0.102
3.Census areas included.: 5512, 5511
Coordinates / radius ..: (9.66308e+06,345463) / 44.08
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Population : 13
Number of cases : 6
Overall relative risk.: 4.849
Log likelihood ratio ..: 4.838338
Monte Carlo rank : 434/1000
P-value : 0.434
(1. 24 expected)
4.Census areas included.: 4904, 4903
Coordinates / radius ..: (9.66276e+06,346181) / 52.48
Population : 14
Number of cases : 5 (1.33 expected)
Overall relative risk.: 3.752
Log likelihood ratio ..: 3.020072
Monte Carlo rank : 959/1000
P-value : 0.959
5.Census areas included.: 5011
Coordinates / radius ..: (9.66301e+06,346207) / 0.00
Population : 6
Number of cases : 3 (0.57 expected)
Overall relative risk.: 5.253
Log likelihood ratio ..: 2.580298
Monte Carlo rank : 988/1000
P-value : 0.988
6.Census areas included.: 5509
Coordinates / radius ..: (9.66293e+06,345564) / 0.00
Population : 3
Number of cases : 2 (0.29 expected)
OVerall relative risk.: 7.004
Log likelihood ratio ..: 2.194735
Monte Carlo rank : 999/1000
P-value : 0.999
The log likelihood ratio value required for an observed
cluster to be significant at level
0.01: 9.112805
... 0.05: 7.456156
Warning: According to the input data, the following tracts
have a population totalling zero for the specified year{s) .
Tract 4613, 2000
Tract 4923, 2000
Tract 4924, 2000
Tract 5007, 2000
Tract 5018, 2000
Tract 5019, 2000
Tract 5020, 2000
Tract 5115, 2000
214
Tract 5116, 2000
Tract 5202, 2000
Tract 5311, 2000
Tract 5312, 2000
Tract 5313, 2000
Tract 5314, 2000
Tract 5315, 2000
Tract 5513, 2000
Tract 5514, 2000
Tract 5702, 2000
Tract 5715, 2000
Tract 5812, 2000
Tract 6004, 2000
PARAMETER SETTINGS
Input Files
Case File
population File
Coordinates File
D:\Sol\Send\caseOO.txt
D:\Sol\Send\populationOO seen.txt
D:\Sol\Send\coordinates.txt
Precision of Times
Coordinates
None
Cartesian
Analysis
Type of Analysis
Probability Model
Scan for Areas with
Purely Spatial
poisson
High Rates
Number of Replications : 999
Scanning Window
---------------
Maximum Spatial Cluster Size 50.00 %
Criteria for Reporting Secondary Clusters No
Geographical OVerlap
Program completed
Total Running Time
Sun Mar 23 08:51:18 2003
10 seconds
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SaTScan V.3.0.4
Program run on: Sat Mar 22 18:42:51 2003
Purely Spatial analysis
scanning for clusters with
high rates using the Poisson model.
SUMMARY OF DATA (Two month follow-up)
Study period : 2000/9/19 - 2000/9/26
Number of census areas: 205
Total population : 905
Total cases : 19
MOST LIKELY CLUSTER
1.Census areas included.: 4902, 4903
Coordinates / radius ..: (9.66281e+06,346214) / 33.83
Population : 12
Number of cases : 4 (0.25 expected)
Overall relative risk.: 15.877
Log likelihood ratio ..: 7.713928
Monte Carlo rank : 38/1000
P-value : 0.038
SECONDARY CLUSTERS
2.Census areas included.: 5811, 5810, 5809, 5808
Coordinates / radius ..: (9.66318e+06,344821) / 99.81
Population : 17
Number of cases : 4 (0.36 expected)
Overall relative risk.: 11.207
Log likelihood ratio ..: 6.404924
Monte Carlo rank : 103/1000
P-value : 0.103
3.Census areas included.: 4709
Coordinates / radius ..: (9.6635ge+06,346407) / 0.00
Population : 4
Number of cases : 2 (0.08 expected)
OVerall relative risk.: 23.816
Log likelihood ratio ..: 4.525166
Monte Carlo rank : 460/1000
P-value : 0.460
4.Census areas included.: 5109
216
Coordinates / radius ..: (9.66332e+06,345745) / 0.00
Population : 6
Number of cases : 2 (0.13 expected)
Overall relative risk.: 15.877
Log likelihood ratio ..: 3.752014
Monte Carlo rank : 734/1000
P-value : 0.734
5.Census areas included.: 5511
Coordinates / radius ..: (9.66305e+06,345489) / 0.00
Population : 9
Number of cases : 2 (0.19 expected)
Overall relative risk.: 10.585
Log likelihood ratio ..: 2.997908
Monte Carlo rank : 919/1000
P-value : 0.919
6.Census areas included.:
Coordinates / radius ..:
Population :
Number of cases :
Overall relative risk.:
Log likelihood ratio ..:
Monte Carlo rank :
P-value :
5015
(9.66342e+06,346209) / 0.00
3
1
15.877
1.851441
999/1000
0.999
(0.06 expected)
The log likelihood ratio value required for an observed
cluster to be significant at level
0.01: 9.258291
... 0.05: 7.234497
Warning: According to the input data, the following tracts
have a population totalling zero for the specified year(s) .
Tract 4609, 2000
Tract 4610, 2000
Tract 4611, 2000
Tract 4613, 2000
Tract 4707, 2000
Tract 4913, 2000
Tract 4918, 2000
Tract 4923, 2000
Tract 4924, 2000
Tract 5007, 2000
Tract 5012, 2000
Tract 5018, 2000
Tract 5019, 2000
Tract 5020, 2000
Tract 5115, 2000
Tract 5116, 2000
Tract 5202, 2000
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Tract 5312, 2000
Tract 5313, 2000
Tract 5314, 2000
Tract 5315, 2000
Tract 5413, 2000
Tract 5505, 2000
Tract 5513, 2000
Tract 5514, 2000
Tract 5702, 2000
Tract 5715, 2000
Tract 5812, 2000
Tract 6004, 2000
PARAMETER SETTINGS
Input Files
Case File
population File
Coordinates File
0:\Sol\Send\case02. txt
D:\Sol\Send\population02 seen.txt
D:\Sol\Send\coordinates.txt
Precision of Times
Coordinates
None
Cartesian
Analysis
Type of Analysis
Probability Model
Scan for Areas with
Purely Spatial
Poisson
High Rates
Number of Replications : 999
Scanning Window
Maximum Spatial Cluster Size 50.00 %
Criteria for Reporting Secondary Clusters No
Geographical OVerlap
Program completed
Total Running Time
Sat Mar 22 18:43:02 2003
11 seconds
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SaTScan V.3.0.4
Program run on: Sun Mar 23 09:06:42 2003
Purely Spatial analysis
scanning for clusters with
high rates using the Poisson model.
SUMMARY OF DATA (Six month follow-up)
Study period : 2001/1/17 - 2001/1/24
Number of census areas: 205
Total population : 879
Total cases : 13
MOST LIKELY CLUSTER
I.Census areas included.: 4603
Coordinates / radius ..: (9.66301e+06,346498) / 0.00
Populat ion : 4
Number of cases : 2 (O.06 expected)
Overall relative risk.: 33.808
Log likelihood ratio ..: 5.253953
Monte Carlo rank : 271/1000
P-value : 0.271
SECONDARY CLUSTERS
2.Census areas included.: 5511
Coordinates / radius ..: (9.66305e+06,345489) / 0.00
Population : 9
Number of cases : 2 (0.13 expected)
Overall relative risk.: 15.026
Log likelihood ratio ..: 3.695130
Monte Carlo rank : 702/1000
P-value : 0.702
3.Census areas included.: 5018, 5019, 5006
Coordinates / radius ..: (9.66322e+06,346272) / 36.93
Population : 9
Number of cases : 2 (0.13 expected)
Overall relative risk.: 15.026
Log likelihood ratio ..: 3.695130
Monte Carlo rank : 716/1000
P-value : 0.716
4.Census areas included.: 5710
219
Coordinates / radius ..: (9.66326e+06,345204) / 0.00
population : 2
Number of cases : 1 (0.03 expected)
Overall relative risk.: 33.808
Log likelihood ratio ..: 2.587511
Monte Carlo rank : 985/1000
P-value : 0.985
The log likelihood ratio value required for an observed
cluster to be significant at level
0.01: 9.320457
... 0.05: 7.276175
Warning: According to the input data, the following tracts
have a population totalling zero for the specified year(s) .
Tract 4613, 2001
Tract 4707, 2001
Tract 4920, 2001
Tract 4923, 2001
Tract 4924, 2001
Tract 5007, 2001
Tract 5013, 2001
Tract 5019, 2001
Tract 5020, 2001
Tract 5115, 2001
Tract 5116, 2001
Tract 5202, 2001
Tract 5314, 2001
Tract 5315, 2001
Tract 5404, 2001
Tract 5413, 2001
Tract 5514, 2001
Tract 5809, 2001
Tract 5903, 2001
Tract 5904, 2001
Tract 6004, 2001
PARAMETER SETTINGS
Input Files
Case File
population File
Coordinates File
D:\Sol\Send\case06.txt
D:\Sol\Send\population06 seen. txt
D:\sol\Send\coordinates.txt
Precision of Times
Coordinates
None
Cartesian
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Analysis
Type of Analysis
Probability Model
Scan for Areas with
Purely Spatial
Poisson
High Rates
Number of Replications : 999
Scanning Window
Maximum Spatial Cluster Size: 50.00 %
Criteria for Reporting Secondary Clusters No
Geographical Overlap
Program completed
Total Running Time
Sun Mar 23 09:06:52 2003
10 seconds
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SaTScan V.3.0.4
Program run on: Sun Mar 23 09:17:43 2003
Purely Spatial analysis
scanning for clusters with
high rates using the Poisson model.
SUMMARY OF DATA (Twelve month follow-up)
Study period : 2001/7/23 - 2001/8/2
Number of census areas: 205
Total population : 907
Total cases : 8
MOST LIKELY CLUSTER
1.Census areas included.: 5709, 5710
Coordinates / radius ..: (9.66326e+06,345153) / 52.00
population : 10
Number of cases : 3 (0.09 expected)
Overall relative risk.: 34.013
Log likelihood ratio ..: 8.285599
Monte Carlo rank : 15/1000
P-value : 0.015
SECONDARY CLUSTERS
2.Census areas included.: 4603
Coordinates / radius ..: (9.66301e+06,346498) / 0.00
population : 4
Number of cases : 2 (0.04 expected)
Overall relative risk.: 56.687
Log likelihood ratio ..: 6.375534
Monte Carlo rank : 108/1000
P-value : 0.108
3.Census areas included.: 5809, 5810
Coordinates / radius ..: (9.66313e+06,344820) / 26.59
population : 6
Number of cases : 2 (0.05 expected)
Overall relative risk.: 37.792
Log likelihood ratio ..: 5.577908
Monte Carlo rank : 230/1000
P-value : 0.230
The log likelihood ratio value required for an observed
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cluster to be significant at level
0.01: 8.679177
... 0.05: 7.026134
Warning: According to the input data, the following tracts
have a population totalling zero for the specified year(s).
Tract 4613, 2001
Tract 4707, 2001
Tract 4920, 2001
Tract 4923, 2001
Tract 5007, 2001
Tract 5012, 2001
Tract 5013, 2001
Tract 5202, 2001
Tract 5315, 2001
Tract 5413, 2001
Tract 5509, 2001
Tract 5514, 2001
Tract 5809, 2001
Tract 5903, 2001
Tract 5904, 2001
PARAMETER SETTINGS
Input Files
Case File
population File
Coordinates File
D:\Sol\Send\case12.txt
D:\Sol\Send\population12 seen.txt
D:\Sol\Send\coordinates.txt
Precision of Times
Coordinates
None
Cartesian
Analysis
Type of Analysis
Probability Model
Scan for Areas with
Purely Spatial
poisson
High Rates
Number of Replications : 999
scanning Window
Maximum Spatial Cluster Size: 50.00 %
Criteria for Reporting Secondary Clusters No
Geographical Overlap
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Program completed
Total Running Time
Sun Mar 23 09:17:53 2003
10 seconds
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SaTScan V.3.0.4
Program run on: Sun Mar 23 09:47:02 2003
Purely Spatial analysis
scanning for clusters with
high rates using the poisson model.
SUMMARY OF DATA (Eighteen month follow-up)
Study period : 2001/12/23 - 2002/1/3
Number of census areas: 205
Total population : 888
Total cases : 5
MOST LIKELY CLUSTER
1.Census areas included.: 5809, 5810
Coordinates / radius ..: (9.66313e+06,344820) / 26.59
population : 6
Number of cases : 2 (0.03 expected)
Overall relative risk.: 59.200
Log likelihood ratio ..: 6.649705
Monte Carlo rank : 80/1000
P-value : 0.080
SECONDARY CLUSTERS
2.Census areas included.: 4603
Coordinates / radius ..: (9.66301e+06,346498) / 0.00
population : 3
Number of cases : 1 (0.02 expected)
OVerall relative risk.: 59.200
Log likelihood ratio ..: 3.201884
Monte Carlo rank : 876/1000
P-value : 0.876
3.Census areas included.: 5411
Coordinates / radius ..: (9.66332e+06,345400) / 0.00
population : 4
Number of cases : 1 (0.02 expected)
OVerall relative risk.: 44.400
Log likelihood ratio ..: 2.918724
Monte Carlo rank : 965/1000
P-value : 0.965
4.Census areas included.: 4810
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Coordinates / radius ..: (9.66365e+06,346613) / 0.00
population : 5
Number of cases : 1 (0.03 expected)
Overall relative risk.: 35.520
Log likelihood ratio ..: 2.700108
Monte Carlo rank : 993/1000
P-value : 0.993
The log likelihood ratio value required for an observed
cluster to be significant at level
0.01: 8.025813
.., 0.05: 6.893353
Warning: According to the input data, the following tracts
have a population totalling zero for the specified year(s).
Tract 4707, 2002
Tract 4913, 2002
Tract 4918, 2002
Tract 4920, 2002
Tract 5012, 2002
Tract 5013, 2002
Tract 5105, 2002
Tract 5115, 2002
Tract 5202, 2002
Tract 5303, 2002
Tract 5315, 2002
Tract 5413, 2002
Tract 5509, 2002
Tract 5809, 2002
Tract 5903, 2002
PARAMETER SETTINGS
Input Files
Case File
Population File
Coordinates File
D:\Sol\Send\case18.txt
D:\Sol\Send\population18 seen. txt
D:\Sol\Send\coordinates.txt
Precision of Times
Coordinates
None
Cartesian
Analysis
Type of Analysis
Probability Model
Scan for Areas with
purely Spatial
poisson
High Rates
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Number of Replications 999
Scanning Window
Maximum Spatial Cluster Size: 50.00 %
Criteria for Reporting Secondary Clusters No
Geographical Overlap
Program completed
Total Running Time
Sun Mar 23 09:47:12 2003
10 seconds
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